Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof

By developing a compound or salt thereof for inhibiting AXL, Mer and c-Met enzymes, the problem of treating these enzyme-related diseases in the prior art is solved, and effective inhibition of AXL, Mer and c-Met enzymes is achieved. Improved treatment effect.

CN119032087APending Publication Date: 2024-11-26CMG PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033868.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-16
Filing Date
2023-01-31
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing treatment methods are difficult to effectively inhibit AXL, Mer and c-Met enzymes, resulting in poor treatment effects on related diseases.

Method used

A compound or pharmaceutically acceptable salt thereof is developed for inhibiting AXL, Mer and c-Met enzymes in cells, to treat or prevent diseases mediated by these enzymes by administration of an effective amount of the compound or salt thereof.

Benefits of technology

Effectively inhibit AXL, Mer and c-Met enzymes, potentially used to treat a variety of diseases associated with these enzymes, such as cancer, asthma and dermatitis, improving therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032087A_ABST
    Figure CN119032087A_ABST
Patent Text Reader

Abstract

The present invention provides an inhibitor of AXL, Mer and / or c-Met of Formula (I): # imgabs0 # wherein R1, R2, R3, G and Q are described herein, or a pharmaceutically acceptable salt thereof. The present invention further provides a method of treating or preventing AXL-mediated diseases, Mer-mediated diseases and / or c-Met-mediated diseases using an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof. When AXL, MER and / or c-Met are inhibited, the compounds or pharmaceutically acceptable salts thereof are capable of resensitizing cancer cells, such as non-small cell lung cancer cells, that have developed resistance to anti-cancer agents.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to prior applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 310,840, filed February 16, 2022, which is hereby incorporated by reference in its entirety. Background Art

[0003] Receptor tyrosine kinases (RTKs) are transmembrane proteins that transduce signals from the extracellular environment to the cytoplasm and nucleus to regulate normal cellular processes, including survival, growth, differentiation, adhesion, and migration. Overexpression or activation of RTKs has been implicated in the pathogenesis of various cancers and is associated with cell transformation, tumor formation, and cancer metastasis.

[0004] TAM receptors are expressed in various cells and tissues. AXL is a member of the TAM RTK family, which also includes TYR03 and Mer, and was initially identified as a transforming gene expressed in cells of patients with chronic myeloid leukemia (O'Bryan et al., Mol. Cell Biol., 1991, 11, 5016-5031) and chronic myeloproliferative disorders (Janssen et al., Oncogene, 1991, 6 (11), 2113-2120). AXL promotes at least three of the six fundamental mechanisms of malignancy in cancer by promoting cancer cell migration and invasion, participating in tumor angiogenesis, and promoting cancer cell survival and tumor growth (Holland et al., Cancer Res., 2005, 65(20), 9294-9303; Tai et al., Oncogene, 2008, 27, 4044-4055; Li et al., Oncogene, 2009, 28, 3442-3455; and Mudduluru et al., Mol. Cancer Res., 2010, 8(2), 159-169).

[0005] In addition, overexpression of AXL is also associated with asthma, pain and dermatitis (Shibata et al., J Immunol, 2014, 192(8), 3569-3581; Liang et al., Molecular Pain, 2020, 16, 1-13; and Bauer et al., J Exp Med, 2012, 209(11), 2033-2047).

[0006] Overexpression of c-MET is associated with the development and poor prognosis of a variety of solid tumors, including breast, prostate, thyroid, lung, gastric, colorectal, pancreatic, renal, ovarian and uterine cancers, malignant gliomas, uveal melanoma, and bone and soft tissue sarcomas (Jiang et al., Critical Reviews in Oncology / Hematology, 2005, 53(1), 35-69).

[0007] Given the roles of AXL, Mer, and c-MET in various diseases, there remains a need to develop agents that act as AXL, Mer, and / or c-Met inhibitors to therapeutically treat these diseases. Summary of the Invention

[0008] The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0009]

[0010] where R 1 、R 2 、R 3 , G and Q are described in this article.

[0011] The present invention also provides a method for treating or preventing AXL-mediated diseases, Mer-mediated diseases and / or c-Met-mediated diseases in a subject, comprising administering to the subject an effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0012] The present invention provides a method for inhibiting AXL enzyme, Mer enzyme and / or c-Met enzyme in cells, comprising administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to the cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0014] Figure 2 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0015] Figure 3 The present invention relates to the chemical synthesis of (E)-N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0016] Figure 4 The present invention relates to the chemical synthesis of (E)-N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0017] Figure 5 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-cyanopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0018] Figure 6 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0019] Figure 7 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0020] Figure 8 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0021] Figure 9 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(pyridin-2-ylethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0022] Figure 10 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(4-phenoxyphenyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0023] Figure 11 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3,5-dimethylisoxazol-4-yl)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0024] Figure 12 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(1-propyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0025] Figure 13 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-((1-propyl-1H-pyrazol-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0026] Figure 14 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-morpholino-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0027] Figure 15 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(piperidin-4-ylalkynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0028] Figure 16 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-((1-(2-methoxyethyl)piperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0029] Figure 17The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0030] Figure 18 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)prop-1-ylynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0031] Figure 19 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0032] Figure 20 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-methylbut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0033] Figure 21 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxopropyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0034] Figure 22 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-phenylpyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0035] Figure 23The present invention relates to the chemical synthesis of N-(4-(2-amino-3-((1-methylpiperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0036] Figure 24 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0037] Figure 25 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0038] Figure 26 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0039] Figure 27 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0040] Figure 28 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(1-(2-methoxyethyl)piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0041] Figure 29 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(1-isopropylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0042] Figure 30 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0043] Figure 31 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0044] Figure 32 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0045] Figure 33 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0046] Figure 34 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0047] Figure 35 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0048] Figure 36 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0049] Figure 37 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0050] Figure 38 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0051] Figure 39 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0052] Figure 40 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0053] Figure 41 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0054] Figure 42 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, which is an aspect of the present invention.

[0055] Figure 43 The present invention relates to the chemical synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, which is an aspect of the present invention.

[0056] Figure 44 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, which is an aspect of the present invention.

[0057] Figure 45 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide.

[0058] Figure 46 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide.

[0059] Figure 47 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0060] Figure 48The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0061] Figure 49 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0062] Figure 50 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is one aspect of the present invention.

[0063] Figure 51 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0064] Figure 52 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0065] Figure 53 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0066] Figure 54The present invention is one aspect of the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0067] Figure 55 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0068] Figure 56 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0069] Figure 57 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0070] Figure 58 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0071] Figure 59 The present invention relates to the chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which is an aspect of the present invention.

[0072] Figure 60The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-(methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0073] Figure 61 The present invention is one aspect of the chemical synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0074] Figure 62 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0075] Figure 63 The present invention relates to a chemical synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0076] Figure 64 The present invention relates to a chemical synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0077] Figure 65 The present invention relates to a chemical synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0078] Figure 66 The present invention relates to a chemical synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0079] Figure 67 The present invention relates to a chemical synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

[0080] Figure 68 The present invention relates to a chemical synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. DETAILED DESCRIPTION

[0081] A compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0082]

[0083] in:

[0084] R 1 is H, alkyl, haloalkyl, halo or CN;

[0085] R 2 is H, alkyl, haloalkyl, halo or CN;

[0086] R 3 is H or halogen;

[0087] Q is H, CN, halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkenyl or alkynyl is selected from the group consisting of:

[0088] -CH=CR 4 (CX′) m (CH2) n NR 5 R 6 、-C≡C(CX′) m (CH2) n NR 5 R 6 、

[0089] -CH=CR 4 (CX′) m (CH2) n CHR 5 R 6 、-C≡C(CX′) m (CH2) n CHR 5 R 6 、

[0090] -CH=CR 4 (CX′) m (CH2) n NR 7 OR 8 and -C≡C(CX′) m (CH2) n NR 7 OR 8 ;

[0091] in

[0092] R 4 is hydrogen or a halogen group;

[0093] X' is H2, (C 1-6 alkyl)2 or =O;

[0094] m is 0 or 1;

[0095] n is 0 or 1 to 3;

[0096] -NR 5 R 6 forming a 4- to 7-membered heterocyclic ring or not forming a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring,

[0097] When-NR 5 R 6 When forming a 4- to 7-membered heterocyclic ring, the 4- to 7-membered heterocyclic ring is excluding -NR 5 R 6 The alkyl radical comprises an optional second heteroatom in addition to the nitrogen and is optionally substituted with one or more substituents independently selected from the group consisting of a linear C1-C6 alkyl group, a branched C3-C6 alkyl group, a hydroxyl group, a C1-C6 alkoxyalkyl group, a carboxylic acid, a linear C1-C4 alkylcarboxylic acid, and a branched C3-C4 alkylcarboxylic acid;

[0098] When-NR 5 R 6 When no ring structure is formed, R 5 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 6 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, branched C3-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, and cycloalkyl optionally substituted by at least one fluorine or at least one hydroxyl group;

[0099] -CHR 5 R 6 forming a 4- to 7-membered heterocyclic ring or not forming a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring,

[0100] When-CHR 5 R 6 When forming a 4- to 7-membered heterocyclic ring, the 4- to 7-membered heterocyclic ring includes one or two heteroatoms and is optionally substituted with one or more substituents independently selected from the group consisting of linear C1-C6 alkyl, branched C3-C6 alkyl, hydroxy, C1-C6 alkoxyalkyl, carboxylic acid, linear C1-C4 alkylcarboxylic acid, and branched C3-C4 alkylcarboxylic acid;

[0101] When-CHR 5 R 6 When no ring structure is formed, R 5 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 6 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, branched C3-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, and cycloalkyl optionally substituted by at least one fluorine or at least one hydroxyl group;

[0102] -NR 7 OR 8 No ring structure is formed, R 7 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 8 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group, branched C3-C6 alkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group, and cycloalkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group;

[0103] G is

[0104] in

[0105] R 9 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, or heteroarylalkyl, wherein the heteroaryl in the heteroarylalkyl may be substituted or unsubstituted;

[0106] R 10is H, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, alkyl or cycloalkyl, cycloalkylalkyl, alkenyl or alkynyl, wherein the alkyl, alkenyl or cycloalkyl may be substituted by one, two or three groups selected from the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino (wherein the two alkyl groups in the dialkylamino may be the same or different), heteroaryl, substituted heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl (wherein the two alkyl groups in the dialkylcarbamoyl may be the same or different) and heterocyclylcarbonyl; and

[0107] Y is N, CH or C-alkyl.

[0108] Pyrimidinedione-based inhibitors are useful for treating a variety of diseases and conditions associated with AXL, Mer and / or c-Met without requiring a specific mode of administration.

[0109] In some aspects of Formula (I), R 1 and R 2 It's all hydrogen.

[0110] In some aspects of Formula (I), R 3 It is a halogen group.

[0111] In some aspects of Formula (I), Q is CN, halo, optionally substituted phenyl, optionally substituted heterocyclyl, or an alkenyl or alkynyl moiety selected from the group consisting of: -CH=CR 4 (CX′) m (CH2) n NR 5 R 6 、-C≡C(CX′) m (CH2) n NR 5 R 6 、-CH=CR 4 (CX′) m (CH2) n CHR 5 R 6 、-C≡C(CX′) m (CH2) n CHR 5 R 6 、-CH=CR 4 (CX′) m (CH2) n NR 7 OR 8 and -C≡C(CX′)m (CH2) n NR 7 OR 8 ,

[0112] in

[0113] R 4 is hydrogen or a halogen group;

[0114] X' is H2, (C 1-6 alkyl)2 or =O;

[0115] m is 0 or 1;

[0116] n is 0 or 1;

[0117] -NR 5 R 6 is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group,

[0118] -CHR 5 R 6 is tetrahydropyranyl, morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group,

[0119] R 7 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and

[0120] R 8 Selected from the group consisting of a straight-chain C1-C6 alkyl group optionally substituted with at least one alkoxy group and a branched-chain C3-C6 alkyl group optionally substituted with at least one alkoxy group.

[0121] In some aspects of Formula (I), R 9 is phenyl substituted with alkyl, haloalkyl, halogen and / or CN; and (i) Y is CH or (ii) Y is N.

[0122] In some aspects, the compound of formula (I) is a compound of formula (Ib):

[0123]

[0124] in It is -C≡C- or -CH=CH-.

[0125] In some aspects of Formula (Ib), R 1 and R 2 It's all hydrogen.

[0126] In some aspects of Formula (Ib), R 3 It is a halogen group.

[0127] In some aspects of Formula (Ib), X′ is H2, (C 1-6 alkyl)2 or =O; and -NR 5 R 6 is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group (e.g., tert-butyloxycarbonyl (Boc), fluorenylmethyloxycarbonyl (Fmoc), carboxybenzyl (Cbz), acetyl, trifluoroacetamide, phthalimide, benzyl, trityl, benzylamine or tosyl), alkyl, hydroxy, alkoxy and alkoxyalkyl.

[0128] In some aspects of Formula (Ib), R 9 is phenyl substituted with alkyl, haloalkyl, halo and / or CN; and (i) Y is CH or (ii) Y is N.

[0129] In some aspects, the compound of formula (I) is a compound of formula (Ic):

[0130]

[0131] in It is -C≡C- or -CH=CH-.

[0132] In some aspects of Formula (Ic), R 1 and R 2 It's all hydrogen.

[0133] In some aspects of Formula (Ic), R 3 It is a halogen group.

[0134] In some aspects of Formula (Ic), X′ is H2, (C 1-6 alkyl)2 or =O; R 7 is selected from the group consisting of a linear C1-C6 alkyl group and a branched C3-C6 alkyl group, and R 8 Selected from the group consisting of linear C1-C6 alkyl groups and branched C3-C6 alkyl groups.

[0135] In some aspects of Formula (Ic), R 9 is phenyl substituted with alkyl, haloalkyl, halo and / or CN; and (i) Y is CH or (ii) Y is N.

[0136] Exemplary compounds of formula (I), including compounds of formula (Ib) and formula (Ic), are described below in the Examples. Pharmaceutically acceptable salts of these exemplary compounds are also contemplated. Specifically, the compounds of formula (I) are selected from

[0137]

[0138]

[0139]

[0140]

[0141]

[0142]

[0143]

[0144]

[0145]

[0146]

[0147] or a pharmaceutically acceptable salt thereof.

[0148] In any of the above aspects, the term "alkyl" means a straight or branched chain alkyl substituent containing, for example, about 1 to about 8 carbon atoms (e.g., about 1 to about 6 carbon atoms). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, etc. This definition also applies when "alkyl" occurs as part of a group, such as in C3-C6 cycloalkylalkyl, hydroxyalkyl, haloalkyl (e.g., monohaloalkyl, dihaloalkyl, and trihaloalkyl), cyanoalkyl, aminoalkyl, alkylamino, dialkylamino, arylalkyl, etc. As described herein, alkyl groups can be substituted or substituted. Even when alkyl is an alkylene chain (e.g., -(CH2)n-), alkyl groups can also be substituted or unsubstituted. Examples of substituted alkylene chains include -CH2CH2-methoxy.

[0149] In any of the above aspects, the term "alkenyl" as used herein means a straight chain alkenyl substituent containing, for example, about 2 to about 8 carbon atoms (branched alkenyl is about 3 to about 8 carbon atoms), such as about 3 to about 6 carbon atoms (branched alkenyl is about 3 to about 6 carbon atoms). According to one aspect, the alkenyl is a C2-C4 alkenyl. Examples of alkenyl include vinyl, allyl, 2-propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 1-hexenyl, etc. As described herein, the alkenyl group can be substituted or unsubstituted.

[0150] In any of the above aspects, the term "alkynyl" as used herein refers to a straight chain alkynyl substituent containing at least one carbon-carbon triple bond and, for example, from about 2 to about 8 carbon atoms (branched alkynyl is from about 4 to about 12 carbon atoms), for example, from about 2 to about 6 carbon atoms (branched alkynyl can be from about 4 to about 8 carbon atoms), for example, from about 2 to about 4 carbon atoms. Examples of such substituents include propynyl, propargyl, n-butynyl, pentynyl, isopentenyl, hexynyl, octynyl, and the like. As described herein, alkynyl groups can be substituted or unsubstituted.

[0151] In any of the above aspects, the term "cycloalkyl" as used herein refers to a cyclic alkyl moiety containing, for example, 3 to 6 carbon atoms or 5 to 6 carbon atoms. Examples of such moieties include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. As described herein, cycloalkyl groups can be substituted or unsubstituted.

[0152] In any of the above aspects, the term "hydroxy" refers to the group -OH.

[0153] In any of the above aspects, the term "alkoxy" encompasses a straight or branched chain alkyl group attached to a divalent oxygen. The alkyl group is the same as described herein.

[0154] In any of the above aspects, the term "halo" refers to a halogen group selected from fluoro, chloro, bromo and iodo.

[0155] In any of the above aspects, the term "aryl" refers to a monocyclic, bicyclic or tricyclic carbocyclic system having one, two or three aromatic rings, such as phenyl, naphthyl, anthracenyl or biphenyl. The term "aryl" refers to an unsubstituted or substituted aromatic carbocyclic moiety as generally understood in the art, and includes monocyclic and polycyclic aromatic groups, such as phenyl, biphenyl, naphthyl, anthracenyl, pyrenyl, etc. The aryl moiety generally contains, for example, 6 to 30 carbon atoms, 6 to 18 carbon atoms, 6 to 14 carbon atoms or 6 to 10 carbon atoms. It should be understood that the term aryl includes a planar and, according to Hückel's Rule, 4n+2π electron carbocyclic moieties, where n=1, 2 or 3. When "aryl" appears as part of a group, for example, in halogenated aryl (e.g., monohalogenated aryl, dihalogenated aryl and trihalogenated aryl), arylalkyl, etc., this definition also applies. As described herein, aryl groups can be substituted or unsubstituted.

[0156] In any of the above aspects, the term "heteroaryl" refers to an aromatic 5- or 6-membered monocyclic group, a 9- or 10-membered bicyclic group, and an 11- to 14-membered tricyclic group having at least one heteroatom (O, S, or N) in at least one ring. Each ring of the heteroaryl containing heteroatoms may contain one or two oxygen or sulfur atoms and / or one to four nitrogen atoms, with the proviso that the total number of heteroatoms in each ring is four or less and that each ring has at least one carbon atom. The fused rings that complete the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated, or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atoms may optionally be quaternized. A bicyclic or tricyclic heteroaryl must include at least one fully aromatic ring, but the other fused ring may be an aromatic ring or a non-aromatic ring. The heteroaryl group may be attached to any available nitrogen or carbon atom in any ring. Illustrative examples of heteroaryl groups are pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzimidazolyl, triazinyl, imidazolyl, (1,2,3)-triazolyl and (1,2,4)-triazolyl, pyrazinyl, tetrazolyl, furanyl, pyrrolyl, thienyl, isothiazolyl, thiazolyl, isoxazolyl and oxadiazolyl. As described herein, heteroaryl groups can be substituted or unsubstituted.

[0157] The term "heterocyclic radical" means a stable, saturated or partially unsaturated monocycle, bicyclic and spirocyclic system containing 3 to 7 ring members of carbon atoms and other atoms selected from nitrogen, sulphur and / or oxygen. In one aspect, heterocyclic radical is a 5-, 6- or 7-membered monocycle and contains one, two or three heteroatoms selected from nitrogen, oxygen and sulphur. Heterocyclic radical can be connected to the parent structure by carbon atoms or by any heteroatoms (such as nitrogen atoms) that produce a stable structure of the heterocyclic radical. Examples of these heterocycles are isoxazolyl, thiazolinyl, imidazolidinyl, piperazinyl, homopiperazinyl, pyrrolyl, pyrrolinyl, pyrazolyl, pyranyl, dihydropyranyl, tetrahydropyranyl, piperidinyl, oxazolyl and morpholinyl. Preferably, heterocyclic radical is piperazinyl, piperidinyl or morpholinyl. As described herein, heterocyclic radical can be substituted or unsubstituted.

[0158] In other aspects, any substituent that is not hydrogen (e.g., alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocyclyl) can be an optionally substituted moiety. The substituted moiety typically comprises at least one substituent (e.g., 1, 2, 3, 4, 5, 6, etc.) at any suitable position (e.g., 1, 2, 3, 4, 5, 6, etc.). When an aryl group is substituted with a substituent (e.g., halo, amino, alkyl, OH, alkoxy, etc.), the aromatic ring hydrogen is replaced with the substituent, and this can occur at any available hydrogen at, for example, 2, 3, 4, 5, and / or 6, where position 1 is the point of attachment for the aryl group in the compounds of the invention. Suitable substituents include, for example, halo, alkyl, alkenyl, alkynyl, hydroxy, nitro, cyano, amino, alkylamino, alkoxy, aryloxy, aralkyloxy, carboxyl, carboxylalkyl, carboxylalkoxy, amido, alkylamido, haloalkylamido, aryl, heteroaryl, and heterocyclyl, each of which is described herein.

[0159] In any of the above aspects, when a range of atoms in a structure is specified (e.g., C 1-12 Alkyl, C 1-8 Alkyl, C 1-6 Alkyl or C 1-4 alkyl, cycloalkyl, etc.), it is specifically contemplated that any subrange or individual number of carbon atoms within the specified range may also be used. Thus, for example, reference to 1 to 8 carbon atoms (e.g., C1-C8), 1 to 6 carbon atoms (e.g., C1-C6), 1 to 4 carbon atoms (e.g., C1-C8) with respect to any chemical group (e.g., alkyl, cycloalkyl, etc.) mentioned herein is specifically contemplated. 1- Recitation of a range from 1 to 3 carbon atoms (e.g., C1-C4), 1 to 3 carbon atoms (e.g., C1-C3), or 2 to 8 carbon atoms (e.g., C2-C8) encompasses and specifically describes 1, 2, 3, 4, 5, 6, 7, and / or 8 carbon atoms, as appropriate, and any subranges thereof (e.g., 1 to 2 carbon atoms, 1 to 3 carbon atoms, 1 to 4 carbon atoms, 1 to 5 carbon atoms, 1 to 6 carbon atoms, 1 to 7 carbon atoms, 1 to 8 carbon atoms, 2 to 3 carbon atoms, 2 to 4 carbon atoms, 2 to 5 carbon atoms, 2 to 6 carbon atoms, 2 to 7 carbon atoms, 2 to 8 carbon atoms, 3 to 4 carbon atoms, 3 to 5 carbon atoms, 3 to 6 carbon atoms, 3 to 7 carbon atoms, 3 to 8 carbon atoms, 4 to 5 carbon atoms, 4 to 6 carbon atoms, 4 to 7 carbon atoms, 4 to 8 carbon atoms, etc., as appropriate).

[0160] The subscript "m" indicates the number of (CX') repeating units. The subscript m can be 0 or 1. When m is 0, then (CX') is absent in the molecule.

[0161] The subscript "n" represents the number of methylene (CH2) repeating units. The subscript n can be 0 or an integer from 1 to 3 (i.e., 1, 2, or 3). When n is 0, the corresponding portion does not contain any methylene repeating units.

[0162] In any of the above aspects, the phrase "salt" or "pharmaceutically acceptable salt" is intended to include non-toxic salts synthesized by conventional chemical methods from the parent compound containing a basic or acidic moiety. In general, these salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent, or in a mixture of the two solvents. Lists of suitable salts can be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445 and Journal of Pharmaceutical Science, 66, 2-19 (1977). For example, the salt can be selected from the group consisting of acetate, benzoate, benzenesulfonate, bitartrate, bromide, carbonate, chloride, edetate, edisylate, etopoate, fumarate, glucoheptonate, gluconate, hydrobromide, hydrochloride, iodide, formate, lactate, lactobionate, malate, maleate, mandelate, methanesulfonate, methylbromide, methylsulfate, mucate, naphthenate, nitrate, oxalate, pamoate, phosphate, diphosphate, salicylate, disalubelinate, stearate, succinate, sulfate, tartrate, toluenesulfonate, triethiodide, trifluoroacetate, and valerate.

[0163] The methods described herein include administering a compound of formula (I) or a pharmaceutically acceptable salt thereof in the form of a pharmaceutical composition. Specifically, the pharmaceutical composition will comprise at least one compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Pharmaceutically acceptable excipients (e.g., vehicles, adjuvants, carriers, or diluents) described herein are well known to those skilled in the art and readily available to the public. Typically, a pharmaceutically acceptable carrier is a carrier that is chemically inert to the active compound and is free of harmful side effects or toxicity under the conditions of use.

[0164] The pharmaceutical composition can be administered orally, sublingually, transdermally, subcutaneously, topically, by absorption through epithelial or mucocutaneous linings, intravenously, intranasally, intraarterially, intramuscularly, intratumorally, peritumorally, intraperitoneally, intrathecally, rectally, vaginally, or in the form of an aerosol formulation. In some aspects, the pharmaceutical composition is administered orally or intravenously.

[0165] According to any aspect, the compound of formula (I) or a pharmaceutically acceptable salt thereof can be administered orally to a subject in need thereof. Formulations suitable for oral administration can consist of: (a) liquid solutions, such as an effective amount of the compound dissolved in a diluent (such as water, saline or orange juice), and including additives such as cyclodextrins (e.g., α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin, hydroxypropyl cyclodextrin) or polyethylene glycol (e.g., PEG400); (b) capsules, sachets, tablets, buccal tablets and dragees, each containing a predetermined amount of the active ingredient in the form of a solid or granules; (c) powders; (d) suspensions in appropriate liquids; and (e) suitable emulsions and gels. Liquid formulations can include diluents such as water and alcohols, such as ethanol, benzyl alcohol and polyvinyl alcohol, with or without the addition of pharmaceutically acceptable surfactants, suspending agents or emulsifiers. Capsule forms can have common hard or soft shell gelatin types containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of the following: lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, gum arabic, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffers, disintegrants, wetting agents, preservatives, flavorings, and other pharmacologically compatible carriers. Lozenge forms can contain the active ingredient in a flavoring, which is typically sucrose and gum arabic or tragacanth, and lozenges also contain the active ingredient in an inert matrix such as gelatin and glycerol or sucrose and gum arabic, emulsions, gels, etc., containing carriers known in the art in addition to the active ingredient.

[0166] Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents, solubilizers, thickening agents, stabilizers and preservatives. The compound of formula (I) or a salt thereof can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or liquid mixture, including water, saline, aqueous dextrose, and related sugar solutions; an alcohol, such as ethanol, isopropanol, or hexadecyl alcohol; a glycol, such as propylene glycol or polyethylene glycol; a glycerol ketal, such as 2,2-dimethyl-1,3-dioxolane-4-methanol; an ether, such as poly(ethylene glycol) 400; an oil; a fatty acid; a fatty acid ester or glyceride; or an acetylated fatty acid glyceride; with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or detergent; a suspending agent, such as pectin, carbomer, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose; or an emulsifier and other pharmaceutical adjuvants.

[0167] The oil that can be used for parenteral preparations comprises petroleum, animal oil, vegetable oil or synthetic oil.The specific example of oil comprises peanut oil, soybean oil, sesame oil, cottonseed oil, corn oil, olive oil, paraffin oil and mineral oil.The fatty acid that is suitable for parenteral preparations comprises oleic acid, stearic acid and isostearic acid.Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters. Suitable soaps for use in parenteral formulations include fatty alkali metal salts, ammonium salts, and triethanolamine salts, and suitable detergents include: (a) cationic detergents such as dimethyldialkylammonium halides and alkylpyridinium halides; (b) anionic detergents such as alkyl, aryl, and olefin sulfonates, alkyl sulfates, olefin sulfates, ether sulfates, and monoglyceride sulfates, and sulfosuccinates; (c) nonionic detergents such as fatty amine oxides, fatty acid alkanolamides, and polyoxyethylene / polypropylene copolymers; (d) amphoteric detergents such as alkyl-β-aminopropionates and 2-alkyl-imidazoline quaternary ammonium salts; and (e) mixtures thereof.

[0168] Parenteral formulations will typically contain about 0.5% to about 25% by weight of an inhibitor in solution. Suitable preservatives and buffers can be used in these formulations. In order to minimize or eliminate irritation at the injection site, the composition can contain one or more nonionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 12 to about 17. The various surfactants in these formulations are within the range of about 5% to about 15% by weight. Suitable surfactants include polyethylene sorbitol fatty acid esters, such as sorbitol monooleate; and high molecular weight adducts of ethylene oxide and a hydrophobic matrix formed by condensation of propylene oxide and propylene glycol. Parenteral formulations can be present in unit dose or multidose sealed containers (such as ampoules and vials) and can be stored under freeze-dried (lyophilized) conditions, requiring only the addition of a sterile liquid carrier (e.g., water for injection) just before use. Ready-to-use injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the types described previously.

[0169] Inhibitors can be made into injectable formulations. Those of ordinary skill in the art are familiar with the requirements for effective pharmaceutical carriers for injectable compositions. See Pharmaceutics and Pharmacy Practice, JB Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., pp. 238-250 (1982) and ASHP Handbook on Injectable Drugs, Toissel, 4th ed., pp. 622-630 (1986).

[0170] Topical compositions are generally in the form of liquids (e.g., mouthwashes), creams, pastes, emulsions, and gels. Topical application includes application to the oral mucosa, including the oral cavity, oral epithelium, palate, gums, and nasal mucosa. In some respects, the composition contains at least one active ingredient and a suitable vehicle or carrier. The composition can also contain other components, such as anti-irritants. The carrier can be a liquid, solid, or semisolid. In many aspects, the composition is an aqueous solution, such as a mouthwash. Alternatively, the composition can be a dispersion, emulsion, gel, emulsion, or cream vehicle for various components. In one aspect, the main vehicle is water or a substantially neutral or biocompatible solvent that has been rendered substantially neutral. The liquid vehicle can include other materials, such as buffer, alcohol, glycerol, and mineral oil and various emulsifiers or dispersants known in the art, to obtain desired pH, consistency, and viscosity. Possibly, the composition can be produced as a solid, such as a powder or granules. The solid can be applied directly or dissolved in water or a biocompatible solvent before use to form a solution that is or has been rendered substantially neutral and can then be applied to the target site. In various aspects of the invention, vehicles for topical application to the skin can include water, buffered solutions, various alcohols, glycols (such as glycerol), lipid materials (such as fatty acids), mineral oils, phosphoglycerides, collagen, gelatin, and silicone-based materials.

[0171] The compound of formula (I) or its pharmaceutically acceptable salt, alone or in combination with other suitable components, can be made into aerosol formulations for administration by inhalation. These aerosol formulations can be placed into acceptable pressurized propellants such as dichlorodifluoromethane, propane, nitrogen, etc. It can also be formulated as a medicine for non-pressurized preparations such as in a sprayer or nebulizer.

[0172] According to the present invention, the dosage administered to a subject (especially humans and other mammals) should be sufficient to affect the desired response. Those skilled in the art will recognize that dosage will depend on a variety of factors, including the age, condition or disease state, disease susceptibility, one or more genetic defects, and body weight of the mammal. The size of the dosage will also be determined by the presence, nature, and extent of any adverse side effects that may accompany the administration of a specific inhibitor and the desired effect. It will be appreciated by those skilled in the art that various conditions or disease states may require extended treatment involving multiple administrations.

[0173] The present invention method comprises administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. "Effective amount" means an amount sufficient to show a huge significant benefit in an individual, cell or tissue. Significant benefit means preventing, alleviating, suspending or eliminating one or more symptoms of a disease or condition (e.g., asthma, cancer) after administering a compound of formula (I) (including a compound of formula (Ib) or (Ic)) or a pharmaceutically acceptable salt thereof, thereby effectively treating the disease at least to a certain extent. For example, a significant benefit can be at least one aspect of promoting tumor cell toxicity (e.g., inhibiting growth, inhibiting cancer cell survival, reducing proliferation, reducing the size and / or quality of a tumor (e.g., a solid tumor), or treating, healing, preventing other one or more related medical conditions associated with a specific disease or condition, delaying its onset, suspending it or improving it. The significant benefit observed in the subject to be treated can reach any suitable degree (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or higher).

[0174] The effective amount can vary depending on the desired biological effect of the individual, the condition to be treated, and / or the compound of formula (I) (including the compound of formula (lb) or (Ic)) or a pharmaceutically acceptable salt thereof, and the specific characteristics of the individual. In this regard, any suitable dose of a compound of formula (I) or a pharmaceutically acceptable salt thereof can be administered to a subject (e.g., a human) depending on the disease or condition to be treated (e.g., asthma, cancer). Various general considerations considered in determining an "effective amount" are known to those skilled in the art and are described in, for example, Goodman and Gilman, ed., The Pharmacological Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Remington's Pharmaceutical Sciences, 17th ed., Mark Publishing Company, Easton, Pennsylvania, 1990, each of which is incorporated herein by reference. The dosage of a compound of formula (I) (including a compound of formula (Ib) or (Ic)) or a pharmaceutically acceptable salt thereof preferably includes about 0.01 mg per kilogram (kg) of subject body weight (mg / kg) or more per day (e.g., about 0.05 mg / kg or more, 0.1 mg / kg or more, 0.5 mg / kg or more, 1 mg / kg or more, 2 mg / kg or more, 5 mg / kg or more, 10 mg / kg or more, 15 mg / kg or more, 20 mg / kg or more, 30 mg / kg or more, 40 mg / kg or more, 50 mg / kg or more). or more, 75 mg / kg or more, 100 mg / kg or more, 125 mg / kg or more, 150 mg / kg or more, 175 mg / kg or more, 200 mg / kg or more, 225 mg / kg or more, 250 mg / kg or more, 275 mg / kg or more, 300 mg / kg or more, 325 mg / kg or more, 350 mg / kg or more, 375 mg / kg or more, 400 mg / kg or more, 425 mg / kg or more, 450 mg / kg or more or 475 mg / kg or more).Typically, the dose will be about 500 mg / kg or less (e.g., about 475 mg / kg or less, about 450 mg / kg or less, about 425 mg / kg or less, about 400 mg / kg or less, about 375 mg / kg or less, about 350 mg / kg or less, about 325 mg / kg or less, about 300 mg / kg or less, about 275 mg / kg or less, about 250 mg / kg or less, about 225 mg / kg or less, about 200 mg / kg or less, about 175 mg / kg or less).

[0015] In some embodiments, the present invention provides an endpoint or a combination of the following: about 1 mg / kg or less, about 2 mg / kg or less, about 15 mg / kg or less, about 10 mg / kg or less, about 5 mg / kg or less, about 2 mg / kg or less, about 1 mg / kg or less, about 0.5 mg / kg or less, or about 0.1 mg / kg or less. Any two of the above endpoints can be used to define a closed range, or a single endpoint can be used to define an open range.

[0175] In one aspect, the compound of formula (I) or a salt thereof inhibits one or more enzymes selected from AXL, Mer and c-Met. Thus, the present invention provides a method for inhibiting AXL, Mer and / or c-Met enzymes in a cell, comprising administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a cell in need of such inhibition (e.g., a cell overexpressing AXL, Mer and / or c-Met). For example, the cell can be any cell that overexpresses AXL, Mer and / or c-Met and is associated with any suitable tissue (particularly a tissue associated with diseases such as papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer, neuroblastoma, pain, cachexia (wasting syndrome), dermatitis and asthma). The tissue can be from, for example, the thyroid, pancreas, lung, colon, breast, skin or adrenal gland. According to one aspect, the cell is a cancer cell that overexpresses AXL, Mer and / or c-Met, such as a cell from papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer and neuroblastoma. In another aspect, the cancer cell is a non-small cell lung cancer cell.

[0176] Elevated levels of AXL, Mer, and c-Met are associated with certain diseases, and it is conceivable that inhibition of one or more of AXL, Mer, and c-Met is a viable treatment for these diseases. Thus, the present invention provides a method for treating or preventing an AXL-mediated disease, a Mer-mediated disease, and / or a c-Met-mediated disease in a subject using a compound of formula (I). Typically, the compound of formula (I) will be provided to the subject in the form of a pharmaceutical composition as described herein. The type of disease to be treated or prevented is not particularly limited, but typically, the disease is characterized by increased expression of AXL, Mer, and c-Met relative to normal tissue of the same type. In some aspects, the disease is selected from the group consisting of: papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer, neuroblastoma, pain, cachexia (wasting syndrome), dermatitis, and asthma. The method comprises administering to a subject in need of such treatment a pharmaceutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. In some preferred aspects of this method, the disease is lung cancer (e.g., non-small cell lung cancer).

[0177] The present invention also provides a method for treating a subject whose cancer cells are resistant to an anticancer agent, comprising administering to the subject an effective amount of a compound of formula (I) (including a compound of formula (Ib) or (Ic)) or a pharmaceutically acceptable salt thereof and an anticancer agent, wherein the compound or a pharmaceutically acceptable salt thereof resensitizes the cancer cells to the anticancer agent. The cancer cells are the same as described herein. According to one aspect, the cancer cells are selected from papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer, and neuroblastoma. In another aspect, the cancer cells are non-small cell lung cancer cells.

[0178] In certain aspects of this method, a compound of formula (I) (including a compound of formula (Ib) or (Ic)) or a pharmaceutically acceptable salt thereof can be co-administered with an anticancer agent (e.g., a chemotherapeutic agent) and / or radiotherapy. In one aspect, the method comprises administering an amount of the compound or a salt thereof, preferably in the form of a pharmaceutical composition, that is effective to sensitize cancer cells to one or more treatment regimens (e.g., chemotherapy or radiotherapy). The term "co-administered" or "co-administration" refers to administration simultaneously or sequentially. A compound can be administered before, simultaneously with, or after administration of another compound using any suitable time frame.

[0179] One or more, for example two, three or more, anticancer agents may be administered. In this regard, the present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination of a compound of formula (I) (including a compound of formula (Ib) or (Ic)) or a pharmaceutically acceptable salt thereof and at least one anticancer agent (e.g., a chemotherapeutic agent).

[0180] Examples of anticancer agents include platinum compounds (e.g., cisplatin, carboplatin, oxaliplatin), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, nitrogen mustard, thiotepa, melphalan, busulfan, procarbazine, streptozotocin, temozolomide, dacarbazine, bendamustine), antitumor antibiotics (e.g., daunorubicin, doxorubicin, idarubicin, epirubicin, mitoxantrone, bleomycin, mitomycin C), and sirolimus.C), plicamycin, dactinomycin), taxanes (e.g., paclitaxel and docetaxel), antimetabolites (e.g., 5-fluorouracil, cytarabine, pemetrexed, thioguanine, floxuridine, capecitabine, and methotrexate), nucleoside analogs (e.g., fludarabine, clofarabine, cladribine, pentostatin, nelarabine), topoisomerase inhibitors (e.g., topotecan and irinotecan), hypomethylating agents (e.g., azacitidine and decitabine), proteasome inhibitors (e.g., bortezomib), b)), epipodophyllotoxins (e.g., etoposide and teniposide), DNA synthesis inhibitors (e.g., hydroxyurea), vinca alkaloids (e.g., vincristine, vindesine, vinorelbine, and vinblastine), tyrosine kinase inhibitors (e.g., imatinib, dasatinib, nilotinib, sorafenib, sunitinib), monoclonal antibodies (e.g., rituximab, cetuximab, panitumumab, tositumomab, trastuzumab, alemtuzumab, gemtuzumab),ozogamicin), bevacizumab), nitrosoureas (e.g., carmustine, fotemustine, and lomustine), enzymes (e.g., L-asparaginase), biologics (e.g., interferons and interleukins), hexamethylmelamine, mitotane, angiogenesis inhibitors (e.g., thalidomide, lenalidomide) , steroids (e.g., prednisone, dexamethasone, and prednisolone), CDK4 / 6 inhibitors (e.g., abemaciclib, palbociclib, ribociclib), anticancer hormonal agents (e.g., tamoxifen, fulvestrant, raloxifene, leuprolide, bicalutamide, granisetron, flutamide, goserelin), aromatase inhibitors (e.g., exemestane, letrozole, and anastrozole), arsenic trioxide, tretinoin, nonselective cyclooxygenase inhibitors (e.g., nonsteroidal anti-inflammatory drugs, salicylates, aspirin, piroxicam, ibuprofen, en), indomethacin, naprosyn, diclofenac, tolmetin, ketoprofen, nabumetone, oxaprozin), selective cyclooxygenase-2 (COX-2) inhibitors, immune checkpoint inhibitors (e.g., anti-PD1, anti-CTLA4, and anti-PD-L1), cellular immunotherapy (e.g., chimeric antigen receptor T cell therapy, tumor infiltrating lymphocyte therapy), or any combination thereof.

[0181] For the purposes of the present invention, the term "subject" preferably refers to a mammal. Mammals include, but are not limited to, rodents, such as mice; and lagomorphs, such as rabbits. Preferably, the mammal is from the order Carnivora, including Felidae (cats) and Canids (dogs). More preferably, the mammal is from the order Artiodactyla, including Bovidae (cows) and Suidae (pigs); or belongs to the order Persistodactyla, including Equine (horses). Most preferably, the mammal belongs to the order Primates, Cebids, or Simoids (monkeys) or the order Anthropoides (humans and apes). A particularly preferred mammal is a human.

[0182] The present invention is further described by the following aspects.

[0183] A compound of formula (I) or a pharmaceutically acceptable salt thereof:

[0184]

[0185] in:

[0186] R 1 is H, alkyl, haloalkyl, halo or CN;

[0187] R 2 is H, alkyl, haloalkyl, halo or CN;

[0188] R 3 is H or halogen;

[0189] Q is H, CN, halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl, or aryl, wherein the alkenyl or alkynyl is selected from the group consisting of:

[0190] -CH=CR 4 (CX′) m (CH2) n NR 5 R 6 、-C≡C(CX′) m (CH2) n NR 5 R 6 、

[0191] -CH=CR 4 (CX′) m (CH2) n CHR 5 R 6 、-C≡C(CX′) m (CH2) n CHR 5 R 6 、

[0192] -CH=CR4 (CX′) m (CH2) n NR 7 OR 8 and -C≡C(CX′) m (CH2) n NR 7 OR 8 ;

[0193] in

[0194] R 4 is hydrogen or a halogen group;

[0195] X' is H2, (C 1-6 alkyl)2 or =O;

[0196] m is 0 or 1;

[0197] n is 0 or 1 to 3;

[0198] -NR 5 R 6 forming a 4- to 7-membered heterocyclic ring or not forming a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring,

[0199] When-NR 5 R 6 When forming a 4- to 7-membered heterocyclic ring, the 4- to 7-membered heterocyclic ring is excluding -NR 5 R 6 The alkyl radical comprises an optional second heteroatom in addition to the nitrogen and is optionally substituted with one or more substituents independently selected from the group consisting of a linear C1-C6 alkyl group, a branched C2-C6 alkyl group, a hydroxyl group, a C1-C6 alkoxyalkyl group, a carboxylic acid, a linear C1-C4 alkylcarboxylic acid, and a branched C3-C4 alkylcarboxylic acid;

[0200] When-NR 5 R 6 When no ring structure is formed, R 5 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 6 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, branched C3-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, and cycloalkyl optionally substituted by at least one fluorine or at least one hydroxyl group;

[0201] -CHR 5 R 6 forming a 4- to 7-membered heterocyclic ring or not forming a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring,

[0202] When-CHR 5 R6 When forming a 4- to 7-membered heterocyclic ring, the 4- to 7-membered heterocyclic ring includes one or two heteroatoms and is optionally substituted with one or more substituents independently selected from the group consisting of linear C1-C6 alkyl, branched C3-C6 alkyl, hydroxy, C1-C6 alkoxyalkyl, carboxylic acid, linear C1-C4 alkylcarboxylic acid, and branched C3-C4 alkylcarboxylic acid;

[0203] When-CHR 5 R 6 When no ring structure is formed, R 5 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 6 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, branched C3-C6 alkyl optionally substituted by at least one fluorine or at least one hydroxyl group, and cycloalkyl optionally substituted by at least one fluorine or at least one hydroxyl group;

[0204] -NR 7 OR 8 No ring structure is formed, R 7 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 8 Selected from the group consisting of hydrogen, linear C1-C6 alkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group, branched C3-C6 alkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group, and cycloalkyl optionally substituted with at least one fluorine, hydroxy or alkoxy group;

[0205] G is

[0206] in

[0207] R 9 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, or heteroarylalkyl, wherein the heteroaryl in the heteroarylalkyl may be substituted or unsubstituted;

[0208] R 10is H, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, alkyl or cycloalkyl, cycloalkylalkyl, alkenyl or alkynyl, wherein the alkyl, alkenyl or cycloalkyl may be substituted by one, two or three groups selected from the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino (wherein the two alkyl groups in the dialkylamino may be the same or different), heteroaryl, substituted heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl (wherein the two alkyl groups in the dialkylcarbamoyl may be the same or different) and heterocyclylcarbonyl; and

[0209] Y is N, CH or C-alkyl.

[0210] 2. The compound according to aspect 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

[0211] 3. The compound according to aspect 1 or 2, or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

[0212] 4. The compound according to any one of aspects 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Q is CN, halo, optionally substituted phenyl, optionally substituted heterocyclyl, or an alkenyl or alkynyl moiety selected from the group consisting of: -CH=CR 4 (CX′) m (CH2) n NR 5 R 6 、-C≡C(CX′) m (CH2) n NR 5 R 6 、-CH=CR 4 (CX′) m (CH2) n CHR 5 R 6 、-C≡C(CX′) m (CH2) n CHR 5 R 6 、-CH=CR 4 (CX′) m (CH2) n NR 7 OR 8 and -C≡C(CX′) m (CH2) nNR 7 OR 8 , where R 4 is hydrogen or halogen; X' is H2, (C 1-6 alkyl)2 or =O; m is 0 or 1; n is 0 or 1; -NR 5 R 6 is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group, -CHR 5 R 6 is tetrahydropyranyl, morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group, R 7 is selected from the group consisting of hydrogen, linear C1-C6 alkyl and branched C3-C6 alkyl, and R 8 Selected from the group consisting of a straight-chain C1-C6 alkyl group optionally substituted with at least one alkoxy group and a branched-chain C3-C6 alkyl group optionally substituted with at least one alkoxy group.

[0213] 5. The compound according to any one of aspects 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted with alkyl, haloalkyl, halo and / or CN; and (i) Y is CH, or (ii) Y is N.

[0214] 6. The compound according to any one of aspects 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ib):

[0215]

[0216] in It is -C≡C- or -CH=CH-.

[0217] 7. The compound according to aspect 6 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

[0218] 8. The compound according to aspect 6 or 7, or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

[0219] 9. The compound according to any one of aspects 6 to 8, or a pharmaceutically acceptable salt thereof, wherein X′ is H 2 , (C 1-6 alkyl)2 or =O; and -NR 5 R 6is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group.

[0220] 10. The compound according to any one of aspects 6 to 9, or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted with alkyl, haloalkyl, halo and / or CN; and (i) Y is CH, or (ii) Y is N.

[0221] 11. The compound according to any one of aspects 1 to 5, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ic):

[0222]

[0223] in It is -C≡C- or -CH=CH-.

[0224] 12. The compound according to aspect 11 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

[0225] 13. The compound according to aspect 11 or 12, or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

[0226] 14. The compound according to any one of aspects 11 to 13, or a pharmaceutically acceptable salt thereof, wherein X′ is H 2 , (C 1-6 alkyl)2 or =O; R 7 is selected from the group consisting of a linear C1-C6 alkyl group and a branched C3-C6 alkyl group, and R 8 Selected from the group consisting of linear C1-C6 alkyl groups and branched C3-C6 alkyl groups.

[0227] 15. The compound according to any one of aspects 11 to 14, or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted with alkyl, haloalkyl, halo and / or CN; and (i) Y is CH, or (ii) Y is N.

[0228] 16. The compound according to aspect 1, which is selected from

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239] or a pharmaceutically acceptable salt thereof.

[0240] 17. A pharmaceutical composition comprising at least one compound according to any one of aspects 1 to 16 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0241] 18. A method for treating or preventing an AXL-mediated disease, a Mer-mediated disease and / or a c-Met-mediated disease in a subject, wherein the disease is selected from the group consisting of papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer, neuroblastoma, pain, cachexia, dermatitis and asthma, the method comprising administering to the subject in need of such treatment a pharmaceutically effective amount of a compound according to any one of aspects 1 to 16 or a pharmaceutically acceptable salt thereof.

[0242] 19. The method of aspect 18, wherein the lung cancer is non-small cell lung cancer.

[0243] 20. A method of inhibiting AXL, Mer and / or c-Met enzymes in a cell, the method comprising administering a pharmaceutically effective amount of a compound according to any one of aspects 1 to 16 or a pharmaceutically acceptable salt thereof to a cell in need of such inhibition.

[0244] The following examples further illustrate the invention but, of course, should not be construed as limiting its scope in any way.

[0245] Example

[0246] NMR spectra were recorded at 30° C. in CDCl 3 and DMSO-d 6 solutions in 5-mm OD tubes (Norell, Inc. 507-HP) and collected at 400 MHz on a Varian VNMRS-400. 1H. Chemical shifts (δ) are relative to tetramethylsilane (TMS = 0.00 ppm) and are expressed in ppm. LC / MS data were acquired on an ion-trap mass spectrometer on a FINNIGAN Thermo LCQ AdvantageMAX Agilent LC 1200 series (column: YMC Hydrosphere (C18, 3μm, 40° C.); flow rate = 1.0 mL / min, mobile phase = 0.01% heptafluorobutyric acid (HFBA) and 1.0% isopropanol (IPA) in water or CH 3 CN.

[0247] Intermediate Example 1

[0248] This example describes the synthesis of 1-morpholinoprop-2-yn-1-one (Intermediate 1).

[0249]

[0250] n-BuLi (2.5M in hexane, 4.89mL, 12.22mmol) is slowly added to a solution of ethynyltrimethylsilane (1.45mL, 10.18mmol) in tetrahydrofuran (THF) (50mL) at -78 ° C. The reaction mixture is stirred at the same temperature for 1 hour, and morpholine-4-carbonyl chloride (1.27mL, 11.20mmol) is added. The reaction mixture is stirred for another 2 hours at room temperature (rt). Water is added to the reaction mixture and stirred for 10 minutes. Ethyl acetate (EtOAc) is poured into the mixture, and the separated organic layer is extracted with EtOAc. The organic layer is dried with Na2SO4, filtered and concentrated in vacuo. The residue is purified by SiO2 column chromatography (hexane / EtOAc=1 / 1) to obtain 1-morpholineprop-2-yn-1-one (1.03g, 73%) as a pale solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ3.14(1H,s), 3.64-3.69(4H,m), 3.70-3.73(2H,m), 3.77-3.79(2H,m).

[0251]

[0252] This example describes the synthesis of 4-(prop-2-ynyl)morpholine (Intermediate 2).

[0253]

[0254] To a solution of morpholine (0.50 g, 5.74 mmol) in acetone (30.0 mL) was added 3-bromoprop-1-yne (0.82 g, 6.89 mmol) and potassium carbonate (1.03 g, 7.46 mmol). The reaction mixture was stirred at room temperature for 8 hours. The reaction mixture was purified by CELITE TM The mixture was filtered through a pad of Celite(R) (Sigma-Aldrich, St. Louis, MO), and the filtrate was concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc = 1 / 1) to give 4-(prop-2-ynyl)morpholine (370 mg, 52%) as a yellow oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.27 (1H, s), 2.57 (4H, t, J = 4.8Hz), 3.29 (2H, t, J = 2.0Hz), 3.74 (4H, t, J = 4.4Hz).

[0255]

[0256] This example describes the synthesis of tert-butyl 4-(prop-2-ynyl)piperazine-1-carboxylate (Intermediate 3).

[0257]

[0258] To a mixture of tert-butyl piperazine-1-carboxylate (5.00 g, 26.8 mmol) and K2CO3 (7.42 g, 53.7 mmol) in CH3CN (140 mL) was added 3-bromoprop-1-yne (2.63 mL, 34.9 mmol) dropwise at 0°C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was purified by CELITE TM The reaction mixture was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO), and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (hexane / EtOAc=1 / 1) to give tert-butyl 4-(prop-2-ynyl)piperazine-1-carboxylate (5.39 g, 90%) as a yellow oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.46 (9H, s), 2.26 (1H, brs), 2.51 (4H, brs), 3.32 (2H, s), 3.47 (4H, t, J = 4.4Hz).

[0259]

[0260]

[0261] This example describes the synthesis of tert-butyl 4-propioloylpiperazine-1-carboxylate (Intermediate 4).

[0262]

[0263] To a solution of propiolic acid (0.67 g, 9.66 mmol) in dichloromethane (DCM) (22 mL) was added N, N'-dicyclohexylcarbodiimide (DCC) (1.76 mL, 9.66 mmol) at -5 ° C and stirred for 1 hour. To the reaction mixture was added tert-butyl piperazine-1-carboxylate (2.0 g, 10.74 mmol) and N, N-diisopropylethylamine (DIPEA) (5.75 mL, 32.2 mmol). The reaction mixture was stirred at room temperature for 1 hour. By CELITE TM The reaction mixture was filtered through a Celite® pad (Sigma-Aldrich, St. Louis, MO) and the filtrate was concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc = 1 / 1) to give tert-butyl 4-propioloylpiperazine-1-carboxylate (1.09 g, 43%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.47(9H,s), 3.15(1H,s), 3.43(2H,t,J=5.6Hz), 3.49(2H,t,J=5.6Hz), 3.61(2H,t,J=5.6Hz), 3.74(2H,t,J=5.6Hz).

[0264]

[0265] This Example describes the synthesis of tert-butyl 4-acryloylpiperazine-1-carboxylate (Intermediate 5).

[0266]

[0267] Triethylamine (TEA) (1.39 mL, 10.0 mmol) was added to a solution of acryloyl chloride (0.89 mL, 11.0 mmol) and tert-butyl piperazine-1-carboxylate in DCM (60 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was washed with water and saturated NaHCO (aqueous solution). The organic layer was dried over NaSO, filtered, and concentrated in vacuo to give tert-butyl 4-acryloylpiperazine-1-carboxylate (2.33 g, 97%) as a pale yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.37 (9H, s), 3.35 (8H, brs), 5.36 (1H, dd, J = 10.4Hz), 6.19 (1H, dd, J = 16.8Hz), 6.48 (1H, dd, J = 16.8Hz).

[0268]

[0269] This example describes the synthesis of tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (Intermediate 6).

[0270]

[0271] To a solution of tert-butyl piperazine-1-carboxylate (0.50 g, 2.68 mmol), 3-chloro-3-methylbut-1-yne (0.39 mL, 3.50 mmol) and TEA (0.48 mL, 3.50 mmol) in tetrahydrofuran (THF) (10.0 mL) was added copper (I) chloride (0.02 g, 0.19 mmol) under N2 atmosphere. The reaction mixture was stirred at room temperature for 30 minutes. Water-1N HCl (v / v=2 / 1, 3.0 mL) was poured into the mixture and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give tert-butyl 4- (2-methylbut-3-yne-2-yl) piperazine-1-carboxylate (0.66 g, 97%) as a milky white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.39(6H,s),1.46(9H,s),2.29(1H,s),2.58(4H,m),3.44-3.46(4H,m).

[0272]

[0273] This example describes the synthesis of 4-(2-methylbut-3-yn-2-yl)morpholine (Intermediate 7).

[0274]

[0275] To a solution of morpholine (0.50g, 5.74mmol), 3-chloro-3-methylbutan-1-ynes (0.83mL, 7.46mmol) and TEA (1.0mL, 7.46mmol) in THF (10.0mL) was added copper chloride (I) (0.04g, 0.40mmol) under N atmosphere. The reaction mixture was stirred at room temperature for 30 minutes. Water-1N HCl (v / v=2 / 1, 3.0mL) was poured into the mixture and extracted with EtOAc. The organic layer was dried over NaSO, filtered and concentrated in vacuo to give 4- (2-methylbutan-3-ynes-2-yl) morpholine (0.66g, 97%) as a milky white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.38(6H,s), 2.30(1H,s), 2.62-2.64(4H,m), 3.73-3.76(4H,m).

[0276]

[0277] This example describes the synthesis of 1-methyl-4-(prop-2-ynyl)piperazine (Intermediate 8).

[0278]

[0279] To a solution of 1-methylpiperazine (3.80 mL, 33.7 mmol) and KCO (4.70 g, 33.7 mmol) in acetone (40 mL) was added a solution of 3-bromoprop-1-yne (1.70 mL, 22.5 mmol) in acetone (10 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 4 hours and concentrated in vacuo. Water was poured into the residue and extracted with DCM. The organic layer was dried over NaSO, filtered and concentrated in vacuo to give 1-methyl-4-(prop-2-ynyl)piperazine (2.10 g, 45%) as a dark yellow oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.14-2.16 (1H, m), 2.19 (3H, s), 2.74-2.48 (8H, m), 3.17 (1H, d, J = 2.4Hz).

[0280]

[0281] Intermediate Example 9

[0282] This example describes the synthesis of 4-ethynyl-1-propyl-1H-pyrazole (Intermediate 9).

[0283]

[0284] Step A: 4-iodo-1-propyl-1H-pyrazole

[0285]

[0286] A mixture of 4-iodo-1H-pyrazole (500 mg, 2.58 mmol) and K2CO3 (430 mg, 3.09 mmol) in dimethylfuran (DMF) (10 mL) was stirred at room temperature for 5 minutes. 1-Iodopropane (0.28 mL, 2.84 mmol) was added to the mixture and stirred at room temperature for 17 hours. TM The reaction mixture was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO) and the filtrate was concentrated in vacuo. Water was added to the residue and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=7 / 3) to give 4-iodo-1-propyl-1H-pyrazole (430 mg, 71%) as a brown solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ0.61-0.67(3H,m), 1.57-1.67(2H,m), 3.81-3.86(2H,m), 7.22(1H,d,J=6.8Hz), 7.75(1H,d,J=6.4Hz).

[0287] Step B: 1-propyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole

[0288]

[0289] A mixture of 4-iodo-1-propyl-1H-pyrazole (430 mg, 1.82 mmol), ethynyltrimethylsilane (0.36 mL, 2.55 mmol), DIPEA (0.41 mL, 2.37 mmol), copper (I) iodide (21 mg, 0.11 mmol), PPh (96 mg, 0.36 mmol) and Pd (OAc) (29 mg, 0.13 mmol) in DMF (4 mL) was heated at 60 ° C for 3 hours under an Ar atmosphere. After cooling at room temperature, water was poured into the mixture, followed by extraction with EtOAc. The combined organic layers were dried over Na SO, filtered and concentrated in vacuo. The residue was purified by SiO column chromatography (hexane / EtOAc = 9 / 1) to give 1-propyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole (260 mg, 69%) as a brown oil. 1H-NMR (CDCl3, Varian, 400MHz): δ0.09 (9H, s), 0.66 (3H, t, J = 5.4 Hz), 1.59-1.68 (2H, m), 3.81 (2H, t, J = 6.8 Hz), 7.29 (1H, s), 7.37 (1H, s).

[0290] Step C: 4-Ethynyl-1-propyl-1H-pyrazole

[0291]

[0292] To a solution of 1-propyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole (260 mg, 1.26 mmol) in MeOH (8 mL) was added KCO (192 mg, 1.39 mmol) at room temperature. The reaction mixture was stirred at room temperature for 10 minutes, and the solvent was removed in vacuo. The residue was dissolved with EtOAc and washed with water. The organic layer was dried over NaSO, filtered and concentrated in vacuo to give 4-ethynyl-1-propyl-1H-pyrazole (120 mg, 71%) as a dark brown oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ0.90 (3H,t,J=7.6Hz), 1.84-1.90 (2H,m), 3.01 (1H,s), 4.05 (2H,t,J=7.2Hz), 7.54 (1H,s), 7.61 (1H,s).

[0293]

[0294] This example describes the synthesis of 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 10).

[0295]

[0296] Step A: Diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate

[0297]

[0298] To a solution of 2-(aminoethylidene) diethyl malonate (500mg, 2.67mmol) in dichloroethane (13mL) was added 1-fluoro-4-isocyanatobenzene (318 μL, 2.80mmol) at room temperature, followed by addition of DIPEA (513 μL, 2.94mmol). The reaction mixture was stirred at 100°C for 8 hours and cooled to room temperature. The resulting precipitate was collected by filtration, washed with Et2O, and dried under vacuum to give diethyl 2-((3-(4-fluorophenyl)urea groups)methylene) malonate (465mg, 54%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.22-1.29 (6H, m), 4.15 (2H, q, J = 7.2Hz), 4.24 (2H, q, J = 7.2Hz), 7.17-7.21(2H,m),7.49-7.53(2H,m),8.46(1H,d,J=12.8Hz), 10.41(1H,s),10.58(1H,d,J=12.4Hz).

[0299] Step B: Ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0300]

[0301] To a solution of diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate (465 mg, 1.43 mmol) in EtOH (7 mL) was added NaOEt (156 mg, 2.29 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was distributed over EtOAc and 30% citric acid (aqueous solution) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was ground with DCM and isopropyl ether (IPE) to give ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (342 mg, 86%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ 1.23 (3H, t, J = 7.2 Hz), 4.18 (2H, q, J = 7.2 Hz), 7.29-7.31 (4H, m), 8.25 (1H, s). *NH peak not observed.

[0302] Step C: Ethyl 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0303]

[0304] To a solution of 3- (4- fluorophenyl) -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid ethyl ester (342 mg, 1.23 mmol) in DMF (3 mL) was added K2CO3 (340 mg, 2.46 mmol) at room temperature, followed by 2- iodopropane (246 μL, 2.46 mmol). The reaction mixture was stirred at 70 ° C overnight and quenched with saturated NH4Cl solution (aqueous solution). The aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc = 3 / 2) to give 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid ethyl ester (276 mg, 70%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.36 (3H, t, J = 7.2Hz), 1.45 (6H, d, J = 6.8Hz), 4.35 (2H, q, J = 7.2Hz), 4.89-4.95 (1H, m), 7.17-7.18 (4H, m), 8.36 (1H, s).

[0305] Step D: 3-(4-Fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0306]

[0307] A mixture of ethyl 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (276 mg, 0.86 mmol) and HCl (1.08 mL, 4.31 mmol; 4 M solution in dioxane) in water (0.25 mL) was stirred at 70 ° C. overnight. After cooling at room temperature, water was added to the reaction mixture. The resulting precipitate was collected by filtration, washed with water and hexanes, and dried under vacuum to give 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (202 mg, 80%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ 1.38 (6H, d, J = 6.8 Hz), 4.69-4.74 (1H, m), 7.30-7.35 (4H, m), 8.58 (1H, s). *COOH peak not observed.

[0308]

[0309] This example describes the synthesis of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 11).

[0310]

[0311] Step A: tert-Butyl 4-chloropyridin-2-ylcarbamate

[0312]

[0313] To a solution of 4-chloropyridin-2-amine (3.00 g, 23.3 mmol) in THF (200 mL) was added NaHMDS (1 M in THF, 46.7 mL, 46.7 mmol) at -10 ° C. A solution of di-tert-butyl dicarbonate (5.09 g, 23.34 mmol) in THF (10 mL) was then added at the same temperature. The reaction mixture was stirred at room temperature for 16 hours. Saturated NH4Cl was added to the reaction mixture, and the layers were separated. The aqueous phase was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give tert-butyl 4-chloropyridin-2-ylcarbamate (5.00 g, 94%) as a brown solid, which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.53 (9H, s), 6.95-6.97 (1H, m), 7.59 (1H, brs), 8.04 (1H, s), 8.13 (1H, d, J = 5.6Hz).

[0314] Step B: tert-Butyl 4-chloro-3-iodopyridin-2-ylcarbamate

[0315]

[0316] n-BuLi (2M in hexane, 8.75mL, 21.9mmol) was added dropwise to a solution of tert-butyl 4-chloropyridin-2-ylcarbamate (2.00g, 8.75mmol) and tetramethylethylenediamine (TMEDA) (3.27mL, 21.87mmol) in THF (292mL) at -78°C for 30 minutes. The mixture was stirred at the same temperature for 1 hour, followed by addition of THF (100mL) containing I (11.1g, 43.7mmol). After completion of the addition, the reaction mixture was stirred at -78°C for 30 minutes, then allowed to warm to room temperature. The mixture was treated with a solution of sodium bisulfite (16.0g) in H2O (100mL), stirred for 30 minutes, and then extracted with EtOAc. The extract was washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (hexane / EtOAc=1 / 1) to give tert-butyl 4-chloro-3-iodopyridin-2-ylcarbamate (2.10 g, 68%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.45 (9H,s), 7.48 (1H,d,J=4.8Hz), 8.30 (1H,d,J=4.8Hz), 9.48 (1H,s).

[0317] Step C: 4-Chloro-3-iodopyridin-2-amine

[0318]

[0319] The suspension of 4-chloro-3-iodopyridin-2-yl tert-butyl carbamate (2.10g, 5.92mmol) in HBr (10mL, 5.92mmol) was heated at 0°C for 10 minutes to obtain a clear solution. After cooling at 0°C, the reaction mixture was treated with crushed ice and basified with 6M NaOH (aqueous solution). The precipitated product was collected by vacuum filtration, washed with water and partially sucked on a funnel to obtain a white solid. The product was dissolved in THF, and the solution was dried and concentrated in a vacuum to obtain 4-chloro-3-iodopyridine-2-amine (1.50g, quantitative) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ6.43 (2H, s), 6.72 (1H, d, J = 5.2Hz), 7.84 (1H, d, J = 5.2Hz).

[0320] Step D: 4-(2-Fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine

[0321]

[0322] A mixture of 4-chloro-3-iodopyridin-2-amine (1.50 g, 5.89 mmol), 2-fluoro-4-nitrophenol (1.85 g, 11.8 mmol), DIPEA (1.54 mL, 8.84 mmol) and N-methylpyrrolidone (NMP) (8 mL) was placed in a glass pressure vessel and rapidly heated to 170 ° C. The heating lasted for 18 hours. After cooling at room temperature, the reaction mixture was dissolved in EtOAc and washed with saturated NaHCO solution (aqueous solution). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=3 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (1.48 g, 67%) as a light yellow solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ6.19 (1H, d, J = 5.6Hz), 6.41 (2H, s), 7.33 (1H, t ,J=8.6Hz),7.87(1H,d,J=5.6Hz),8.11-8.14(1H,m),8.40(1H,dd,J=2.4,10.4Hz).

[0323] Step E: 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine

[0324]

[0325] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (150 mg, 0.40 mmol) and SnCl2 (361 mg, 1.60 mmol) in EtOH (10 mL) was vigorously stirred at 90 ° C for 2 hours. After cooling at room temperature, the solvent was removed under reduced pressure and EtOAc was poured into the residue. The mixture was neutralized with saturated NaHCO3 (aqueous solution) and 2N NaOH until pH 9, and then filtered through CELITE HPLC. TM The filtrate was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO). The filtrate was extracted with EtOAc, dried over NaSO, and concentrated in vacuo to give 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (130 mg, 94%) as a yellow solid, which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400MHz): δ3.78 (2H, brs), 5.08 (2H, brs), 5.87 (1H, d, J = 5.6Hz), 6.44-6.53 (2H, m), 6.97 (1H, t, J = 8.8Hz), 7.76 (1H, d, J = 5.6Hz)

[0326] Step F: N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0327]

[0328] To a mixture of 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 11, 2.12 g, 7.24 mmol) and hexafluorophosphate (HATU) (3.03 g, 7.97 mmol) was added EA (3.15 mL, 18.1 mmol) in DMF (18 mL) at room temperature and stirred for 1 hour. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (2.50 g, 7.24 mmol) was added to the reaction mixture and stirred at room temperature for 3 hours. Water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbamate (3.60 g, 80%) as a beige solid which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400MHz): δ10.9(1H,s),8.68(1H,s),7.82-7.79(2H,m),7.26-7.25(4H,m),7.19(1H,d, J=9.2Hz), 6.95(1H,t,J=8.4Hz), 6.02(1H,d,J=6.0Hz), 5.09(2H,s), 5.01-4.94(1H,m), 1.49(6H,d,J=6.4Hz).

[0329]

[0330] This example describes the synthesis of tert-butyl 4-(3-(2-amino-4-(4-amino-2-fluorophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate (Intermediate 12).

[0331]

[0332] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-nitrophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate

[0333]

[0334] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (Intermediate 11, step D, 1.00 g, 2.67 mmol), tert-butyl 4-propioloylpiperazine-1-carboxylate (Intermediate 4, 953 mg, 4.00 mmol) and TEA (1.49 mL, 10.7 mmol) in DMF (9 mL) was added copper (I) iodide (102 mg, 0.53 mmol) and Pd (PPh 3 ) 4 (308 mg 0.27 mmol) at room temperature under N 2. The reaction mixture was microwaved at 90° C. for 1 hour. The mixture was concentrated in vacuo, and the residue was purified by SiO2 column chromatography (EtOAc / MeOH=97 / 3) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-nitrophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate (1.04 g, 80%) as a brown solid. 1 H-NMR(CDCl3,Varian,400MHz): δ1.47(9H,s),3.43(4H,brs),3.64(2H brs), 3.73 (2H, brs), 5.35 (2H, brs), 6.10 (1H, d, J = 6.0Hz), 7.29 (1H, d, J = 8.4Hz), 8.03 (1H, d, J = 6.0Hz), 8.14 (2H, t, J = 10.4Hz).

[0335] Step B: tert-Butyl 4-(3-(2-amino-4-(4-amino-2-fluorophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate

[0336]

[0337] A mixture of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-nitrophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate (1.04 g, 2.14 mmol), zinc (1.40 g, 21.4 mmol) and ammonium chloride (1.15 g, 21.4 mmol) in THF / MeOH (v / v=1 / 1, 22 mL) was stirred at 60° C. for 45 minutes. The reaction mixture was filtered and the filtrate was partitioned between EtOAc and saturated NaHCO (aqueous solution). The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na SO and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / MeOH=95 / 5) to give tert-butyl 4-(3-(2-amino-4-(4-amino-2-fluorophenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate (636 mg, 65%) as a yellow solid. 1H-NMR(CDCl3,Varian,400MHz): δ1.46(9H,s),3.45(4H,brs),3.65(2H brs),3.81(2H,brs),3.85(2H,brs),5.22(2H,brs),5.98(1H,d,J=6.0Hz),6.45(1H,d ,J=8.4Hz), 6.51(1H,dd,J=11.6,2.4Hz), 6.93(1H,t,J=8.4Hz), 7.90(1H,d,J=6.0Hz).

[0338]

[0339] This example describes the synthesis of tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (Intermediate 13).

[0340]

[0341] Step A: 4-Methylbenzenesulfonyl azide

[0342]

[0343] To a solution of 4-methylbenzene-1-sulfonyl chloride (5.0 g, 26.2 mmol) in acetone (65 mL) was added a solution of sodium azide (2.56 g, 39.3 mmol) in water (65 mL) at 0 ° C. The reaction mixture was allowed to warm to room temperature and stirred for 3 hours. Acetone was removed in vacuo, and the mixture was extracted with DCM. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo to give 4-methylbenzenesulfonyl azide (4.9 g, 95%) as a colorless oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.46 (3H, s), 7.39 (2H, d, J = 8.4Hz), 7.82 (2H, d, J = 8.0Hz).

[0344] Step B: Dimethyl 1-diazo-2-oxopropylphosphonate

[0345]

[0346] To a stirred suspension of sodium hydride (4.9 g, 24.9 mmol) in toluene (50 mL) and THF (16 mL) was added a solution of dimethyl 2-oxopropylphosphonate (3.78 mL, 27.3 mmol) in toluene (6 mL) at 0 ° C. A white solid was formed and stirring was continued for 1 hour. A solution of 4-methylbenzenesulfonyl azide (1.19 g, 27.3 mmol) in toluene (10 mL) was added. The reaction mixture was stirred at room temperature for 12 hours, then filtered through a pad of celite. The filtrate was evaporated in vacuo to remove volatile materials. The residue was purified by SiO2 column chromatography (hexane / EtOAc=1 / 1) to obtain dimethyl 1-diazo-2-oxopropylphosphonate (3.4 g, 71%) as a yellow oil. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.16(3H,s), 3.73(3H,s), 3.76(3H,s).

[0347] Step C: tert-Butyl 4-(prop-2-ynyl)piperidine-1-carboxylate

[0348]

[0349] To a solution of tert-butyl 4-(2-oxoethyl)piperidine-1-carboxylate (3.3 g, 14.5 mmol) and potassium carbonate (4.01 g, 29.0 mmol) in MeOH (48 mL) was added dimethyl 1-diazo-2-oxopropylphosphonate (3.35 g, 17.4 mmol) at 0°C. The reaction mixture was stirred at room temperature for 12 hours. The mixture was then extracted with EtOAc, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=2 / 1) to give tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (2.9 g, 89%) as a light yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.02-1.16(2H,m),1.32(9H,s),1.38-1.56(1H,m),1.63(2H ,d,J=12.8Hz), 1.87(1H,t,J=2.4Hz), 2.01(2H,dd,J=2.2,6.6Hz), 2.56(2H,s), 3.98(2H,s).

[0350]

[0351] This example describes the synthesis of 1-methyl-4-(prop-2-ynyl)piperidine hydrochloride (Intermediate 14).

[0352]

[0353] Step A: 4-(Prop-2-ynyl)piperidine hydrochloride

[0354]

[0355] A mixture of tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (1.2 g, 5.37 mmol) and HCl (4 M in dioxane, 8.0 mL, 269 mmol) in DCM (20 mL) was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the residue was triturated with diethyl ether. The precipitated solid was collected by filtration to give 4-(prop-2-ynyl)piperidine hydrochloride (739 mg, 86%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.34-1.44(2H,m),1.66-1.71(1H,m),1.79(2H,d,J=13.6Hz),2.14(2H ,dd,J=2.4,6.0Hz), 2.79(2H,t,J=12.2Hz), 2.88(1H,d,J=2.4Hz), 3.20(2H,d,J=12.8Hz), 8.78(1H,s).

[0356] Step B: 1-Methyl-4-(prop-2-ynyl)piperidine hydrochloride

[0357]

[0358] A mixture of 4- (prop-2-ynyl) piperidine hydrochloride (739 mg, 4.63 mmol), formaldehyde (37 wt.% aqueous solution, 0.26 mL, 6.94 mmol), sodium cyanoborohydride (582 mg, 9.26 mmol) and acetic acid (0.53 mL, 9.26 mmol) in MeOH (23 mL) was stirred at room temperature for 18 hours. The reaction mixture was quenched with NaHCO (aqueous solution) and extracted with DCM, dried over NaSO, filtered and concentrated in vacuo. The residue was ground together with ether containing HCl. The precipitated solid was collected by filtration to obtain 1- methyl -4- (prop-2-ynyl) piperidine hydrochloride (410 mg, 51%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.73-1.83(2H,m),1.93-1.96(1H,m),1.98-2.09 (3H,m),2.22-2.24(2H,m),2.68-2.76(2H,m),2.78(3H,s),3.54(2H,d,J=12.0Hz).

[0359]

[0360] This example describes the synthesis of 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 15).

[0361]

[0362] Step A: Diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate

[0363]

[0364] To a solution of diethyl 2-(aminoethylidene) malonate (1.0g, 5.34mmol) in dichloroethane (1.5mL) was added 1-fluoro-4-isocyanatobenzene (0.64mL, 5.61mmol) at room temperature, followed by addition of DIPEA (1.03mL, 2.94mmol). The reaction mixture was stirred at 100°C for 6 hours and cooled to room temperature. The solvent was removed in a vacuum. The resulting precipitate was collected by filtration, washed with Et2O, and dried under vacuum to obtain diethyl 2-((3-(4-fluorophenyl)urea groups)methylene) malonate (776mg, 44%) as a brown solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.22-1.29 (6H, m), 4.15 (2H, q, J = 7.2Hz), 4.24 (2H, q, J = 7.2Hz), 7.17-7.21(2H,m),7.49-7.53(2H,m),8.46(1H,d,J=12.8Hz), 10.41(1H,s),10.58(1H,d,J=12.4Hz).

[0365] Step B: Ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0366]

[0367] To a solution of diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate (776 mg, 2.39 mmol) in EtOH (6 mL) was added NaOEt (261 mg, 3.83 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was distributed over EtOAc and 1M citric acid (aqueous solution) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was ground with diethyl ether and hexane to give ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (562 mg, 85%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ 1.23 (3H, t, J = 7.2 Hz), 4.18 (2H, q, J = 7.2 Hz), 7.29-7.31 (4H, m), 8.25 (1H, s). *NH peak not observed.

[0368] Step C: Ethyl 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0369]

[0370] To a solution of ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (510 mg, 1.83 mmol) in DMF (5 mL) was added K2CO3 (507 mg, 3.67 mmol) at room temperature, followed by 2-chloro-N,N-dimethylacetamide (0.38 mL, 3.67 mmol). The reaction mixture was heated in a sealed tube at 70 ° C overnight. The reaction mixture was diluted with EtOAc and then filtered through a celite pad. The filtrate was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc only) to give ethyl 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (560 mg, 84%) as a slightly yellowish white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.33(3H,t,J=6.8Hz), 3.01(3H,s), 3.06(3H,s), 4.29-4.35(2H,m), 4.65(2H,s), 7.12-7.25(4H,m), 8.25(1H,s).

[0371] Step D: 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0372]

[0373] A mixture of 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (560 mg, 1.54 mmol) and HCl (4M in dioxane, 1.93 mL, 7.71 mmol) in water (0.5 mL) was stirred at 70 ° C overnight. After cooling at room temperature, water was added to the reaction mixture. The reaction mixture was extracted with DCM, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The resulting residue was triturated with hexane to give 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (419 mg, 81%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ2.84(3H,s),2.97(3H,s),4.85(2H,s),7.29-7.31(4H,m),8.65(1H,s),12.58(1H,s).

[0374]

[0375] This example describes the synthesis of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16).

[0376]

[0377] Step A: 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine

[0378]

[0379] By 4- (2- fluoro- 4- nitrophenoxy) -3- iodopyridine -2- amine (1.04g, 2.77mmol) and SnCl2 (2.1g, 11.09mmol) in EtOH (27mL) mixture is vigorously stirred at 90 DEG C for 2 hours.After cooling at room temperature, solvent is removed under reduced pressure, and EtOAc is poured into residue. The mixture is neutralized with 2N NaOH solution until pH is 9, then filtered through celite pad. The filtrate is extracted with EtOAc, used Na2SO4 dry, and concentrated in vacuo to obtain 4- (4- amino -2- fluorophenoxy) -3- iodopyridine -2- amine (914mg, 96%) as a yellow solid, which is used for the next step without further purification. 1 H-NMR (CDCl3, Varian, 400MHz): δ3.78 (2H, brs), 5.08 (2H, brs), 5.87 (1H, d, J = 5.6Hz), 6.44-6.53 (2H, m), 6.97 (1H, t, J = 8.8Hz), 7.76 (1H, d, J = 5.6Hz)

[0380] Step B: N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0381]

[0382] To a mixture of 1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 15, 194 mg, 0.58 mmol) and HATU (331 mg, 0.87 mmol) was added DIPEA (0.30 mL, 1.74 mmol) in DMF (5.8 mL) at room temperature and stirred for 10 minutes. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (200 mg, 0.58 mmol) was added to the reaction mixture at room temperature and stirred overnight. Cold water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (375 mg, 98%) as a beige solid which was used in the next step without further purification. 1H-NMR (DMSO-d6,Varian,400MHz): δ2.85(3H,s),3.00(3H,s),4.93(2H,s),5.79(1H,d,J=5.6Hz),6.23(2H,s),7.28-7 .23(1H,m),7.36-7.23(4H,m),7.46-7.44(1H,m),7.71(1H,d,J=5.6Hz),7.92-7.89(1H,m),8.75(1H,s),10.89(1H,s).

[0383]

[0384] This example describes the synthesis of 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 17).

[0385]

[0386] Step A: Diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate

[0387]

[0388] To a solution of diethyl 2-(aminoethylidene) malonate (3.0g, 16.03mmol) in dichloroethane (4.5mL) was added 1-fluoro-4-isocyanatobenzene (1.9mL, 16.83mmol) at room temperature, followed by addition of DIPEA (3.08mL, 17.63mmol). The reaction mixture was stirred at 100°C for 6 hours. After cooling to room temperature, the solvent was removed in vacuo. The resulting precipitate was collected by filtration, washed with Et2O, and dried under vacuum to give diethyl 2-((3-(4-fluorophenyl)urea groups)methylene) malonate (1.79g, 34%) as a brown solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.22-1.29 (6H, m), 4.15 (2H, q, J = 7.2Hz), 4.24 (2H, q, J = 7.2Hz), 7.17-7.21(2H,m),7.49-7.53(2H,m),8.46(1H,d,J=12.8Hz), 10.41(1H,s),10.58(1H,d,J=12.4Hz).

[0389] Step B: Ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0390]

[0391] To a solution of diethyl 2-((3-(4-fluorophenyl)ureido)methylene)malonate (1.79 g, 5.54 mmol) in EtOH (14 mL) was added NaOEt (604 mg, 8.87 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 2 hours and concentrated in vacuo. The residue was distributed over EtOAc and 1M citric acid (aqueous solution) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was ground with diethyl ether and hexane to give ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.4 g, 91%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ 1.23 (3H, t, J = 7.2 Hz), 4.18 (2H, q, J = 7.2 Hz), 7.29-7.31 (4H, m), 8.25 (1H, s). *NH peak not observed.

[0392] Step C: Ethyl 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0393]

[0394] To a solution of ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (600 mg, 2.15 mmol) in DMF (6 mL) was added KCO (596 mg, 4.31 mmol) at room temperature followed by 24-(chloromethyl)-2-methylthiazole (0.5 mL, 4.31 mmol). The reaction mixture was heated at 70 ° C in a sealed tube overnight. The reaction mixture was diluted with EtOAc and then filtered through a pad of celite. The filtrate was extracted with EtOAc, washed with brine, dried over NaSO, filtered and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (EtOAc / hexane = 1 / 1 to EtOAc only) to give ethyl 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (608 mg, 72%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.24-1.20(3H,m),2.62(3H,s),4.16-4.21(2H,m),5.10(2H,s),7.26-7.28(4H,m),7.46(1H,s),8.73(1H,s).

[0395] Step D: 3-(4-Fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0396]

[0397] A mixture of ethyl 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (608 mg, 1.56 mmol) and HCl (4M in dioxane, 2.0 mL, 7.82 mmol) in water (0.5 mL) was stirred at 70 ° C overnight. After cooling at room temperature, water was added to the reaction mixture. The reaction mixture was extracted with DCM, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The resulting residue was triturated with hexane to give 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (565 mg, quantitative) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ2.62(3H,s),5.12(2H,s),7.27-7.35(4H,m),7.47(1H,s),8.83(1H,s),12.63(1H,brs).

[0398]

[0399] This example describes the synthesis of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18).

[0400]

[0401] To a mixture of 3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 17, 209 mg, 0.58 mmol) and HATU (331 mg, 0.87 mmol) was added DIPEA (0.30 mL, 1.74 mmol) in DMF (2 mL) at room temperature and stirred for 10 minutes. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (200 mg, 0.58 mmol) was added to the reaction mixture at room temperature and stirred overnight. Cold water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (318 mg, 80%) as a beige solid which was used in the next step without further purification. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ2.66 (3H, s), 5.20 (2H, s), 5.78 (1H, d, J = 5.6Hz), 6.19 (2 H,s),7.45-7.22(7H,m),7.71(1H,d,J=6Hz),7.93-7.89(1H,m),8.83(1H,s),10.94(1H,s).

[0402]

[0403] This example describes the synthesis of 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid (Intermediate 19).

[0404]

[0405] Step A: Ethyl 4-(4-fluorophenyl)-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate

[0406]

[0407] A mixture of diethyl 2-oxomalonate (2.5 mL, 16.20 mmol) and N-(4-fluorophenyl)hydrazinethioamide (3.0 g, 16.20 mmol) in EtOH (60 mL) was heated under reflux for 3 days (72 hours). The mixture was cooled to room temperature, and the resulting precipitate was collected by filtration and dried under vacuum to give ethyl 4-(4-fluorophenyl)-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (2.88 g, 60%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.25 (3H, t, J = 7.2Hz), 4.27 (2H, q, J = 7.2Hz), 7.31 (4H, d, J = 7.2Hz)

[0408] Step B: Ethyl 4-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate

[0409]

[0410] To a solution of 4-(4-fluorophenyl)-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid ethyl ester (2.88 g, 9.78 mmol) in DMF (25 mL) and AcOH (10.64 mL, 186 mmol) was added H2O2 (35% aqueous solution, 5.14 mL, 58.7 mmol). The mixture was stirred at room temperature for 2 days (48 hours). The reaction mixture was extracted with EtOAc and water and washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude material was ground with DCM and hexane to give 4-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid ethyl ester (2.40 g, 88%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.24 (3H, t, J = 7.2Hz), 4.26 (2H, q, J = 7.2Hz), 7.29-7.38 (4H, m), 13.15 (s, 1H).

[0411] Step C: Ethyl 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate

[0412]

[0413] To a solution of ethyl 4-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (2.40 g, 8.61 mmol) in DMF (20 mL) was added K2CO3 (3.93 g, 28.4 mmol) and MeI (4.85 mL, 77.0 mmol). The mixture was stirred at 60 ° C overnight. The residue was diluted with EtOAc, then filtered through a celite pad and washed with EtOAc. The filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=2 / 1) to give ethyl 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (1.84 g, 73%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.25 (3H, t, J = 7.2Hz), 3.57 (3H, s), 4.28 (2H, q, J = 6.8Hz), 7.33 (4H, d, J = 6.4Hz).

[0414] Step D: 4-(4-Fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid

[0415]

[0416] A mixture of ethyl 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylate (1.74 g, 5.94 mmol) and HCl (4M in dioxane, 7.43 mL, 29.7 mmol) in water (2 mL) was stirred at 70 ° C for 2 days (48 hours). After cooling at room temperature, water was added to the reaction mixture. The resulting precipitate was collected by filtration, washed with water and hexane, and dried under vacuum to give 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid (1.57 g, quantitative) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ3.55 (3H, s), 7.32-7.34 (4H, m).

[0417]

[0418] This example describes the synthesis of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20).

[0419]

[0420] To a mixture of 4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxylic acid (Intermediate 19, 660 mg, 2.51 mmol) and HATU (1.43 g, 3.76 mmol) was added DIPEA (1.31 mL, 7.53 mmol) in DMF (13 mL) at room temperature and stirred for 10 minutes. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (860 mg, 2.51 mmol) was added to the reaction mixture at room temperature and stirred overnight. Cold water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (1.3 g, 88%) as a beige solid which was used in the next step without further purification. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ3.65 (3H, s), 5.79 (1H, d, J = 5.6Hz), 6.25 (2H, brs), 7.28- 7.38(5H,m),7.49-7.52(1H,m),7.71(1H,d,J=5.6Hz),7.88(1H,d,J=12.4Hz),10.87(1H,s).

[0421]

[0422] This example describes the synthesis of 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 21).

[0423]

[0424] A mixture of ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.0 g, 3.59 mmol) and HCl (4 M in dioxane, 4.49 mL, 17.97 mmol) in water (1.2 mL) was stirred at 70 ° C overnight. After cooling at room temperature, water was added to the reaction mixture. The resulting precipitate was collected by filtration, washed with water and hexane, and dried under vacuum to give 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (776 mg, 86%) as a beige solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ7.27-7.36 (4H, m), 8.35 (1H, s), 12.30 (1H, brs), 12.54 (1H, brs).

[0425]

[0426] This example describes the synthesis of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 22).

[0427]

[0428] To a mixture of 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 21, 636 mg, 2.54 mmol) and HATU (1.45 g, 3.82 mmol) was added DIPEA (1.33 mL, 7.63 mmol) in DMF (11 mL) at room temperature and stirred for 10 minutes. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (877 mg, 2.54 mmol) was added to the reaction mixture at room temperature and stirred overnight. Water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.31 g, 89%) as a yellow solid which was used in the next step without further purification. 1H-NMR (DMSO-d6, Varian, 400 MHz): δ 5.80 (1H, d, J = 5.6 Hz), 6.21 (2H, s), 7.28-7.23 (1H, t, J = 8.8 Hz), 7.45-7.32 (5H, m), 7.73 (1H, d, J = 5.2 Hz), 7.92-7.89 (1H, m), 8.44 (1H, s), 10.96 (1H, s). *NH peak not observed.

[0429]

[0430] This example describes the synthesis of 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 23).

[0431]

[0432] Step A: Ethyl 3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0433]

[0434] To a mixture of ethyl 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.0 g, 3.59 mmol) and KCO (993 mg, 7.19 mmol) in DMF (10 mL) was added 4-bromotetrahydro-2H-pyran (809 μL, 7.19 mmol). The mixture was heated overnight at 100 ° C in a sealed tube. After cooling to room temperature, the reaction mixture was diluted with EtOAc and filtered through a celite pad. The filtrate was washed with water and brine, dried over NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (hexane / EtOAc=1 / 1) to give ethyl 3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (457 mg, 35%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.36 (3H, t, J = 6.8Hz), 1.93-1.98 (4H, m), 3.50-3.58 (2H, m) ,4.13-4.16(2H,m),4.35(2H,q,J=6.8Hz),4.75-4.83(1H,m),7.17-7.19(4H,m),8.36(1H,s)

[0435] Step B: 3-(4-Fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0436]

[0437] A mixture of ethyl 3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate (457 mg, 1.26 mmol) and HCl (4M in dioxane, 1.58 mL, 6.32 mmol) in water (1 mL) was stirred at 70 ° C overnight. After cooling at room temperature, water was added to the reaction mixture. The reaction mixture was extracted with DCM, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The resulting residue was triturated with hexane to give 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (282 mg, 67%) as a beige solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.94-1.99(4H,m),3.49-3.56(2H,m),4.13-4 .16(2H,m),4.75-4.83(1H,m),7.22-7.26(4H,m),8.58(1H,s),12.28(1H,brs).

[0438]

[0439] This example describes the synthesis of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24).

[0440]

[0441] To a mixture of 3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 23, 273 mg, 0.82 mmol) and HATU (466 mg, 1.23 mmol) was added DIPEA (0.43 mL, 2.45 mmol) in DMF (8 mL) at room temperature and stirred for 10 minutes. 4-(4-amino-2-fluorophenoxy)-3-iodopyridin-2-amine (282 mg, 0.82 mmol) was added to the reaction mixture at room temperature and stirred overnight. Water was poured into the reaction mixture. The resulting solid was collected by filtration, washed with water and diethyl ether, and dried under vacuum to give N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (490 mg, 91%) as a cream-colored solid which was used in the next step without further purification. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.83-1.88(2H,m),1.96-2.03(2H,m),3.35-3.45(2H,m),3.96-3.98(2H,m),4.60-4.64(1H,m),5.78(1H,d,J=6. 0Hz),6.19(2H,s),7.24(1H,t,J=8.8Hz),7.31-7.35(2H,m),7.38-7.45(3 H,m),7.71(1H,d,J=5.6Hz),7.90-7.94(1H,m),8.61(1H,s),10.94(1H,s).

[0442]

[0443] This example describes the synthesis of 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 25).

[0444]

[0445] Step A: Diethyl 2-((3-cyclohexylureido)methylene)malonate

[0446]

[0447] A mixture of diethyl 2-(aminomethylene) malonate (3.0 g, 16.03 mmol), DIPEA (3.36 mL, 19.23 mmol), isocyanatocyclohexane (2.25 mL, 17.63 mmol) in DCE (160 mL) was refluxed for 48 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed with brine. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane=1 / 1) to give diethyl 2-((3-cyclohexylurea)methylene) malonate (4.00 g, 80%) as a yellow oil. 1 H-NMR(DMSO-d6,Varian,400MHz): δ1.10-1.24(11H,m),1.49-1.52(1H,m),1.60-1.70(2H,m),1.71-1.80(2H,m),3.47(1H , brs) 4.09 (2H, q, J = 7.0Hz), 4.17 (2H, q, J = 6.9Hz), 8.04 (1H, d, J = 7.6Hz), 8.40 (1H, d, J = 13.2Hz), 10.28 (1H, d, J = 12.8Hz).

[0448] Step B: Ethyl 3-cyclohexyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0449]

[0450] A mixture of diethyl 2-((3-cyclohexylureido)methylene)malonate (1.10 g, 3.52 mmol) and NaOEt (359 mg, 5.28 mmol) in EtOH (35.2 mL) was refluxed for 18 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with EtOAc and washed with brine. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane=1 / 1) to give ethyl 3-cyclohexyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (320 mg, 34%) as a white solid. 1 H-NMR(DMSO-d6,Varian,400MHz): δ1.07-1.26(6H,m),1.47-1.50(2H,m),1.54-1.61(1H,m), 1.70-1.80(2H,m),2.20-2.30(2H,m),4.08(2H,q,J=7.2Hz),4.51-4.60(1H,m),8.05(1H,s).

[0451] Step C: Ethyl 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0452]

[0453] A mixture of 3-cyclohexyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (220 mg, 0.83 mmol), K2CO (171 mg, 1.24 mmol) and iodoethane (80.0 μL, 0.99 mmol) in DMF (8.26 mL) was stirred at 70 ° C for 6 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed with brine. The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane=1 / 1) to give 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (130 mg, 53%) as a yellow solid. 1 H-NMR(DMSO-d6,Varian,400MHz): δ1.16-1.30(9H,m),1.45-1.50(2H,m),1.55-1.64(1H,m),1.70-1.80 (2H,m),2.22-2.31(2H,m),3.82(2H,q,J=7.1Hz),4.16(2H,q,J=7.1Hz),4.60-4.66(1H,m),8.46(1H,s).

[0454] Step D: 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0455]

[0456] A mixture of 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (130 mg, 0.44 mmol) and LiOH (106 mg, 4.42 mmol) in EtOH (3.68 mL) and water (0.74 mL) was stirred at room temperature for 6 hours. The reaction mixture was concentrated under vacuum and acidified with 1N HCl aqueous solution. The precipitated solid was collected by filtration and dried in vacuo to give 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (110 mg, 94%) as a white solid, which was used in the next step without further purification. 1H-NMR(DMSO-d6,Varian,400MHz): δ1.08-1.31(7H,m),1.56-1.62(2H,m),1.75-1.78(2H,m) ,2.21-2.30(2H,m),3.87(2H,q,J=7.1Hz),4.62-4.68(1H,m),8.67(1H,s),12.95(1H,brs).

[0457]

[0458] This example describes the synthesis of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 26).

[0459]

[0460] A mixture of 3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (intermediate 26, 110 mg, 0.41 mmol), HATU (236 mg, 0.62 mmol), DIPEA (0.22 mL, 1.24 mmol) and 4-(4-amino-2-fluorophenoxy)-3-iodopyridine-2-amine (143 mg, 0.41 mmol) in DMF (4.13 mL) was stirred for 4 hours at room temperature. The reaction mixture was diluted with EtOAc and washed with brine. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane = 1 / 1) to give N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (180 mg, 73%) as a yellow solid. 1 H-NMR(DMSO-d6,Varian,400MHz): δ1.17-1.34(6H,m),1.55-1.61(3H,m),1. 78-1.80(2H,m),2.30-2.33(2H,m),3.91-3.99(2H,m),4.47-4.74(1H,m),5. 79(1H,d,J=5.6Hz),6.20(2H,s),7.26(1H,t,J=8.8Hz),7.45(1H,d,J=8.0Hz ),7.72(1H,d,J=5.6Hz),7.92(1H,d,J=14.8Hz),8.69(1H,s),11.15(1H,s).

[0461] Intermediate Example 27

[0462] This example describes the synthesis of 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 27).

[0463]

[0464] Step A: Ethyl 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0465]

[0466] A mixture of ethyl 2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.0 g, 5.43 mmol), K2CO3 (1.87 g, 13.6 mmol) and 3-iodoprop-1-ene (1.24 mL, 13.6 mmol) in DMF (54.3 mL) was stirred at 80 ° C for 6 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc and washed with brine. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane=1 / 1) to give ethyl 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.1 g, 77%) as a yellow oil. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.22 (3H, t, J = 7.0Hz), 4.18 (2H, q, J = 7.6Hz), 4.38 (2H, d, J = 5.2Hz), 4.4 7(2H,d,J=5.6Hz),5.07-5.09(2H,m),5.16-5.21(2H,m),5.73-5.83(1H,m),5.86-5.95(1H,m),8.48(1H,s)

[0467] Step B: 1,3-Diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0468]

[0469] A mixture of 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester (1.1 g, 4.16 mmol) and LiOH (997 mg, 41.6 mmol) in EtOH (41.6 mL) was stirred at room temperature for 18 hours. The reaction mixture was acidified with 1N HCl aqueous solution and extracted with EtOAc. The separated organic layer was dried with Na2SO4, filtered and concentrated under vacuum to give 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (810 mg, 82%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ4.41 (2H, d, J = 5.2 Hz), 4.50 (2H, d, J = 4.8 Hz), 5.07-5.11 (2H, m), 5.19-5.24 (2H, m), 5.76-5.94 (2H, m), 8.61 (1H, s) *No protons from OH were observed.

[0470]

[0471] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28).

[0472]

[0473] A mixture of 1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (810 mg, 3.43 mmol), HATU (1.96 g, 5.14 mmol), DIPEA (1.78 mL, 10.29 mmol) and 4- (4-amino-2-fluorophenoxy) -3-iodopyridine-2-amine (1.18 g, 3.43 mmol) in DMF (34.3 mL) was stirred at room temperature for 4 hours. The reaction mixture was diluted with EtOAc and washed with brine. The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / hexane = 1 / 1) to give 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.5 g, 78%) as a yellow solid. 1H-NMR (DMSO-d6, Varian, 400MHz): δ4.48-4.52(2H,m),4.57(2H,d,J=5.6Hz),5.12-5.15(2H,m),5.22-5.27(2H,m),5.79(1H,d,J=5.2Hz),5.81- 5.92(2H,m)6.19(2H,s),7.27(1H,t,J=9.0Hz),7.45(1H,d,J=9.2Hz),7 .72(1H,d,J=5.2Hz), 7.92(1H,d,J=15.2Hz), 8.68(1H,s), 11.05(1H,s).

[0474] Example 1

[0475] This example describes the synthesis of N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 1 .

[0476]

[0477] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate

[0478]

[0479] To a degassed solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 11, 8.40 g, 13.6 mmol), tert-butyl 4-propioloylpiperazine-1-carboxylate (Intermediate 4, 6.46 g, 27.1 mmol), copper (I) iodide (0.52 g, 2.71 mmol) and TEA (7.52 mL, 54.2 mmol) in DMF (45 mL) was added Pd(PPh3)4 (1.57 g, 1.36 mmol) under argon atmosphere. The reaction mixture was stirred at 90 ° C overnight. After cooling to room temperature, EtOAc and saturated NH4Cl solution (aq.) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by SiO column chromatography (EtOAc / MeOH=97 / 3) to afford tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)propioloyl)piperazine-1-carboxylate (5.20 g, 53%) in a dark brown form. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.46 (9H, s), 1.51 (6H, d, J = 6.8Hz), 3.45 (4H, brs), 3.65 (2H, brs), 3.82 (2H, brs), 4.96-4.99 (1H, m), 5.32 (2H) ,brs),5.97(1H,d,J=6.0Hz),7.11(1H,t,J=8.0Hz),7.23-7.27(5H,m), 7.85(1H,d,J=7.6Hz), 7.91(1H,d,J=5.6Hz), 8.69(1H,s), 10.95(1H,s).

[0480] Step B: N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0481]

[0482] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)propioyl)piperazine-1-carboxylate (300 mg, 0.41 mmol) in DCM (8 mL) was added TFA (0.32 mL, 4.11 mmol) at 0 ° C. The mixture was stirred at room temperature for 18 hours. Excess TFA was removed by evaporation, and DCM was poured into the residue. The mixture was neutralized with saturated NaHCO solution (aqueous solution). The separated aqueous layer was extracted with DCM, and the combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (230 mg, 90%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.8 Hz), 2.86 (4H, brs), 3.65 (2H, brs), 3.81 (2H, brs), 4.96-4.99 (1H, m), 5.32 (2H, brs), 5.98 (1H, d, J = 6.4 Hz), 7.10 (1H, t, J = 8.8 Hz), 7.21-7.26 (5H, m), 7.84 (1H, d, J = 11.6 Hz), 7.91 (1H, d, J = 4.8 Hz), 8.68 (1H, s), 10.95 (1H, s). *NH peak not observed.

[0483] Example 2

[0484] This example describes the synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 2 .

[0485]

[0486] A mixture of N-(4-(2-amino-3-(3-oxo-3-(piperazine-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 1, 30 mg, 0.05 mmol), 1-bromo-2-methoxyethane (5.37 μL, 0.06 mmol), potassium iodide (7.90 mg, 0.05 mmol) and KCO (6.59 mg, 0.09 mmol) in CHCN (1.0 mL) was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was washed with saturated NaHCO (aqueous solution) and extracted with EtOAc. The organic layer was dried over NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=99 / 1) to give N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (28 mg, 85%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.51 (6H, d, J = 6.4Hz), 2.50 (4H, brs), 2.59 (2H, t, J=5.2Hz),3.34(3H,s),3.50(2H,t,J=5.2Hz),3.71(2H,brs),3.86(2H,brs),4.94- 5.01(1H,m),5.28(2H,brs),5.97(1H,d,J=6.0Hz),7.11(1H,t,J=8.4Hz),7.22-7.2 6(5H,m),7.84(1H,d,J=10.0Hz),7.90(1H,d,J=5.6Hz),8.68(1H,s),10.94(1H,s).

[0487] Example 3

[0488] This example describes the synthesis of (E)-N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 3 .

[0489]

[0490] Step A: (E)-tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)acryloyl)piperazine-1-carboxylate

[0491]

[0492] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 200 mg, 0.32 mmol), tert-butyl 4-acryloylpiperazine-1-carboxylate (intermediate 5, 116 mg, 0.48 mmol), PPh3(3.62 mg, 0.02 mmol), TEA (90 μL, 0.70 mmol) and Pd(OAc)2(3.62 mg, 0.02 mmol) in DMF (3.0 mL) was stirred at 90 ° C for 16 hours. After cooling to room temperature, the reaction mixture was concentrated under vacuum. The residue was diluted with EtOAc and washed with saturated NH4Cl solution (aqueous solution). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give (E)-tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)acryloyl)piperazine-1-carboxylate (140 mg, 59%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.47 (9H, s), 1.50 (6H, d, J = 6.4 Hz), 3.45 (4H, d, J = 4.4 Hz), 3.55 (2H, s), 3.70 (2H, s), 4.97-5.01 (1H, m), 6.04 (1H, d, J = 5.6 Hz), 7.07 (1H, t, J = 8.00 Hz), 7.15 (2H, d, J = 6.8 Hz), 7.18-7.27 (5H, m), 7.71 (1H, d, J = 15.6 Hz), 7.82-7.85 (2H, m), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0493] Step B: (E)-N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0494]

[0495] To a solution of tert-butyl (E)-4-(3-(2-amino-4-(2-fluoro-4-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)acryloyl)piperazine-1-carboxylate (140 mg, 0.19 mmol) in DCM (2.2 ml) was added TFA (0.15 mL, 1.90 mmol) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (DCM / EtOAc=10 / 1) to give (E)—N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (104 mg, 87%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.4 Hz), 2.89 (4H, brs), 3.55 (2H, brs), 3.71 (2H, brs), 4.96-5.01 (1H, m), 6.04 (1H, d, J = 6.0 Hz), 7.07 (1H, t, J = 8.8 Hz), 7.17 (2H, d, J = 16.0 Hz), 7.25-7.26 (6H, m), 7.70 (1H, d, J = 15.6 Hz), 7.82-7.86 (2H, m), 8.68 (1H, s), 11.3 (1H, s). *NH peak not observed.

[0496] Example 4

[0497] This example describes the synthesis of (E)-N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 4 .

[0498]

[0499] A solution of (E)-N-(4-(2-amino-3-(3-oxo-3-(piperazin-1-yl)prop-1-enyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 3, 90 mg, 0.14 mmol), 1-bromo-2-methoxyethane (14 μL, 0.14 mmol), potassium iodide (24 mg, 0.14 mmol) and KCO (20 mg, 0.14 mmol) in CHCN (2 mL) was heated to 90° C. over 18 hours. After cooling to room temperature, the reaction mixture was washed with saturated NaHCO (aqueous solution) and extracted with EtOAc. The organic layer was dried over NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (52 mg, 53%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.50 (6H, d, J = 6.8Hz), 2.52 (4H, brs), 2.60 (2H, t, J=5.6Hz),3.36(3H,s),3.51(2H,t,J=5.6Hz),3.62(2H,brs),3.78(2H,brs),4.96-4 0.99 (1H, m), 6.03 (1H, d, J = 5.2 Hz), 7.07 (1H, t, J = 8.8 Hz), 7.17 (2H, d, J = 15.6 Hz), 7.25-7.26 (5H, m), 7.70 (1H, d, J = 15.6 Hz), 7.82-7.85 (2H, m), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0500] Example 5

[0501] This example describes the synthesis of N-(4-(2-amino-3-cyanopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 5 .

[0502]

[0503] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 11, 200 mg, 0.32 mmol) in DMF (4.0 mL) was added dicyanozinc (76.0 mg, 0.65 mmol) and Pd(PPh3)4 (37.3 mg, 0.03 mmol). The reaction mixture was sealed and subjected to microwave irradiation at 90°C for 8 hours. The product was purified by CELITE HPLC. TM The mixture was filtered through a pad of 4% paraffin wax (Sigma-Aldrich, St. Louis, MO) and the filtrate was concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=10 / 1). The product was purified by preparative LC to give N-(4-(2-amino-3-cyanopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (50.0 mg, 30%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.4 Hz), 4.94-5.00 (1H, m), 5.28 (2H, s), 5.96 (1H, d, J = 6.0 Hz), 7.14 (1H, t, J = 8.8 Hz), 7.24-7.26 (4H, m), 7.86 (1H, dd, J = 2.4 Hz, 12.0 Hz), 8.01 (1H, d, J = 6.0 Hz), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0504] Example 6

[0505] This example describes the synthesis of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 6 .

[0506]

[0507] Step A: 3,4-Dichloropyridin-2-amine

[0508]

[0509] Hydrogen peroxide (1.49 mL, 15.6 mmol) was added to a solution of 4-chloropyridine-2-amine (2.00 g, 15.6 mmol) in concentrated HCl (11 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into water and basified by adding Na2CO3 until the pH was 10, followed by extraction with EtOAc. The organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=2 / 1) to give 3,4-dichloropyridine-2-amine (594 mg, 23%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ5.24 (2H, s), 6.75 (1H, d, J = 5.6Hz), 7.85 (1H, d, J = 5.2Hz).

[0510] Step B: 3-Chloro-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine

[0511]

[0512] A solution of 3,4-dichloropyridine-2-amine (200 mg, 1.23 mmol) and 2-fluoro-4-nitrophenol (771 mg, 4.91 mmol) in NMP (3.0 mL) was stirred at 120 ° C for 24 hours in a sealed tube. After cooling at room temperature, the reaction mixture was dissolved in EtOAc and washed with water. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=1 / 1) to give 3-chloro-4-(2-fluoro-4-nitrophenoxy)pyridine-2-amine (58 mg, 17%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ5.19 (2H, s), 5.31 (1H, s), 6.23 (1H, d, J = 5.2 Hz), 7.19 (1H, t, J = 8.4 Hz), 7.92 (1H, d, J = 5.6 Hz), 8.11 (1H, dd, J = 9.2, 20.0 Hz).

[0513] Step C: 4-(4-amino-2-fluorophenoxy)-3-chloropyridin-2-amine

[0514]

[0515] To a solution of 3-chloro-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine (58.0 mg, 0.20 mmol) in EtOH (2.0 mL) was added tin (II) chloride dihydrate (185 mg, 0.82 mmol) at room temperature. The reaction mixture was stirred at 90 ° C for 1 hour. After cooling at room temperature, the solvent was removed under vacuum. The residue was dissolved in EtOAc and neutralized with 2N NaOH until the pH was 9 and filtered through CELITE HPLC. TM The filtrate was filtered through a pad of 4-nitro-2-nitropropene (Sigma-Aldrich, St. Louis, MO). The filtrate was extracted with EtOAc and dried over NaSO, filtered and concentrated in vacuo to give 4-(4-amino-2-fluorophenoxy)-3-chloropyridin-2-amine (26.0 mg, 50%) as a brown solid which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 4.95 (2H, s), 6.01 (1H, d, J = 6.00 Hz), 6.44 (1H, d, J = 8.8 Hz), 6.50 (1H, dd, J = 2.4, 11.8 Hz), 6.95 (1H, t, J = 8.8 Hz), 7.77 (1H, d, J = 6.0 Hz). *NH2 peak not observed.

[0516] Step D: N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0517]

[0518] A solution of 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Intermediate 10, 40.0 mg, 0.14 mmol) in thionyl chloride (3.0 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to give the corresponding acid chloride, which was used in the next reaction without further purification.

[0519] The acyl chloride obtained above was redissolved in DCM (2.0 mL), and 4- (4- amino -2- fluorophenoxy) -3- chloropyridine -2- amine (20.0 mg, 0.08 mmol) and TEA (22.0 μL, 0.16 mmol) were added to the solution. The reaction mixture was stirred at room temperature for 2 hours. The mixture was washed with water and extracted with DCM. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=10 / 1) to give N- (4- (2- amino -3- chloropyridin-4-yloxy) -3- fluorophenyl) -3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxamide (18 mg, 42%) as a light yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.4 Hz), 4.91-4.99 (1H, m), 6.03 (1H, d, J = 5.2 Hz), 7.11 (2H, t, J = 8.4 Hz), 7.20-7.26 (5H, m), 7.79 (1H, brs), 7.84 (1H, dd, J = 2.0 Hz, 12.4 Hz), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0520] Example 7

[0521] This example describes the synthesis of N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 7 .

[0522]

[0523] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine

[0524]

[0525] By 4- (2- fluoro -4- nitrophenoxy) -3- iodopyridin -2- amine (intermediate 11 step D, 0.20 g, 0.53 mmol), 1- methyl -4- (4,4,5,5- tetramethyl -1,3,2- dioxaborolan -2- bases) -1H- pyrazole (0.17 g, 0.80 mmol) and K2CO3 (0.22 g, 1.60 mmol) and Pd (PPh3) 4 (62 mg, 0.05 mmol) in 1,4- dioxane / H2O (v / v = 2: 1, 6.0 mL) in a mixture was refluxed at 90 ° C for 18 hours under an argon atmosphere. The mixture was poured into saturated NaHCO3 (aqueous solution) and then extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (DCM / MeOH=9 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (0.14 g, 80%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ3.91 (3H, s), 4.90 (2H, s), 6.22 (1H, d, J = 5.6Hz), 7.0 5(1H,t,J=8.6Hz),7.56(1H,s),7.64(1H,s),7.93(1H,d,J=5.6Hz),7.95-8.03(2H,m).

[0526] Step B: 4-(4-amino-2-fluorophenoxy)-3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine

[0527]

[0528] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (0.14 g, 0.42 mmol) in EtOH (5.0 mL) was added tin (II) chloride dihydrate (0.38 g, 1.70 mmol) at room temperature. The reaction mixture was stirred at 90° C. for 1 hour. After cooling at room temperature, the solvent was removed in vacuo and EtOAC was poured into the residue. The mixture was neutralized with saturated NaHCO 3 (aqueous solution) and 2N NaOH (aqueous solution) until the pH was 9.0 and filtered through a CELITE filter. TMThe filtrate was extracted with EtOAc, and the combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to afford 4-(4-amino-2-fluorophenoxy)-3-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (0.11 g, 86%) as a yellow form, which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 3.96 (3H, s), 4.73 (2H, brs), 6.05 (1H, d, J = 6.0 Hz), 6.04-6.42 (1H, m), 6.46-6.50 (1H, m), 6.87 (1H, t, J = 8.4 Hz), 7.66 (1H, s), 7.73 (1H, s), 7.80 (1H, d, J = 6.4 Hz). *NH2 peak not observed.

[0529] Step C: N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0530]

[0531] By 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 0.10g, 0.36mmol), HATU (0.15g, 0.40mmol) and DIPEA (0.16mL, 0.91mmol) in DMF (3.0mL) is stirred at room temperature for 30 minutes. 4- (4- amino -2- fluorophenoxy) -3- (1- methyl -1H- pyrazole -4- bases) pyridine -2- amine (0.11g, 0.36mmol) is added to the reaction mixture at room temperature and stirred for 18 hours. The reaction mixture is quenched with water and extracted with EtOAc. The combined organic layer is dried with NaSO, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (0.14 g, 66%) as a white solid. 1H-NMR (CDCl3, Varian, 400 MHz): δ 1.49 (6H, d, J = 6.8 Hz), 3.96 (3H, s), 4.93-5.00 (1H, m), 6.07 (1H, d, J = 5.6 Hz), 7.02 (1H, t, J = 8.4 Hz), 7.18 (1H d, J = 8.8 Hz), 7.24-7.25 (4H, m), 7.64 (1H, s), 7.75-7.84 (3H, m), 8.67 (1H, s), 10.87 (1H, s). *NH2 peak not observed.

[0532] Example 8

[0533] This example describes the synthesis of N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 8 .

[0534]

[0535] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(prop-1-en-2-yl)pyridin-2-amine

[0536]

[0537] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (step D of Intermediate 11, 0.20 g, 0.53 mmol), potassium isopropenyltrifluoroborate (0.12 g, 0.80 mmol), Na2CO3 (0.40 g, 3.73 mmol) and PdCl2(dppf) (dppf: 1,1'-bis(diphenylphosphino)ferrocene) (44 mg, 0.05 mmol) in THF / H2O (v / v=1:1, 6.0 mL) was refluxed at 60°C under an argon atmosphere for 16 hours. The mixture was poured into saturated NaHCO3 (aq.) and extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc = 1 / 4) to give 4-(2-fluoro-4-nitrophenoxy)-3-(prop-1-en-2-yl)pyridin-2-amine (0.15 g, 71%) as a yellow oil. 1H-NMR (CDCl3, Varian, 400MHz): δ2.05(3H,s),4.80(2H,s),5.08(1H,s),5.38(1H,s),6.16(1H, d,J=5.2Hz),7.12(1H,t,J=8.8Hz),7.91(1H,d,J=6.0Hz),8.01-8.05(1H,m),8.07-8.10(1H,m).

[0538] Step B: 4-(4-amino-2-fluorophenoxy)-3-isopropylpyridin-2-amine

[0539]

[0540] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-(prop-1-en-2-yl)pyridin-2-amine (110 mg, 0.38 mmol), platinum (IV) oxide (25 mg, 0.11 mmol) and 10% palladium on carbon (40 mg, 0.038 mmol) in EtOH / MeOH (v / v=1:2, 8.0 mL) was stirred at room temperature under H atmosphere for 2 hours. TM The mixture was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO), the filter cake was washed with MeOH and the filtrate was concentrated in vacuo to give 4-(4-amino-2-fluorophenoxy)-3-isopropylpyridin-2-amine (63 mg, 63%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.38 (6H, d, J = 4.0Hz), 3.18-3.30 (1H, m), 3.78 (2H, s), 4.51 (2H, s), 5.97 (1H, d, J = 5.2Hz), 6.40 (1H, dd, J = 2.4Hz, 8.4Hz), 6.47 (1H, dd, J = 2.4Hz, 11.8Hz), 6.86 (1H, t, J = 8.8Hz), 7.69 (1H, d, J = 6.0Hz).

[0541] Step C: N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0542]

[0543] By 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 70mg, 0.24mmol), HATU (0.10g, 0.26mmol) and DIPEA (0.10mL, 0.60mmol) in DMF (2.0mL) was stirred at room temperature for 30 minutes. 4- (4- amino -2- fluorophenoxy) -3- isopropyl pyridine -2- amine (63mg, 0.36mmol) was added to the reaction mixture at room temperature and stirred for 16 hours. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (47 mg, 36%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.40 (6H, d, J = 7.2 Hz), 1.50 (6H, d, J = 6.8 Hz), 4.47-4.52 (1H, m), 4.93-5.00 (1H, m), 6.00 (1H, d, J = 5.6 Hz), 7.03 (1H, t, J = 8.4 Hz), 7.20 (1H, d, J = 8.0 Hz), 7.25 (5H, d, J = 6.0 Hz), 7.75 (1H, d, J = 6.0 Hz), 7.79 (1H, dd, J = 2.4 Hz, 12.6 Hz), 8.68 (1H, s), 10.87 (1H, s). *NH peak not observed.

[0544] Example 9

[0545] This example describes the synthesis of N-(4-(2-amino-3-(pyridin-2-ylethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 9 .

[0546]

[0547] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(pyridine-2-ylalkynyl)pyridin-2-amine

[0548]

[0549] To a degassed solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (step D of intermediate 11, 0.20 g, 0.53 mmol), 2-ethynylpyridine (0.10 mL, 1.06 mmol), CuI (20 mg, 0.10 mmol) and TEA (0.70 mL, 5.33 mmol) in THF (2.0 mL) was added Pd(PPh ) (20 mg, 0.1 mmol) under an argon atmosphere and stirred at 90 ° C for 18 hours. After cooling at room temperature, the mixture was poured into water and extracted with EtOAc. The combined organic layers were dried over Na SO , filtered and concentrated in vacuo. The residue was purified by SiO column chromatography (DCM / MeOH = 9 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-(pyridin-2-ylalkynyl)pyridin-2-amine (0.12 g, 64%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ5.46 (2H, s), 6.16 (1H, d, J = 5.2Hz), 7.24-7.27 (2H, m), 7.39 (1 H,d,J=7.6H),7.65-7.69(1H,m),7.99(1H,d,J=5.2Hz),8.07-8.13(2H,m),8.59(1H,d,J=5.2H).

[0550] Step B: 4-(4-amino-2-fluorophenoxy)-3-(pyridin-2-ylalkynyl)-pyridin-2-amine

[0551]

[0552] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-(pyridin-2-yl alkynyl)pyridine-2-amine (0.12 g, 0.34 mmol), zinc (0.22 g, 3.43 mmol) and ammonium chloride (0.18 g, 3.43 mmol) in MeOH (2.0 mL) was stirred at 60 ° C for 18 hours. The reaction mixture was filtered and the residue was partitioned between EtOAc and saturated NaHCO (aqueous solution). The aqueous solution was extracted with EtOAc. The combined layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give 4-(4-amino-2-fluorophenoxy)-3-(pyridin-2-yl alkynyl)-pyridine-2-amine (23 mg, 20%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400 MHz): δ 5.42 (2H, s), 5.97 (1H, dd, J = 1.2 Hz, 6.0 Hz), 6.42-6.52 (2H, m), 6.97 (1H, t, J = 8.4 Hz), 7.22-7.26 (1H, m), 7.55 (1H, d, J = 8.0 Hz), 7.65-7.69 (1H, m), 7.84 (1H, d, J = 6.0 Hz), 8.60 (1H, d, J = 5.2 Hz). *NH2 peak not observed.

[0553] Step C: N-(4-(2-amino-3-(pyridin-2-ylethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0554]

[0555] By 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 18mg, 0.06mmol), HATU (0.26g, 0.07mmol) and DIPEA (0.3mL, 0.15mmol) in DMF (1.0mL) is stirred at room temperature for 30 minutes. 4- (4- amino -2- fluorophenoxy) -3- (pyridin-2-yl alkynyl) -pyridine -2- amine (20mg, 0.06mmol) is added to the reaction mixture at room temperature and stirred for 18 hours. The reaction mixture is quenched with water and extracted with EtOAc. The combined organic layer is dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(pyridin-2-ylethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (16 mg, 43%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.8Hz), 4.93-5.01 (1H, m), 5.99 (1H, d, J = 5.6Hz), 7.12-7.18 (2H, m), 7.21- 7.24(7H,m),7.52(1H,d,J=7.6Hz),7.64-7.68(1H,m),7.81-7.88(2H,m),8.60(1H,d,J=4.4Hz),8.68(1H,s),10.9(1H,s).

[0556] Example 10

[0557] This example describes the synthesis of N-(4-(2-amino-3-(4-phenoxyphenyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 10 .

[0558]

[0559] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(4-phenoxyphenyl)pyridin-2-amine

[0560]

[0561] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (step D of intermediate 11, 0.30 g, 0.80 mmol) in dioxane / HO (v / v=10 / 1, 1.0 mL) was added 4-phenoxyphenylboronic acid (0.25 g, 1.20 mmol), Pd(OAc) (8.9 mg, 0.04 mmol), SPHOS (32 mg, 0.08 mmol) and KCO (0.33 g, 2.40 mmol) at room temperature under N. The reaction mixture was microwave irradiated at 90°C for 20 minutes. After cooling at room temperature, NaSO was added to the mixture, which was then purified by CELITE HPLC. TM The product was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO) and the filtrate was concentrated in vacuo. The residue was purified by MPLC (EtOAc / Hex = 1 / 4 to MeOH) to give 4-(2-fluoro-4-nitrophenoxy)-3-(4-phenoxyphenyl)pyridin-2-amine (0.29 g, 88%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ4.82 (2H, s), 6.27 (1H, d, J = 6.0 Hz), 6.98-7.09 (4H, m), 7.11-7.16 (2H, m), 7.29-7.37 (4H, m), 7.88-8.05 (3H, m).

[0562] Step B: 4-(4-amino-2-fluorophenoxy)-3-(4-phenoxyphenyl)pyridin-2-amine

[0563]

[0564] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-(4-phenoxyphenyl)pyridine-2-amine (0.29 g, 0.69 mmol), zinc (0.45 g, 6.95 mmol) and ammonium chloride (0.37 g, 6.95 mmol) in THF / MeOH (v / v=1 / 1, 8.0 mL) was stirred at 60 ° C for 18 hours. The reaction mixture was filtered and the residue was partitioned between EtOAc and saturated NaHCO (aqueous solution). The aqueous solution was extracted with EtOAc. The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give 4-(4-amino-2-fluorophenoxy)-3-(4-phenoxyphenyl)pyridine-2-amine (0.26 g, 97%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 6.97-7.04 (6H, m), 7.08-7.14 (2H, m), 7.31-7.37 (6H, m). *NH2 peak not observed.

[0565] Step C: N-(4-(2-amino-3-(4-phenoxyphenyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0566]

[0567] A mixture of 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 0.26 g, 0.67 mmol), HATU (0.28 g, 0.76 mmol), DIPEA (0.30 mL, 1.67 mmol) in DMF (5.0 mL) was stirred at room temperature for 30 minutes. 4- (4- amino -2- fluorophenoxy) -3- (4- phenoxyphenyl) pyridine -2- amine (0.26 g, 0.67 mmol) was added to the reaction mixture at room temperature and stirred for 18 hours. The reaction mixture was quenched with water and extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(4-phenoxyphenyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (0.25 g, 56%) as a white solid. 1H-NMR (DMSO-d6, Varian, 400MHz): δ1.50 (6H, d, J = 6.4Hz), 4.93-5.0 (1H, m), 6.26 (1H, d, J = 6.8Hz), 7.04-7.14 (5 H,m),7.20-7.26(8H,m),7.35-7.41(4H,m),7.72(1H,d,J=6.8Hz),7.87-7.87(1H,m),8.67(1H,s),10.99(1H,s).

[0568] Example 11

[0569] This example describes the synthesis of N-(4-(2-amino-3-(3,5-dimethylisoxazol-4-yl)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 11 .

[0570]

[0571] Step A: 3-(3,5-dimethylisoxazol-4-yl)-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine

[0572]

[0573] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (step D of intermediate 11, 0.20 g, 0.53 mmol) in dioxane / HO (v / v=2 / 1, 6.0 mL) was added 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (0.17 g, 0.80 mmol) and KCO (0.22 g, 1.60 mmol). The mixture was degassed with argon and Pd(PPh3)4 (61 mg, 0.05 mmol) was added. The reaction mixture was stirred at 90 ° C for 20 hours. After cooling at room temperature, the mixture was quenched with water and extracted with EtOAc. The combined organic layers were dried with NaSO4, filtered and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (hexane / EtOAc=1 / 4) to give 3-(3,5-dimethylisoxazol-4-yl)-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine (0.13 g, 74%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ2.19(3H,s),2.32(3H,s),4.70(2H,s),6.18(1H,d,J=4.4Hz),7.14-7.16(1H,m),7.18-7.33(2H,m),8.05(1H,brs).

[0574] Step B: 4-(4-amino-2-fluorophenoxy)-3-(3,5-dimethylisoxazol-4-yl)pyridin-2-amine

[0575]

[0576] To a solution of 3-(3,5-dimethylisoxazol-4-yl)-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine (0.13 g, 0.39 mmol) in EtOH (4.0 mL) was added tin (II) chloride dihydrate (0.09 g, 0.39 mmol). The reaction mixture was stirred at 80 ° C for 2 h. After cooling at room temperature, the solvent was concentrated in vacuo and dissolved with EtOAc. The organic layer was washed with water and dried with Na2SO4, filtered and concentrated in vacuo to give 4-(4-amino-2-fluorophenoxy)-3-(3,5-dimethylisoxazol-4-yl)pyridin-2-amine (90 mg, 72%) as a brown solid, which was used in the next step without further purification. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 2.24 (3H, s), 2.36 (3H, s), 4.57 (2H, s), 5.94 (1H, d, J = 8.4 Hz), 6.34-6.41 (2H, m), 6.80-6.84 (1H, m), 7.96 (1H, d, J = 4.8 Hz). *NH2 peak not observed.

[0577] Step C: N-(4-(2-amino-3-(3,5-dimethylisoxazol-4-yl)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0578]

[0579] A mixture of 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 84 mg, 0.28 mmol), HATU (120 mg, 0.31 mmol) and DIPEA (125 μ L, 0.71 mmol) in DMF (3.0 mL) was stirred at room temperature for 1 hour. 4- (4- amino -2- fluorophenoxy) -3- (3,5- dimethylisoxazol -4- bases) pyridine -2- amine (90 mg, 0.28 mmol) was added to the reaction mixture at room temperature and stirred for 3 hours. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(3,5-dimethylisoxazol-4-yl)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (52 mg, 30%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.8Hz), 2.22 (3H, s), 2.57 (3H, s), 4.45 (2H, s), 4.96-4.98 (1H, m), 6.05 (1H, d, J = 6.4Hz), 7.0 0(1H,t,J=6.4Hz),7.20(1H,d,J=9.6Hz),7.24-7.26(4H,m),7.79(1H,dd,J=2.4Hz,12.0Hz),7.94(1H,d,J=5.6Hz),8.67(1H,s),10.8(s,1H).

[0580] Example 12

[0581] This example describes the synthesis of N-(4-(2-amino-3-(1-propyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 12 .

[0582]

[0583] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(1-propyl-1H-pyrazol-4-yl)pyridin-2-amine

[0584]

[0585] To a degassed solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (step D of intermediate 11, 200 mg, 0.533 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-yl)-1H-pyrazole (189 mg, 0.800 mmol) in 1,4-dioxane (4.0 mL) was added a degassed solution of KCO (221 mg, 1.60 mmol) in HO (2.0 mL) and Pd(PPh) (61 mg, 0.05 mmol). The reaction mixture was stirred at 90 ° C for 18 hours. After cooling at room temperature, saturated NaHCO (aq.) was added to the mixture and extracted with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by SiO 2 column chromatography (DCM / MeOH=9 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-(1-propyl-1H-pyrazol-4-yl)pyridin-2-amine (156 mg, 82%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ0.86 (3H, t, J = 7.6Hz), 1.82-1.91 (2H, m), 4.08 (2H, t, J = 7.2Hz), 4. 84(2H,s),6.30(1H,d,J=5.2Hz),7.02(1H,t,J=8.0Hz),7.58(1H,s),7.66(1H,s),7.96-8.04(3H,m).

[0586] Step B: 4-(4-amino-2-fluorophenoxy)-3-(1-propyl-1H-pyrazol-4-yl)pyridin-2-amine

[0587]

[0588] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-(1-propyl-1H-pyrazol-4-yl)pyridin-2-amine (156 mg, 0.43 mmol), zinc (285 mg, 4.37 mmol) and ammonium chloride (234 mg, 4.37 mmol) in THF / MeOH (v / v=1 / 1, 4.0 mL) was stirred at 60 ° C for 18 hours. After cooling to room temperature, the mixture was filtered and the filtrate was distributed between EtOAc and saturated NaHCO (aqueous solution). The aqueous layer was extracted with EtOAc. The combined organic layer was washed with brine, dried over Na SO, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give 4-(4-amino-2-fluorophenoxy)-3-(1-propyl-1H-pyrazol-4-yl)pyridin-2-amine (140 mg, 98%) as a yellow solid.1 H-NMR (CD3OD, Varian, 400 MHz): δ 0.93 (3H, t, J = 7.6 Hz), 1.88-1.97 (2H, m), 4.17 (2H, t, J = 7.2 Hz), 6.08 (1H, d, J = 6.4 Hz), 6.49-6.55 (2H, m), 6.85-6.89 (1H, m), 7.54-7.57 (1H, m), 7.61-7.68 (1H, m), 7.70 (1H, s), 7.80 (1H, d, J = 6.0 Hz), 7.87 (1H, s). *NH2 peak not observed.

[0589] Step C: N-(4-(2-amino-3-(1-propyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0590]

[0591] By 4- (4- amino -2- fluorophenoxy) -3- (1- propyl -1H- pyrazol -4- bases) pyridine -2- amine (65mg, 0.20mmol), 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 58mg, 0.20mmol), HATU (83mg, 0.22mmol) and DIPEA (0.09mL, 0.50mmol) in DMF (2.0mL) mixture is stirred at room temperature for 18 hours. The reactant is quenched with water and extracted with EtOAc. The organic layer is dried over NaSO, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(1-propyl-1H-pyrazol-4-yl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (25 mg, 21%) as a white solid. 1H-NMR (CDCl3, Varian, 400MHz): δ0.94 (3H, t, J = 13.2Hz), 1.50 (6H, d, J = 6.4Hz), 1.88-1.97 (2H, m), 4.13 (2H, t, J = 7.2Hz), 4.93-5.0 (1H, m), 6. 11(1H,d,J=6.0Hz),7.02(1H,t,J=8.4Hz),7.18(1H,d,J=8.4Hz),7.24- 7.26(6H,m),7.67(1H,s),7.76-7.82(3H,m),8.67(1H,s),10.8(1H,s).

[0592] Example 13

[0593] This example describes the synthesis of N-(4-(2-amino-3-((1-propyl-1H-pyrazol-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 13 .

[0594]

[0595] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 290 mg, 0.47 mmol), 4-ethynyl-1-propyl-1H-pyrazole (intermediate 9, 94 mg, 0.70 mmol), Pd(PPh3)4(54 mg, 0.05 mmol) copper (I) iodide (18 mg, 0.09 mmol) and TEA (0.26 mL, 1.87 mmol) in DMF (3.0 mL) was purified with N2. The reaction mixture was stirred at 90 ° C overnight. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by preparative LC to give N-(4-(2-amino-3-((1-propyl-1H-pyrazol-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (35 mg, 12%) as a white solid. 1H-NMR (CDCl3, Varian, 400MHz): δ0.91 (3H, t, J = 7.2Hz), 1.49 (6H, d, J = 7.2Hz), 1.87(2H,t,J=7.2Hz),4.06(2H,t,J=6.8Hz),4.93-5.00(1H,m),5.20(2H,s),5. 99(1H,d,J=5.6Hz),7.08-7.15(1H,m),7.21(1H,d,J=8.4Hz),7.25-7.27(2H,m) ,7.53-7.56(3H,m),7.59(1H,s),7.79-7.84(2H,m),8.06(1H,s),10.91(1H,s).

[0596] Example 14

[0597] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholino-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 14 .

[0598]

[0599] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 100 mg, 0.16 mmol), 1-morpholinoprop-2-yn-1-one (intermediate 1, 22 mg, 0.16 mmol), Pd(PPh3)4(19 mg, 0.02 mmol) copper (I) iodide (6 mg, 0.03 mmol) and TEA (0.09 mL, 0.64 mmol) in DMF (1.0 mL) was purified with N2. The reaction mixture was stirred at 90 ° C for 5 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (hexane / EtOAc=1 / 9 to EtOAc) to give N-(4-(2-amino-3-(3-morpholino-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10 mg, 10%) as a beige solid. 1H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.4 Hz), 1.63 (2H, brs), 3.67-3.68 (6H, m), 4.94-5.01 (1H, m), 5.25 (2H, s), 5.98 (1H, d, J = 6.0 Hz), 7.21-7.26 (4H, m), 7.85 (1H, dd, J = 2.0 Hz, 12.2 Hz), 7.91 (1H, d, J = 5.6 Hz), 8.68 (1H, s), 10.9 (1H, s). *NH2 peak not observed.

[0600] Example 15

[0601] This example describes the synthesis of N-(4-(2-amino-3-(piperidin-4-ylalkynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 15 .

[0602]

[0603] Step A: tert-Butyl 4-((2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)ethynyl)piperidine-1-carboxylate

[0604]

[0605] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 200 mg, 0.32 mmol), tert-butyl 4-ethynylpiperidine-1-formate (100 mg, 0.48 mmol) Pd(PPh3)4(37 mg, 0.03 mmol), copper (I) iodide (12 mg, 0.06 mmol) and TEA (0.18 mL, 1.3 mmol) in DMF (2 mL) was purified with N2. The reaction mixture was stirred at 90 ° C for 5 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / Hex=9 / 1 to EtOAc) to give tert-butyl 4-((2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)ethynyl)piperidine-1-carboxylate (150 mg, 66%) as a grey solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.45 (9H, s), 1.50 (6H, d, J = 6.8Hz), 1.65-1. 72(3H,m).1.85-1.89(2H,m),3.20-3.27(2H,m),3.71-3.74(2H,m),4.95-4.9 8(1H,m),5.01(2H,s),5.99(1H,d,J=5.6Hz),7.08(1H,t,J=8.8Hz),7.21(1H, d,J=8.8Hz),7.24-7.26(4H,m),7.80-7.83(2H,m),8.68(1H,s),10.8(1H,s).

[0606] Step B: N-(4-(2-amino-3-(piperidin-4-ylalkynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0607]

[0608] To a solution of tert-butyl 4-((2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)ethynyl)piperidine-1-carboxylate (150 mg, 0.21 mmol) in DCM (5.0 ml) was added TFA (0.16 mL, 2.14 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(piperidin-4-ylalkynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (74 mg, 57%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.8 Hz), 1.90-1.92 (2H, m), 2.67-2.73 (2H, m), 2.81-2.83 (1H, m), 3.04-3.10 (2H, m), 4.74 (4H, s), 4.93-5.00 (1H, m), 5.03 (1H, s), 6.00 (1H, d, J = 6.0 Hz), 7.08 (1H, t, J = 8.8 Hz), 7.20 (1H, d, J = 8.8 Hz), 7.24-7.26 (4H, m), 7.79-7.82 (1H, m), 8.68 (1H, s), 10.8 (1H, s). *NH peak not observed.

[0609] Example 16

[0610] This example describes the synthesis of N-(4-(2-amino-3-((1-(2-methoxyethyl)piperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention.

[0611] See also Figure 16 .

[0612]

[0613] By N- (4- (2- amino -3- (piperidin-4-yl alkynyl) pyridin-4-yloxy) -3- fluorophenyl) -3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxamide (Example 15, 30.0 mg, 0.05 mmol), 1- bromo -2- methoxyethane (5.6 μ L, 0.06 mmol), potassium iodide (8.30 mg, 0.05 mmol) and K cO a mixture of (6.90 mg, 0.05 mmol) in CH cN (2 mL) was heated at 80 ° C in a sealed container overnight. After cooling at room temperature, EtOAc and water were poured into the reaction mixture and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na sO , filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-((1-(2-methoxyethyl)piperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (18.0 mg, 55%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.8Hz), 1.78-1.84 (2H, m), 1.95-1.99 (2H ,m),2.02(1H,s),2.29(2H,brs),2.55(2H,t,J=5.6Hz),2.76(2H,brs),3.34(3H,s),3.49( 4.93-5.00 (1H, m), 5.04 (2H, s), 5.98 (1H, d, J = 6.0 Hz), 7.09 (1H, t, J = 8.8 Hz), 7.20 (1H, d, J = 8.4 Hz), 7.24-7.26 (3H, m), 7.79-7.83 (2H, m), 8.68 (1H, s), 10.8 (1H, s). *NH peak not observed.

[0614] Example 17

[0615] This example describes the synthesis of N-(4-(2-amino-3-(3-piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 17 .

[0616]

[0617] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperazine-1-carboxylate

[0618]

[0619] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 200 mg, 0.32 mmol), tert-butyl 4-(prop-2-ynyl)piperazine-1-carboxylate (intermediate 3, 110 mg, 0.48 mmol), Pd(PPh3)4(37 mg, 0.03 mmol), copper (I) iodide (12 mg, 0.06 mmol) and TEA (0.18 mL, 1.3 mmol) in DMF (2 mL) was purified with N2. The reaction mixture was stirred at 90 ° C for 5 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperazine-1-carboxylate (92 mg, 39%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.44 (9H, s), 1.49 (6H, d, J = 6.4 Hz), 2.56-2.58 (4H, m), 3.40-3.62 (4H, m), 3.71 (2H, s), 4.95-4.98 (1H, m), 5.11 (2H, s), 5.97 (1H, d, J = 6.0 Hz), 7.07-7.12 (1H, m), 7.21 (1H, d, J = 8.8 Hz), 7.24-7.27 (3H, m), 7.81-7.84 (2H, m), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0620] Step B: N-(4-(2-amino-3-(3-piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0621]

[0622] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperazine-1-carboxylate (90 mg, 0.13 mmol) in DCM (5.0 ml) was added TFA (96 μL, 1.26 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-piperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (37 mg, 48%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.50 (6H, d, J = 6.4 Hz), 2.58 (4H, brs), 2.92 (3H, t, J = 4.8 Hz), 3.59 (2H, s), 4.93-5.00 (1H, m), 5.07 (2H, s), 5.99 (1H, d, J = 5.6 Hz), 7.09 (1H, t, J = 8.4 Hz), 7.19-7.26 (5H, m), 7.80-7.83 (2H, m), 8.67 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0623] Example 18

[0624] This example describes the synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)prop-1-ylynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 18 .

[0625]

[0626] By N- (4- (2- amino -3- (3- piperazine -1- bases) prop-1- ynyl) pyridin-4-yloxy) -3- fluorophenyl) -3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- formamide (embodiment 17, 27.0 mg, 0.04 mmol), 1- bromo -2- methoxyethane (4.91 μ L, 0.05 mmol), potassium iodide (7.28 mg, 0.04 mmol) and K cO a mixture of (6.06 mg, 0.04 mmol) in CH cN (1 mL) was heated at 80 ° C in a sealed container overnight. After cooling at room temperature, EtOAc and water were poured into the reaction mixture and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na sO , filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)prop-1-ylynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (5.7 mg, 19%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.49-1.60 (8H, m), 2.63-2.74 (8H, m), 3.34 (3H, s), 3.54 (2H, brs), 3.60 (2H, s), 4.95-4.99 (1H, m), 5.09 (2H, s), 5.96 (1H, d0, J=6.0 Hz), 7.10 (1H, t, J=8.4 Hz), 7.24-7.26 (3H, m), 7.79-7.83 (2H, m), 8.68 (1H, s), 10.9 (1H, s). *NH2 peak not observed.

[0627] Example 19

[0628] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 19 .

[0629]

[0630] Step A: tert-Butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate

[0631]

[0632] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 200 mg, 0.32 mmol), tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (intermediate 6, 122 mg, 0.48 mmol), Pd(PPh3)4(37 mg, 0.03 mmol), copper (I) iodide (12 mg, 0.06 mmol) and TEA (0.18 mL, 1.3 mmol) in DMF (2 mL) was purged with N2. The reaction mixture was stirred at 90 ° C for 16 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by MPLC (EtOAc to EtOAc / MeOH) to give tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (110 mg, 46%) as a milky white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.43(9H,s),1.47-1.59(12H,m),2.62-2.64(4H,m),3.43-3.46(4H,m),4.93-5.00(1H,m),5.42(2H,br s), 6.01 (1H, d, J = 6.0Hz), 7.07 (1H, t, J = 8.8Hz), 7.19 (1H, d, J = 1.2Hz), 7.21-7.27 (4H, m), 7.71-7.87 (2H, m), 8.68 (1H, s), 10.9 (1H, s).

[0633] Step B: N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0634]

[0635] To a solution of tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (110 mg, 0.15 mmol) in DCM (5.0 ml) was added TFA (0.11 mL, 1.48 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (32 mg, 33%) as a pale yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.44 (6H, s), 1.48 (6H, d, J = 6.4 Hz), 2.63 (4H, brs), 2.92 (4H, brs), 4.93-4.97 (1H, m), 5.05 (2H, s), 6.04 (1H, d, J = 6.0 Hz), 7.04 (1H, t, J = 8.4 Hz), 7.18 (1H, d, J = 8.4 Hz), 7.23-7.25 (3H, m), 7.78-7.83 (2H, m), 8.67 (1H, s), 10.8 (1H, s). *NH2 peak not observed.

[0636] Example 20

[0637] This example describes the synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-methylbut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 20 .

[0638]

[0639] By N-(4-(2-amino-3-(3-methyl-3-(piperazine-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 19, 27.0 mg, 0.04 mmol), 1-bromo-2-methoxyethane (4.70 μ L, 0.05 mmol), potassium iodide (7.00 mg, 0.04 mmol) and KCO(5.80 mg, 0.04 mmol) in CHCN (1 mL) was heated at 80 ° C in a sealed container overnight. After cooling at room temperature, EtOAc and water were poured into the reaction mixture and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-methylbut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10 mg, 34%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 0.84-0.86 (2H, m), 1.46 (6H, s), 1.50 (6H, d, J = 6.8 Hz), 2.57-2.60 (4H, m), 2.77 (4H, brs), 3.33 (3H, s), 3.48-3.51 (2H, m), 4.93-5.00 (1H, m), 5.06 (2H, s), 6.02 (1H, d, J = 6.0 Hz), 7.07 (1H, t, J = 8.8 Hz), 7.19 (1H, d, J = 8.0 Hz), 7.20-7.24 (3H, m), 7.79-7.82 (2H, m), 8.68 (1H, s), 10.8 (1H, s). *NH peak not observed.

[0640] Example 21

[0641] This example describes the synthesis of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxopropyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 21 .

[0642]

[0643] To a solution of N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 4, 100.0 mg, 0.15 mmol) in methanol (3.0 mL) was added 10% palladium on carbon (11 mg, 10.2 μmol). The reaction mixture was stirred at room temperature under an H atmosphere for 5 hours. The product was purified by CELITE TM The mixture was filtered through a pad of Celite® (Sigma-Aldrich, St. Louis, MO), and the filtrate was concentrated in vacuo. The residue was purified by SiO column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-(2-amino-3-(3-(4-(2-methoxyethyl)piperazin-1-yl)-3-oxopropyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10 mg, 10%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.50 (6H, d, J = 6.8Hz), 2.35 (2H, t, J = 4.8Hz), 2.42 (2H, d, J = 4.8Hz) ,2.54(2H,t,J=5.2Hz),2.72(2H,t,J=6.4Hz),3.01(2H,t,J=6.4Hz),3.34(3H,s),3.45-3.51(4H,m) , 3.64 (2H, t, J = 4.8 Hz), 4.93-5.00 (1H, m), 5.29 (2H, s), 5.94 (1H, d, J = 5.6 Hz), 7.06 (1H, t, J = 8.4 Hz), 7.20-7.26 (4H, m), 7.76 (1H, d, J = 6.0 Hz), 7.82 (1H, dd, J = 2.0 Hz, 12.2 Hz), 8.68 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0644] Example 22

[0645] This example describes the synthesis of N-(4-(2-amino-3-phenylpyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 22 .

[0646]

[0647] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-phenylpyridin-2-amine

[0648]

[0649] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridine-2-amine (step D of intermediate 11, 0.20 g, 0.53 mmol) in 1,4-dioxane / water (v / v=2 / 1, 6.0 mL) is added 4,4,5,5-tetramethyl-2-phenyl-1,3,2-dioxaborolane (163 mg, 0.80 mmol) and KCO(221 mg, 1.60 mmol). The reaction mixture is degassed with argon and Pd(PPh)(62 mg, 0.05 mmol) is added and stirred at 90 ° C for 18 hours. After cooling at room temperature, the mixture is quenched with water and extracted with EtOAc. The combined organic layer is dried with NaSO, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc / hexane=2 / 3) to give 4-(2-fluoro-4-nitrophenoxy)-3-phenylpyridin-2-amine (147 mg, 85%) as a pale yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ4.65 (2H, s), 6.27 (1H, d, J = 6.0Hz), 7.08 (1H, t, J = 8.4Hz), 7.33-7.44 (5H, m), 7.98 (2H, d, J = 9.2Hz), 8.02 (1H, d, J = 6.0Hz).

[0650] Step B: 4-(4-amino-2-fluorophenoxy)-3-phenylpyridin-2-amine

[0651]

[0652] A mixture of 4- (2- fluoro-4-nitrophenoxy) -3-phenylpyridine -2- amine (140 mg, 0.43 mmol), zinc (280 mg, 4.30 mmol) and NH4Cl (230 mg, 4.30 mmol) in THF / MeOH (v / v = 1 / 1, 5.0 mL) was stirred at 60 ° C for 18 hours. The reaction mixture was filtered and the residue was distributed between EtOAc and saturated NaHCO3 solution (aqueous solution). The aqueous solution was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH = 95 / 5) to obtain 4- (4- amino -2- fluorophenoxy) -3-phenylpyridine -2- amine (110 mg, 87%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ3.76(2H,s),5.86(2H,s),6.12-6.15(1H,m),6.38-6.47(2H, m), 6.83 (1H, t, J = 9.2Hz), 7.41 (3H, d, J = 8.4Hz), 7.49 (2H, d, J = 7.2Hz), 8.00 (1H, d, J = 6.4Hz).

[0653] Step C: N-(4-(2-amino-3-phenylpyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0654]

[0655] By 3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- carboxylic acid (intermediate 10, 50mg, 0.17mmol), HATU (71mg, 0.19mmol) and DIPEA (74 μ L, 0.42mmol) mixture was stirred at room temperature for 1 hour. To the reaction mixture, 4- (4- amino -2- fluorophenoxy) -3- phenylpyridine -2- amine (50.0mg, 0.17mmol) was added and stirred at room temperature for 18 hours. The reactant was quenched with water and extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-phenylpyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (15 mg, 16%) as a white solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.48 (6H, d, J = 6.8Hz), 4.53 (2H, s), 4.92-4.99 (1H, m), 6.09 (1H, d, J = 6.0Hz), 7.01 (1H, t, J = 8.8Hz), 7.16 (1 H,d,J=8.8Hz),7.23-7.26(4H,m),7.33-7.40(1H,m),7.45-7.49(4H,m),7.73-7.76(1H,m),7.89(1H,d,J=4.0Hz),8.66(1H,s),10.8(1H,s).

[0656] Example 23

[0657] This example describes the synthesis of N-(4-(2-amino-3-((1-methylpiperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention.

[0658] See also Figure 23 .

[0659]

[0660] By N- (4- (2- amino -3- (piperidin-4-yl alkynyl) pyridin-4-yloxy) -3- fluorophenyl) -3- (4- fluorophenyl) -1- isopropyl -2,4- dioxo -1,2,3,4- tetrahydropyrimidine -5- formamide (embodiment 15, 20 mg, 0.03 mmol) and formaldehyde (37%, 12.4 μ L, 0.17 mmol) in MeOH (2.0 mL) was stirred at room temperature for 30 minutes. NaCNBH (21 mg, 0.33 mmol) was added to the reaction mixture at room temperature and stirred for 18 hours. The mixture was quenched with saturated NaHCO solution (aqueous solution), and diluted with DCM. The separated aqueous layer was extracted with DCM, and the combined organic layer was dried with NaSO, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=20 / 1) to give N-(4-(2-amino-3-((1-methylpiperidin-4-yl)ethynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (7.0 mg, 34%) as a white solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.50(6H,d,J=6.4Hz),1.61(2H,s),1.74(2H,m),1.88-1.96(2H,m),2.25(3H,s),2.68(3H,brs),4.93-4.98 (1H,m),5.99(1H,d,J=5.6Hz),7.08(1H,t,J=8.8Hz),7.20(1H,d,J=8.4Hz),7.24-7.26(5H,m),7.79-7.82(2H,m),8.68(1H,s),10.8(1H,s).

[0661] Example 24

[0662] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 24 .

[0663]

[0664] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 100 mg, 0.16 mmol), 4-(prop-2-ynyl)morpholine (intermediate 2, 30 mg, 0.24 mmol), Pd(PPh3)4(19 mg, 0.016 mmol), copper (I) iodide (6.2 mg, 0.03 mmol) and TEA (0.09 mL, 0.65 mmol) in DMF (1.0 mL) was purified with N2. The reaction mixture was stirred at 90 ° C for 16 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layer was dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc to EtOAc / MeOH) to give N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (46 mg, 46%) as a cream solid. 1 H-NMR (CDCl3, Varian, 400MHz):δ 1H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.8Hz), 2.61-2.63 (4H, m), 5.39 (2H, s), 3.73-3.75 (4H, m), 4.93-5.00 (1H, m ),5.11(2H,s),5.98(1H,d,J=5.6Hz),7.09(1H,t,J=8.8Hz),7.02-7.26(5H,m),7.80-7.83(2H,m),8.68(1H,s),10.9(1H,s).

[0665] Example 25

[0666] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide. Figure 25 .

[0667]

[0668] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 50 mg, 0.08 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (intermediate 7, 13 mg, 0.08 mmol), Pd(PPh3)4(9.3 mg, 0.008 mmol), copper(I) iodide (3.1 mg, 0.016 mmol) and TEA (45 μL, 0.32 mmol) in DMF (1.0 mL) was purged with N2. The reaction mixture was stirred at 90 ° C for 16 hours. After cooling at room temperature, EtOAc and saturated NH4Cl solution (aqueous solution) were added to the mixture, and the separated aqueous layer was extracted with EtOAc. The combined organic layers were dried over NaSO, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOA / hexane=9 / 1) to give N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (18 mg, 35%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz):δ 1H-NMR (CDCl3, Varian, 400MHz): δ1.46 (6H, s), 1.50 (6H, d, J = 6.8Hz), 2.66-2.69 (4H, m), 3.72-3.75 (4H, m), 4.96-5.00 (3H, m), 6. 05(1H,d,J=5.6Hz),7.07(1H,t,J=8.4Hz),7.20(1H,d,J=8.8Hz),7.25-7.26(4H,m),7.79-7.85(2H,m),8.68(1H,s),10.9(1H,s).

[0669] Example 26

[0670] This example describes the synthesis of N-(4-(2-amino-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 26 .

[0671]

[0672] Step A: 4-(2-Fluoro-4-nitrophenoxy)-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-2-amine

[0673]

[0674] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-iodopyridin-2-amine (intermediate 11, 200 mg, 0.53 mmol), 1-methyl-4-(prop-2-ynyl)piperazine (intermediate 8, 110 mL, 0.80 mmol), Pd(PPh ) (62 mg, 53.0 μmol) and copper (I) iodide (20.0 mg, 0.10 mmol) in DMF (2.0 mL) was purged with N . The reaction mixture was stirred at 90° C. for 2 hours. After cooling at room temperature, EtOAc and saturated NH Cl (aqueous solution) were poured into the residue, and the separated aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na SO , filtered, and concentrated in vacuo. The residue was purified by MPLC (EtOAc / MeOH) to give 4-(2-fluoro-4-nitrophenoxy)-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-2-amine (139 mg, 67%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ2.68(3H,s),2.29-2.53(8H,m),3.51(2H,s),5.28(2H,s),6.20(1H, d,J=6.0Hz),7.37(1H,t,J=8.0Hz),8.04(1H,d,J=3.6Hz),8.05-8.06(1H,m),8.10(1H,d,J=11.6Hz).

[0675] Step B: 4-(4-amino-2-fluorophenyl)-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-2-amine

[0676]

[0677] A mixture of 4-(2-fluoro-4-nitrophenoxy)-3-(3-(4-methylpiperazine-1-yl)prop-1-ynyl)pyridine-2-amine (130 mg, 0.36 mmol), zinc (236 mg, 3.61 mmol) and NH4Cl (193 mg, 3.61 mmol) in THF-MeOH (v / v=1 / 1, 6 mL) was stirred at 60 ° C for 18 hours. After cooling at room temperature, the solvent was evaporated in vacuo and dissolved with EtOAc. The organic layer was washed with saturated NaHCO3(aqueous solution) and dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (DCM / MeOH) to give 4-(4-amino-2-fluorophenyl)-3-(3-(4-methylpiperazine-1-yl)prop-1-ynyl)pyridine-2-amine (49.0 mg, 39%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 2.29 (3H, s), 2.52 (4H, brs), 2.70 (4H, brs), 3.62 (2H, s), 5.09 (2H, s), 5.94 (1H, d, J = 6.0 Hz), 6.41-6.44 (1H, m), 6.49 (1H, dd, J = 11.8 Hz), 6.94 (1H, t, J = 8.4 Hz), 7.78 (1H, d, J = 5.6 Hz). *NH2 peak not observed.

[0678] Step C: N-(4-(2-amino-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0679]

[0680] A mixture of 4-(4-amino-2-fluorophenoxy)-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-2-amine (42 mg, 0.12 mmol), 3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (intermediate 10, 35 mg, 0.12 mmol), HATU (49.4 mg, 0.13 mmol) and DIPEA (52.0 μL, 0.30 mmol) in DMF (3.0 mL) was stirred at 50 ° C for 1 hour. After cooling at room temperature, EtOAc and saturated NH4Cl (aqueous solution) were poured into the residue, and the separated aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (DCM / MeOH = 100 / 1) to give N-(4-(2-amino-3-(3-(4-methylpiperazin-1-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (32 mg, 43%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.42 (6H, d, J = 6.4Hz), 2.12 (3H, s), 3.32 (8H, s), 3.53 (2H, s), 4.75-4.78 (1H, m), 5.89 (1H, d, J = 6.4Hz), 6 .23(2H,s),7.25(1H,t,J=8.8Hz),7.35-7.37(2H,m),7.40-7.45(3H,m ),7.78(1H,d,J=6.0Hz),7.92-7.95(1H,m),8.67(1H,s).10.98(1H,s).

[0681] Example 27

[0682] This example describes the synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention.

[0683] See also Figure 27 .

[0684]

[0685] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate

[0686]

[0687] A solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 11, 250 mg, 0.40 mmol), tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (135 mg, 0.61 mmol), TEA (0.23 mL, 1.62 mmol) and copper (I) iodide (15 mg, 0.08 mmol) in DMF (2.0 mL) was degassed with argon. Pd(PPh3)4 (47 mg, 0.04 mmol) was added to the reaction mixture and stirred at 90 ° C for 5 hours. After cooling at room temperature, the mixture was dissolved in EtOAc and washed with saturated NH4Cl solution (aqueous solution). The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (hexane / EtOAc=1 / 9) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (180 mg, 62%) as a brown solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.44 (9H, s), 1.50 (6H, d, J = 6.4Hz), 1.72-1. 73(3H,m),1.81(2H,d,J=13.2Hz),2.45(2H,d,J=6.4Hz),2.69(2H,brs),4.11( 2H,s),4.93-5.00(1H,m),5.06(2H,s),5.99(1H,s),7.08(1H,t,J=8.4Hz),7. 23(1H,d,J=8.0Hz),7.44(4H,s),7.80-7.83(2H,m),8.67(1H,s),10.9(1H,s).

[0688] Step B: N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0689]

[0690] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (180 mg, 0.25 mmol) in DCM (5.0 ml) was added TFA (0.19 mL, 2.52 mmol) at room temperature and stirred overnight at room temperature. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with saturated NaHCO solution (aq.). The organic layer was dried over NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (DCM / MeOH = 98 / 2) to give N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (136 mg, 88%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.4Hz), 1.64-1.74 (1H, m), 1.81 (3H ,d,J=13.2Hz),2.43(2H,d,J=6.8Hz),2.56-2.63(2H,m),3.08(2H,d,J=12.4Hz),4. 93-5.00 (1H, m), 5.05 (2H, s), 5.99 (1H, d, J = 5.6 Hz), 7.08 (1H, t, J = 8.4 Hz), 7.20 (1H, d, J = 5.6 Hz), 7.25 (4H, d, J = 6.4 Hz), 7.79-7.83 (2H, m), 8.67 (1H, s), 10.89 (1H, s). *NH2 peak not observed.

[0691] Example 28

[0692] This example describes the synthesis of N-(4-(2-amino-3-(3-(1-(2-methoxyethyl)piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 28 .

[0693]

[0694] By N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 27, 60 mg, 0.01 mmol), 1-bromo-2-methoxyethane (11.0 μ L, 0.12 mmol), potassium iodide (13.0 mg, 0.01 mmol) and KCO(16.0 mg, 0.01 mmol) in CHCN (2.0 mL) was heated at 80 ° C in a sealed container overnight. After cooling at room temperature, DCM and water were poured into the reaction mixture and the separated aqueous layer was extracted with DCM. The combined organic layer was dried with NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=98 / 2) to give N-(4-(2-amino-3-(3-(1-(2-methoxyethyl)piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (24 mg, 37%) as a milky white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.49 (6H, d, J = 6.8Hz), 1.53-1.61 (1H, m), 1.86 (2H, d, J = 16.0Hz), 2.01(2H,t,J=14.0Hz), 2.42(2H,d,J=6.8Hz), 2.54(2H,t,J=6.0Hz), 2.95(2H,d,J=11.6Hz), 3.34( 3H, s), 3.49 (2H, t, J = 5.6 Hz), 4.93-4.98 (1H, m), 5.01 (2H, s), 5.98 (1H, d, J = 5.6 Hz), 7.08 (1H, t, J = 8.4 Hz), 7.20 (1H, d, J = 7.6 Hz), 7.25 (4H, d, J = 6.8 Hz), 7.79-7.83 (2H, m), 8.67 (1H, s), 10.89 (1H, s). *NH2 peak not observed.

[0695] Example 29

[0696] This example describes the synthesis of N-(4-(2-amino-3-(3-(1-isopropylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 29 .

[0697]

[0698] A mixture of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Example 27, 50.0 mg, 0.08 mmol), 2-iodopropane (16.0 μL, 0.16 mmol) and KCO (22.0 mg, 0.16 mmol) was stirred at 50 ° C for 3 hours. After cooling at room temperature, the reaction mixture was washed with water and extracted with EtOAc. The combined organic layers were dried over NaSO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (DCM / MeOH = 97 / 3) to give N-(4-(2-amino-3-(3-(1-isopropylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (17.0 mg, 32%) as a white solid. 1 H-NMR (MeOD, Varian, 400MHz): δ0.91(6H,d,J=6.8Hz), 1.17(2H,d,J=8.4Hz), 1.41(6H,d,J=6.4 Hz),1.67(2H,d,J=12.4Hz),2.02(2H,t,J=11.2Hz),2.38(2H,d,J=6.0Hz),2.50-2.61(1H,m),2 .71 (2H, d, J = 10.0 Hz), 4.75-4.77 (1H, m), 5.93 (1H, d, J = 5.6 Hz), 6.14 (1H, s), 7.19 (1H, t, J = 8.4 Hz), 7.33-7.41 (5H, m), 7.76 (1H, d, J = 6.0 Hz), 7.93 (1H, d, J = 12.8 Hz), 8.66 (1H, s), 10.9 (1H, s). *NH peak not observed.

[0699] Example 30

[0700] This example illustrates an enzyme assay used to determine the inhibitory activity of exemplary compounds of formula (I) according to one aspect of the invention.

[0701] All kinase reactions were performed using 5 μL of tyrosine kinase buffer containing 0.2 μg / μL poly (Glu4, Tyr1) substrate, 10 μM ATP, serial dilutions of inhibitors, and incubated at room temperature for 60 minutes. After the indicated incubation times, 5 μL of ADP-GLO TMThe reagent (Promega, Madison, WI) was added to the reaction and the plate was incubated at room temperature for 40 minutes. Next, 10 μL of kinase detection reagent was added and after a 40-minute incubation time, luminescence was recorded and the IC was determined. 50 The values ​​were obtained from GLOMAX (Madison, WI). TM All 384-well assay plates were read on a Discover microplate luminometer.To graph, analyze data, and calculate all kinase reaction biochemical values, both Microsoft Excel and Prism from GraphPad 7 software (La Jolla, CA) were used.

[0702] Table 1.

[0703]

[0704] Example 31

[0705] This example describes the preparation of an epidermal growth factor receptor (EGFR) TKI-resistant cell line according to one aspect of the present invention.

[0706] EGFR tyrosine kinase inhibitors (TKIs) inhibit EGFR and are used to treat non-small cell lung cancer (NSCLC) that has activating mutations in the EGFR gene. While most EGFR-mutant NSCLCs respond to EGFR TKIs, the majority of these tumors eventually become resistant to the drug treatment. In approximately 50% of these cases, resistance is due to EGFR T790M About 5% of cases are caused by secondary mutations in the mitochondria, c-MET amplification, and about 20% by overexpression of AXL.

[0707] c-MET amplification contributes to the acquisition of resistance to EGFR TKIs because it is a redundant pathway that activates PI3K / AKT signaling that promotes cancer cell survival, thereby bypassing inhibition of upstream EGFR signaling in the presence of EGFR TKIs.

[0708] AXL is a member of the TAM (TYRO3-AXL-MER) family of receptor tyrosine kinases and can increase tumor cell survival, proliferation, migration and invasion, angiogenesis and tumor-host interaction when activated. Overexpression or abnormal activation of AXL in many malignant tumors from epithelial and blood sources has been described, and it is generally associated with poor prognosis, increased recurrence rate, reduced disease-free survival and poor overall survival. In addition, AXL expression is associated with epithelial-mesenchymal transition (EMT), which is a common feature of metastatic tumors and is generally associated with EGFR TKI resistance. Therefore, AXL is an attractive molecular target for many solid tumors (including NSCLC).

[0709] To explore the c-MET and AXL mechanisms of EGFR TKI resistance, we generated resistant cells of the EGFR TKI-hypersensitive EGFR exon 19 mutant NSCLC cell lines HCC827 and PC9 by exposing them to increasing concentrations of EGFR TKI for more than 3 months.

[0710] Human cell line HCC827 was purchased from the American Type Culture Collection (Manassas, VA), and PC9 cell line was purchased from RIKEN Cell Bank (Ibaraki, Japan). HCC827 / ER, HCC827 / GR, HCC827 / OR, and PC9 / ER cells containing EGFR exon 19 deletion and overexpression of c-MET and AXL were generated by gradually exposing HCC827 or PC9 cells to gefitinib, erlotinib, and osimertinib. Gefitinib-resistant cells are referred to as HCC827 / GR. Erlotinib-resistant cells are referred to as PC9 / ER, HCC827 / ER. Osimertinib-resistant cells are referred to as HCC827 / OR.

[0711] All of these cell lines were maintained in RPMI 1640 medium (GIBCO, Carlsbad, CA) containing 1 μM gefitinib, erlotinib, and osimertinib, 10% fetal bovine serum (FBS), penicillin (100 U / mL), and streptomycin (50 μg / mL) at 37° C. in a humidified CO incubator. All cell lines were authenticated by Sanger sequencing, human phospho-RTK array kit (R&D systems), and Western blot analysis.

[0712] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0713] Example 32

[0714] This example illustrates a cell viability assay for exemplary compounds of formula (I) according to one aspect of the invention.

[0715] Cell viability was determined by plating HCC827 or PC9 resistant cells at 1,000 cells per well into white, transparent bottom 384-well plates. Cells were treated with each TKI in a range of 10 doses from 1 nM to 10,000 nM. After 72 hours of drug treatment, cell viability was measured using CellTiter-Glo 2.0 assay (Promega, Madison, Wisconsin). By continuously exposing cells to EGFR TKI for more than 3 months, EGFR TKI (gefitinib, erlotinib, and osimertinib) resistant cell lines derived from parental EGFR TKI-sensitive HCC827 or PC9 cell lines were formed. Resistant cell lines were designated HCC827 / ER, PC9 / ER, and the resistance to erlotinib was 1,000 times higher than that of parental cells (erlotinib IC 50 , <0.01 μM in HCC827 or PC9 cells, and >10 μM in HCC827 / ER or PC9 / ER). HCC827 / GR exhibited 4,000-fold greater resistance to gefitinib than the parental cells (gefitinib IC 50 , <0.002 μM in HCC827 cells, and 8.9 μM in HCC827 / GR cells). HCC827 / OR exhibited 3,000-fold greater resistance to osimertinib than the parental cells (osimertinib IC 50, <0.0003 μM in HCC827 cells and >1 μM in HCC827 / OR cells). The combination of EGFR TKI and the inhibitor of Formula (I) overcomes acquired resistance to EGFR TKI. Table 2 shows that representative compounds overcome the resistance of EGFR TKI-resistant cells.

[0716] Table 2.

[0717]

[0718]

[0719] Example 33

[0720] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 30 .

[0721]

[0722] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 50.0 mg, 0.08 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (17.0 mg, 0.11 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (8.7 mg, 7.55 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc / MeOH=9 / 1) to give N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (8.0 mg, 15%) as a creamy white solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.46(6H,s),2.69(4H,m),3.02(3H,s),3.10(3H,s),3.74(4H,m),4.74(2H,s)5.14(2 H,brs),6.05(1H,d,J=5.6Hz),7.07(1H,t,J=8.4Hz),7.26-7.18(5H,m),7.78-7.82(2H,m),8.52(1H,s),10.79(1H,s).

[0723] Example 34

[0724] This example describes the synthesis of N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 31 .

[0725]

[0726] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 50.0 mg, 0.08 mmol), 4-(prop-2-yn-1-yl)morpholine (14.0 mg, 0.11 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.7 mg, 7.55 μmol) was added to the reaction mixture and stirred at 90° C. overnight. 4-(Propan-2-yn-1-yl)morpholine (14.0 mg, 0.11 mmol), copper (I) iodide (2.8 mg, 0.02 mmol), TEA (41.0 μL, 0.30 mmol) and Pd(PPh ) (8.7 mg, 7.55 μmol) were added to the reaction mixture again. After degassing with N , the mixture was stirred at 90° C. for 3 hours. After cooling to room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na SO , filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc / MeOH=9 / 1) to give N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (6.0 mg, 11%) as a creamy white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.63-2.64(4H,m),3.02(3H,s),3.10(3H,s),3.60(2H,s),3.73-3.75(4H,m),4.73(2H, s),5.18(2H,brs)5.99(1H,brs),7.08(1H,t,J=8.8Hz),7.19-7.26(5H,m),7.79-7.82(2H,m),8.52(1H,s),10.8(1H,s).

[0727] Example 35

[0728] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 32 .

[0729]

[0730] Step A: tert-Butyl 4-(4-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate

[0731]

[0732] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 100 mg, 0.15 mmol), tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (76.0 mg, 0.30 mmol), copper(I) iodide (5.75 mg, 0.03 mmol) and TEA (82.0 μL, 0.60 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (17.45 mg, 0.02 mmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc / MeOH=95 / 5 to EtOAc / MeOH=9 / 1) to give tert-butyl 4-(4-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (34 mg, 29%) as an orange solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.42(9H,s),1.46(6H,s),2.62(4H,m),3.02(3H,s),3.10(3H,s),3.44(4H,m),4.73(2H,s) ,5.03(2H,s),6.06(1H,d,J=5.6Hz),7.03(1H,t,J=8.8Hz),7.17-7.26(5H,m),7.79-7.81(2H,m),8.51(1H,s),10.79(1H,s).

[0733] Step B: N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0734]

[0735] To a solution of tert-butyl 4-(4-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (34.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (33.0 μL, 0.43 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (32.0 mg, 98%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.44 (6H, s), 2.62 (4H, brs), 2.91 (4H, t, J = 4.8 Hz), 3.02 (3H, s), 3.10 (3H, s), 4.74 (2H, s), 5.02 (2H, s), 6.06 (1H, d, J = 5.6 Hz), 7.04 (1H, t, J = 8.8 Hz), 7.17-7.26 (5H, m), 7.76-7.80 (1H, m), 7.83 (1H, d, J = 6.0 Hz), 8.53 (1H, s), 10.78 (1H, s). *NH peak not observed.

[0736] Example 36

[0737] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 33 .

[0738]

[0739] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 50.0 mg, 0.07 mmol), 1-methyl-4-(2-methylbut-3-yn-2-yl)piperazine (25.0 mg, 0.15 mmol), copper(I) iodide (2.88 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.7 mg, 7.55 μmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc only to EtOAc / MeOH=97 / 3) to give N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (9.7 mg, 15%) as an orange solid. 1 H-NMR (CDCl3,Varian,400MHz): δ1.45(6H,s),2.26(3H,s),2.49(4H,brs),2.73(4H,brs),3.02(3H,s),3.10(3H,s),4.73(2H, s),5.02(2H,s),6.01(1H,d,J=6.0Hz),7.06(1H,t,J=8.8Hz),7.17-7.26(5H,m),7.77-7.81(2H,m),8.51(1H,s).10.78(1H,s).

[0740] Example 37

[0741] This example describes the synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 34 .

[0742]

[0743] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 30.0 mg, 0.04 mmol), 1-methyl-4-(prop-2-yn-1-yl)piperidine hydrochloride (15.7 mg, 0.09 mmol), copper(I) iodide (1.7 mg, 9.06 μmol) and TEA (25.0 μL, 0.18 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (5.23 mg, 4.53 μmol) was added to the reaction mixture and stirred at 90 °C in a sealed tube overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc only to EtOAc / MeOH=95 / 5) to give N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.5 mg, 4.5%) as an orange solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.40-1.45(2H,m),1.56(1H,m),1.84(2H,d,J=12 .8Hz),1.93-2.00(2H,m),2.27(3H,s),2.42(2H,d,J=6.4Hz),2.89(2H,d,J=11Hz) ,3.02(3H,s),3.10(3H,s),4.73(2H,s),5.06(2H,brs),5.97(1H,d,J=6Hz),7.08( 1H,t,J=8.4Hz),7.17-7.26(5H,m),7.77-7.82(2H,m),8.52(1H,s),10.80(1H,s).

[0744] Example 38

[0745] This example describes the synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 35 .

[0746]

[0747] Step A: tert-Butyl 4-(3-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate

[0748]

[0749] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 16, 75.0 mg, 0.11 mmol), tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (50.0 mg, 0.22 mmol), copper(I) iodide (4.26 mg, 0.02 mmol) and TEA (61.0 μL, 0.45 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (12.94 mg, 0.01 mmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc only to EtOAc / MeOH=97 / 3) to give tert-butyl 4-(3-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (31.0 mg, 36%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.44(9H,s),1.71(3H,m),1.81(2H,d,J=8Hz),2.45(2H,d,J=6.8Hz),2.69(2H,brs),3.02(3H,s),3.10(3H,s),4.12 (2H,brs),4.73(2H,s),5.07(2H,brs),5.98(1H,d,J=5.6Hz),7.08(1H,t,J =8.4Hz),7.18-7.26(5H,m),7.77-7.79(2H,m),8.51(1H,s),10.80(1H,s).

[0750] Step B: N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0751]

[0752] To a solution of tert-butyl 4-(3-(2-amino-4-(4-(1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (31.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (32.0 μL, 0.41 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. TFA (32.0 μL, 0.41 mmol) was added to the reaction mixture again at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (14.0 mg, 44%) as a white solid. 1H-NMR(CD3OD,Varian,400MHz): δ1.34-1.42(3H,m),1.75(1H,m),1.88-1.94(2H,m), 2.49(2H,d,J=6.4Hz),2.68-2.75(2H,m),2.99(3H,s),3.11(3H,s),3.11-3.16(2H,m ),4.96(2H,s),6.00(1H,d,J=6Hz),7.12-7.16(1H,m),7.23-7.30(3H,m),7.33-7.37(2H,m),7.71(1H,d,J=6.4Hz),7.89(1H,d,J=12.8Hz),8.67(1H,s)*Amide NH and NH2 peaks were not observed.

[0753] Example 39

[0754] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 36 .

[0755]

[0756] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 50.0 mg, 0.07 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (17.0 mg, 0.11 mmol), copper(I) iodide (2.8 mg, 0.01 mmol) and TEA (40.0 μL, 0.29 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (8.4 mg, 7.26 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO column chromatography (EtOAc / hexane=4 / 1) to give N-(4-((2-amino-3-(3-methyl-3-morpholinobut-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10 mg, 18%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.45 (6H, s), 2.67 (4H, m), 2.71 (3H, s), 3.73 (4H, t, J = 4.8Hz), 5.03 (2H, brs), 5.12 ( 2H,s),6.02(1H,d,J=6.0Hz),7.06(1H,t,J=8.4Hz),7.15-7.26(6H,m),7.79-7.83(2H,m),8.87(1H,s),10.82(1H,s).

[0757] Example 40

[0758] This example describes the synthesis of N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 37 .

[0759]

[0760] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 50.0 mg, 0.07 mmol), 4-(prop-2-yn-1-yl)morpholine (18.0 mg, 0.14 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (40.0 μL, 0.29 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (8.4 mg, 7.26 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO column chromatography (EtOAc only) to give N-(4-((2-amino-3-(3-morpholinoprop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (7.4 mg, 13%) as a cream solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.61-2.63(4H,m),2.71(3H,s),3.59(2H,s),3.73-3.75(4H,m),5.09(2H,brs),5.13 (2H,s),5.97(1H,d,J=6.0Hz),7.08(1H,t,J=8.8Hz),7.17-7.26(6H,m),7.82-7.80(2H,m),8.87(1H,s),10.84(1H,s).

[0761] Example 41

[0762] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 38 .

[0763]

[0764] Step A: tert-Butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate

[0765]

[0766] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 70.0 mg, 0.10 mmol), tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (51.0 mg, 0.20 mmol), copper(I) iodide (3.87 mg, 0.02 mmol) and TEA (55.0 μL, 0.41 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (11.7 mg, 10.17 μmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=97 / 3) to give tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (36.0 mg, 44%) as a brown solid. 1 H-NMR(CDCl3,Varian,400MHz): δ1.42(6H,s),1.44-1.46(9H,m),2.62(4H,brs),2.71(3H,s),3.44-3.45(4H,m),5.0 0(2H,s),5.13(2H,brs),5.99(1H,m),7.06(1H,m),6.99-7.25(6H,m),7.79-7.82(2H,m),8.87(1H,s),10.83(1H,s).

[0767] Step B: N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0768]

[0769] To a solution of tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (36.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (35.0 μL, 0.45 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (5.4 mg, 10%) as a white solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.44 (6H, s), 2.62 (4H, brs), 2.70 (3H, s), 2.90 (4H, brs), 5.01 (2H, brs), 5.12 (2H, s), 6.03 (1H, d, J = 6 Hz), 7.05 (1H, t, J = 8.4 Hz), 7.15-7.26 (6H, m), 7.79-7.83 (2H, m), 8.87 (1H, s), 10.83 (1H, s). *NH peak not observed.

[0770] Example 42

[0771] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 39 .

[0772]

[0773] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 50.0 mg, 0.07 mmol), 1-methyl-4-(2-methylbut-3-yn-2-yl)piperazine (24.0 mg, 0.14 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (40.0 μL, 0.29 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.4 mg, 7.26 μmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (6.3 mg, 10%) as a milky white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.45(6H,s),2.26(3H,s),2.50(4H,brs),2.71(4H,brs),2.71(3H,s),5.04(2H,brs),5. 12(2H,s),6.00(1H,d,J=6.4Hz),7.06(1H,t,J=8.4Hz),7.19-7.26(6H,m),7.78-7.81(2H,m),8.87(1H,s),10.82(1H,s).

[0774] Example 43

[0775] This example describes the synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 40 .

[0776]

[0777] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 50.0 mg, 0.07 mmol), 1-methyl-4-(prop-2-yn-1-yl)piperidine hydrochloride (25.0 mg, 0.14 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (40.0 μL, 0.29 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.4 mg, 7.26 μmol) was added to the reaction mixture and stirred at 90 °C in a sealed tube overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (3.5 mg, 5.8%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.33-1.43(2H,m),1.55(1H,m),1.84(2H,d,J=12H z),2.00(2H,t,J=17.4Hz),2.25(3H,s),2.43(2H,d,J=6.8Hz),2.71(3H,s),2.85(2H ,d,J=12Hz),5.02(2H,brs),5.12(2H,s),5.96(1H,d,J=6Hz),7.08(1H,t,J=8.8Hz), 7.17-7.20(1H,m),7.22-7.25(5H,m),7.77-7.82(2H,m),8.87(1H,s),10.84(1H,s).

[0778] Example 44

[0779] This example describes the synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 41 .

[0780]

[0781] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate

[0782]

[0783] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 18, 77.0 mg, 0.11 mmol), tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (50.0 mg, 0.22 mmol), copper(I) iodide (4.26 mg, 0.02 mmol) and TEA (61.0 μL, 0.45 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (12.9 mg, 0.01 mmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc only) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (27.0 mg, 30%) as an orange solid. 1H-NMR (CDCl3, Varian, 400 MHz): δ 1.44 (9H, s), 1.74-1.83 (3H, m), 2.45 (2H, d, J = 6.8 Hz), 2.69 (2H, brs), 2.71 (3H, s), 4.10 (2H, brs), 5.13 (2H, s), 5.19 (2H, brs), 5.96 (1H, d, J = 6.4 Hz), 7.08 (1H, t, J = 8.4 Hz), 7.14-7.25 (6H, m), 7.77 (1H, d, J = 6 Hz), 7.83-7.80 (1H, m), 8.87 (1H, s), 10.85 (1H, s). *NH2 peak not observed.

[0784] Step B: N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0785]

[0786] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (27.0 mg, 0.03 mmol) in DCM (1 ml) was added TFA (26.0 μL, 0.34 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-3-(4-fluorophenyl)-1-((2-methylthiazol-4-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (7.1 mg, 27%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.30-1.40(3H,m),1.61(1H,m),1.88(2H,d,J =12Hz),2.45(2H,d,J=6.8Hz),2.61-2.70(2H,m),2.71(3H,s),3.19(2H,d,J=1 2Hz),5.02(2H,brs),5.13(2H,s),5.99(1H,d,J=4Hz),7.03-7.08(1H,m),7.17 -7.19(1H,m),7.22-7.24(5H,m),7.79-7.81(2H,m),8.87(1H,s),10.84(1H,s).

[0787] Example 45

[0788] This example describes the synthesis of N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, an aspect of the invention. See Figure 42 .

[0789]

[0790] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20, 70.0 mg, 0.12 mmol), 1-methyl-4-(prop-2-yn-1-yl)piperidine hydrochloride (41.0 mg, 0.24 mmol), copper (I) iodide (4.5 mg, 0.02 mmol) and TEA (64.0 μL, 0.47 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (14.0 mg, 0.01 mmol) was added to the reaction mixture and stirred at 90 ° C in a sealed tube overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-((2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (2.4 mg, 3%) as a yellow solid.1 H-NMR (CDCl3, Varian, 400MHz): δ1.34-1.44(3H,m),1.81(2H,m),1.88-1.97(2H,m),2.26(3H,s),2.43(2H,d,J=6.4Hz),2.83-2 .89(2H,brs),3.93(3H,s),5.01(2H,brs),5.99(1H,m),7.14-7.10(1H,m),7.25-7.28(5H,m),7.82-7.85(2H,m),10.81(1H,s).

[0791] Example 46

[0792] This example describes the synthesis of N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, an aspect of the invention. See Figure 43 .

[0793]

[0794] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate

[0795]

[0796] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20, 75.0 mg, 0.13 mmol), tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (56.0 mg, 0.25 mmol), copper (I) iodide (4.82 mg, 0.02 mmol) and TEA (69.0 μL, 0.51 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (15.0 mg, 0.01 mmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC (EtOAc only) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (17.0 mg, 19%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.43(9H,s),1.62(3H,m),1.78(2H,d,J=12Hz),2.43(2H,d,J=6Hz),2.69(2H,brs),3.92(3H,s),4.09(2H,brs),5.10(2 H,brs),6.01(1H,d,J=5.6Hz),7.08-7.12(1H,m),7.24-7.26(1H,m),7.26-7 .28(4H,m),7.80(1H,d,J=5.6Hz),7.86(1H,dd,J=12,2.8Hz),10.83(1H,s).

[0797] Step B: N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide

[0798]

[0799] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamido)phenoxy)pyridin-3-yl)prop-2-yn-1-yl)piperidine-1-carboxylate (17.0 mg, 0.02 mmol) in DCM (1 mL) was added TFA (20.0 μL, 0.25 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-((2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (5.9 mg, 38%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.29-1.38 (3H, m), 1.72 (1H, m), 1.84-1.91 (2H, m), 2.47 (2H, d, J = 6.8 Hz), 2.62-2.69 (2H, m), 3.10 (2H, d, J = 12 Hz), 3.79 (3H, s), 6.02 (1H, d, J = 5.6 Hz), 7.16-7.20 (1H, m), 7.26-7.30 (2H, m), 7.35-7.41 (3H, m), 7.72 (1H, d, J = 6 Hz), 7.90 (1H, dd, J = 12.4, 2.4 Hz). *Amide NH and NH2 peaks were not observed.

[0800] Example 47

[0801] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, an aspect of the present invention. Figure 44 .

[0802]

[0803] Step A: tert-Butyl 4-(4-(2-amino-4-(2-fluoro-4-(4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide)pyridin-3-yl)-2-methylbut-3-yn-2yl)piperazine-1-carboxylate

[0804]

[0805] To a solution of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20, 100 mg, 0.17 mmol) in DMF (3.4 mL) was added tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (43.0 mg, 0.17 mmol), copper(I) iodide (6.43 mg, 0.03 mmol) and TEA (92.0 μL, 0.68 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After the addition of Pd(PPh3)4 (20.0 mg, 0.02 mmol), the reaction mixture was heated at 90°C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc only) to give 4- (4- (2- amino -4- (2- fluoro -4- (4- (4- fluorophenyl) -2- methyl -3,5- dioxo -2,3,4,5- tetrahydro -1,2,4- triazine -6- carboxamide) pyridin-3-yl) -2- methylbut-3- yn-2 bases) piperazine -1- tert-butyl carboxylate (30.0 mg, 25%) as a yellow solid. 1 H-NMR (DMSO-d6,Varian,400MHz): δ1.31(9H,s),1.36(6H,s),2.44-2.50(4H,m),3.27(4H,s),3.67(3H,s),5.95(1H,d,J=5.6Hz),6.1 3(2H,s),7.22(1H,t,J=9.0Hz),7.35-7.39(4H,s),7.46(1H,d,J=8.8Hz),7.79(1H,d,J=6.0Hz),7.85(1H,d,J=12.4Hz),10.8(1H,s).

[0806] Step B: N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide

[0807]

[0808] To a solution of tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide)pyridin-3-yl)-2-methylbut-3-yn-2yl)piperazine-1-carboxylate (30.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (32.0 μL, 0.42 mmol) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. After cooling to 0° C., the reaction mixture was washed with saturated NaHC03. The O solution was quenched and extracted with DCM. The organic layer was dried over NaSO, filtered and concentrated in vacuo. The residue was ground with DCM and hexane. The resulting solid was collected by filtration and dried under vacuum to give N-(4-(2-amino-3-(3-methyl-3-(piperazine-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (19.3 mg, 75%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400 MHz): δ 1.32 (6H, s), 2.42-2.48 (4H, m), 2.69 (4H, s), 3.67 (3H, s), 5.99 (1H, d, J = 5.6 Hz), 6.11 (2H, s), 7.22 (1H, t, J = 8.8 Hz), 7.39-7.34 (4H, m), 7.47 (1H, d, J = 9.2 Hz), 7.80 (1H, d, J = 5.6 Hz), 7.86 (1H, d, J = 12.8 Hz), 10.8 (1H, s). *NH peak not observed.

[0809] Example 48

[0810] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, an aspect of the present invention. Figure 45 .

[0811]

[0812] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20, 50.0 mg, 0.08 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (19.43 mg, 0.13 mmol), copper(I) iodide (3.22 mg, 0.02 mmol) and TEA (46.0 μL, 0.34 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (9.77 mg, 8.46 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (8.0 mg, 15%) as a brown solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.45(6H,s),2.66(4H,m),3.71-3.74(4H,m),3.93(3H,s),5.05(2H, s), 6.05 (1H, d, J = 6.0Hz), 7.10 (1H, t, J = 8.4Hz), 7.25-7.29 (5H, m), 7.83-7.85 (2H, m), 10.80 (1H, s).

[0813] Example 49

[0814] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide, an aspect of the present invention. Figure 46 .

[0815]

[0816] A mixture of N-(4-((2-amino-3-iodopyridin-4-yl)oxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (Intermediate 20, 50.0 mg, 0.08 mmol), 4-(prop-2-yn-1-yl)morpholine (15.88 mg, 0.13 mmol), copper(I) iodide (3.22 mg, 0.02 mmol) and TEA (46.0 μL, 0.34 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (9.77 mg, 8.46 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EA only to EA / MeOH=97 / 3) to give N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-4-(4-fluorophenyl)-2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carboxamide (4.9 mg, 10%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ2.62(4H,m),3.60(2H,s),3.75(4H,m),3.93(3H,s),5.07(2H,s) ,5.98(1H,d,J=6.4Hz),7.13(1H,t,J=8.6Hz),7.25-7.28(5H,m),7.83-7.86(2H,m),10.82(1H,s).

[0817] Example 50

[0818] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 47 .

[0819]

[0820] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 22, 100 mg, 0.17 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (39.8 mg, 0.26 mmol), copper (I) iodide (6.6 mg, 0.04 mmol) and TEA (94.0 μL, 0.69 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (20.0 mg, 0.02 mmol) was added to the reaction mixture and stirred at 130 ° C for 2 hours in a sealed tube. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO column chromatography (EtOAc / MeOH=9 / 1). The product was purified by NH—SiO preparative TLC (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (8.0 mg, 7.7%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.47 (6H, s), 2.72 (4H, m), 3.70 (4H, m), 6.03 (1H, d, J = 6.4 Hz), 7.12 (1H, t, J = 8.8 Hz), 7.20-7.29 (5H, m), 7.75 (1H, d, J = 6.0 Hz), 7.85-7.88 (1H, m), 8.67 (1H, s). *Amine and amide protons were not observed.

[0821] Example 51

[0822] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 48 .

[0823]

[0824] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 22, 100 mg, 0.17 mmol), 4-(prop-2-yn-1-yl)morpholine (32.5 mg, 0.26 mmol), copper (I) iodide (6.6 mg, 0.04 mmol) and TEA (94.0 μL, 0.69 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (20.0 mg, 0.02 mmol) was added to the reaction mixture and stirred at 130 ° C for 2 hours in a sealed tube. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO column chromatography (EtOAc / MeOH = 85 / 15). The product was purified by NH-SiO preparative TLC (EtOAc / MeOH = 85 / 15) to give N- (4- (2-amino-3- (3-morpholinoprop-1-ynyl) pyridin-4-yloxy) -3-fluorophenyl) -3- (4-fluorophenyl) -2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (5.4 mg, 5.4%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 2.65 (4H, m), 3.59 (2H, s), 3.71 (4H, m), 5.97 (1H, d, J = 6.0 Hz), 7.14 (1H, t, J = 8.4 Hz), 7.20-7.29 (5H, m), 7.74 (1H, d, J = 6.4 Hz), 7.85-7.89 (1H, m), 8.67 (1H, s). *Amine and amide protons were not observed.

[0825] Example 52

[0826] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 49 .

[0827]

[0828] Step A: tert-Butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate

[0829]

[0830] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 22, 200 mg, 0.35 mmol), tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (131 mg, 0.52 mmol), copper (I) iodide (13.2 mg, 0.07 mmol) and TEA (189 μL, 1.39 mmol) in DMF (1.5 mL) was degassed with N2. Pd(PPh3)4 (40.0 mg, 0.04 mmol) was added to the reaction mixture and stirred at 130 ° C for 2 hours in a sealed tube. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / MeOH=97 / 3) to give tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (25.5 mg, 10%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.40 (9H, s), 1.48 (6H, s), 2.67 (4H, m), 3.42 (4H, m), 6.03 (1H, d, J = 6.0 Hz), 7.13 (1H, t, J = 8.4 Hz), 7.23-7.25 (3H, m), 7.32-7.35 (2H, m), 7.75 (1H, d, J = 6.4 Hz), 7.87-7.90 (1H, m), 8.53 (1H, s). *Amine and amide protons were not observed.

[0831] Step B: N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0832]

[0833] To a solution of tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (25.5 mg, 0.04 mmol) in DCM (1 mL) was added TFA (56.0 μL, 0.73 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 preparative TLC (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (7.8 mg, 35%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.49 (6H, s), 2.88 (4H, m), 3.13 (4H, m), 6.04 (1H, d, J = 6.0 Hz), 7.11 (1H, t, J = 8.8 Hz), 7.23-7.30 (5H, m), 7.76 (1H, d, J = 5.6 Hz), 7.88-7.89 (1H, m), 8.63 (1H, s). *Amine and amide protons were not observed.

[0834] Example 53

[0835] This example describes the synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 50 .

[0836]

[0837] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate

[0838]

[0839] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 22, 200 mg, 0.35 mmol), tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (116 mg, 0.52 mmol), copper (I) iodide (13.2 mg, 0.07 mmol) and TEA (0.19 mL, 1.39 mmol) in DMF (2 mL) was degassed with N2. Pd(PPh3)4 (40.0 mg, 0.04 mmol) was added to the reaction mixture and stirred at 130 ° C for 2 hours in a sealed tube. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc only to EtOAc / MeOH=97 / 3) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (77.9 mg, 33%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.16-1.26 (2H, m), 1.42 (9H, s), 1.72 (1H, brs), 1.80 (2H, d, J = 13.2 Hz), 2.46 (2H, d, J = 6.4 Hz), 2.72 (2H, brs), 4.03-4.10 (2H, m), 6.01 (1H, d, J = 6.0 Hz), 7.125 (1H, t, J = 8.6 Hz), 7.23-7.33 (5H, m), 7.72 (1H, m), 7.86-7.90 (1H, d, J = 12.4 Hz), 8.54 (1H, s). *Amine and amide protons were not observed.

[0840] Step B: N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0841]

[0842] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (77.9 mg, 0.12 mmol) in DCM (1 mL) was added TFA (0.18 mL, 2.32 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by SiO2 preparative TLC (EtOAc / MeOH=4 / 1). The product was washed with water and extracted with EtOAc. The organic layer was concentrated in vacuo. The residue was dissolved in MeOH. The solids were removed and the filtrate was concentrated in vacuo and dried under vacuum to give N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (2.5 mg, 4%) as a yellow solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.51-1.58 (2H, m), 1.93 (1H, m), 2.06-2.10 (2H, m), 2.58 (2H, d, J = 6.4 Hz), 2.96-3.03 (2H, m), 3.37-3.40 (2H, m), 6.07 (1H, d, J = 6.0 Hz), 7.18 (1H, t, J = 8.8 Hz), 7.24-7.37 (5H, m), 7.73-7.75 (1H, m), 7.88-7.92 (1H, m), 8.52 (1H, s). *Amine and amide protons were not observed.

[0843] Example 54

[0844] This example describes the synthesis of N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, one aspect of the invention.

[0845] See also Figure 51 .

[0846]

[0847] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 22, 100 mg, 0.17 mmol), 1-methyl-4-(prop-2-yn-1-yl)piperidine hydrochloride (45.0 mg, 0.26 mmol), copper (I) iodide (6.6 mg, 0.04 mmol) and TEA (94.0 μL, 0.70 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (20.0 mg, 0.02 mmol) was added to the reaction mixture and stirred at 130 ° C for 2 hours in a sealed tube. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO preparative TLC (EtOAc / MeOH=4 / 1). The product was purified by SiO preparative TLC (MeOH only) to give N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.8 mg, 1.7%) as a white solid. 1 H-NMR (CD3OD, Varian, 400 MHz): δ 1.44-1.54 (2H, m), 1.61-1.68 (1H, m), 1.92-1.96 (2H, m), 2.43-2.51 (7H, m), 3.12-3.15 (2H, m), 6.02 (1H, d, J = 5.6 Hz), 7.08-7.12 (1H, m), 7.21-7.30 (5H, m), 7.72 (1H, d, J = 5.6 Hz), 7.84-7.88 (1H, m), 8.66 (1H, s). *Amine and amide protons were not observed.

[0848] Example 55

[0849] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 52 .

[0850]

[0851] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 50.0 mg, 0.08 mmol), 4-(2-methylbut-3-yn-2-yl)morpholine (17.0 mg, 0.11 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (8.7 mg, 7.56 μmol) was added to the reaction mixture and stirred at 90 °C overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (DCM / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (16.0 mg, 31%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.45 (6H, s), 1.95-2.05 (4H, m), 2.65-2.6 8(4H,m),3.52-3.57(2H,m),3.71-3.74(4H,m),4.14-4.18(2H,m),4.77-4.8 4(1H,m),5.04(2H,s),6.04(1H,d,J=6.0Hz),7.06(1H,t,J=8.8Hz),7.19-7. 20(1H,m),7.24-7.25(4H,m),7.78-7.83(2H,m),8.68(1H,s),10.83(1H,s).

[0852] Example 56

[0853] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 53 .

[0854]

[0855] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 50.0 mg, 0.08 mmol), 4-(prop-2-yn-1-yl)morpholine (14.0 mg, 0.12 mmol), copper(I) iodide (2.8 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.7 mg, 7.56 μmol) was added to the reaction mixture and stirred at 90° C. overnight. To the mixture was added copper (I) iodide (2.8 mg, 0.02 mmol), TEA (41.0 μL, 0.30 mmol) and Pd (PPh 3 ) 4 (8.7 mg, 7.56 μmol) and stirred at 90 ° C for 7 hours. After cooling at room temperature, the reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (DCM / MeOH = 95 / 5). The product was purified by NH-SiO2 column chromatography (EtOAc only) to give N- (4- (2-amino-3- (3-morpholinoprop-1-ynyl) pyridin-4-yloxy) -3-fluorophenyl) -3- (4-fluorophenyl) -2,4-dioxo -1- (tetrahydro -2H- pyrans -4-yl) -1,2,3,4-tetrahydropyrimidine -5-carboxamide (18.0 mg, 37%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.95-2.07(4H,m),2.61-2.64(4H,m),3.5 1-3.57(2H,m),3.60(2H,s),3.73-3.75(4H,m),4.14-4.19(2H,m),4.78-4.8 4(1H,m),5.07(2H,s),5.98(1H,d,J=5.6Hz),7.09(1H,t,J=8.4Hz),7.19-7. 22(1H,m),7.24-7.25(4H,m),7.78-7.83(2H,m),8.68(1H,s),10.85(1H,s).

[0856] Example 57

[0857] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 54 .

[0858]

[0859] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 50.0 mg, 0.08 mmol), 1-methyl-4-(2-methylbut-3-yn-2-yl)piperazine (19.0 mg, 0.11 mmol), copper(I) iodide (2.88 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.7 mg, 7.56 μmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was diluted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc only) to give N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (16.9 mg, 32%) as a yellow solid. 1 H-NMR (CDCl3,Varian,400MHz): δ1.45(6H,s),1.98-2.05(4H,m),2.26(3H,s) ,2.48(4H,brs),2.73(4H,brs),3.52-3.57(2H,m),4.14-4.17(2H,m),4.78-4 .84(1H,m),5.04(2H,s),6.01(1H,d,J=5.6Hz),7.07(1H,t,J=8.8Hz),7.18-7 .20(1H,m),7.24-7.25(4H,m),7.77-7.81(2H,m),8.68(1H,s),10.83(1H,s).

[0860] Example 58

[0861] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 55 .

[0862]

[0863] Step A: tert-Butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate

[0864]

[0865] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 100 mg, 0.15 mmol), tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (57.0 mg, 0.23 mmol), copper(I) iodide (5.76 mg, 0.03 mmol) and TEA (82.0 μL, 0.61 mmol) in DMF (2 mL) was degassed with N. Pd(PPh) (17.47 mg, 0.02 mmol) was added to the reaction mixture and stirred at 90° C. overnight. To the mixture was added tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (57.0 mg, 0.23 mmol), copper (I) iodide (5.76 mg, 0.03 mmol), TEA (82.0 μL, 0.61 mmol) and Pd(PPh 3 ) 4 (17.47 mg, 0.02 mmol), and stirred overnight at 90° C. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc / MeOH=97 / 3) to give tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (52.6 mg, 44%) as a beige solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.43(9H,s),1.50(6H,s),1.95-2.05(4H,m),2.62(4H,m),3.44(4H,m),3.54(2H,t,J=11Hz),4.14-4.17(2H,m),4.78 -4.84(1H,s),5.06(2H,s),6.03(1H,brs),7.06(1H,t,J=8.0Hz),7.18-7.2 0(1H,m),7.24-7.26(4H,m),7.81-7.78(2H,m),8.64(1H,s),10.84(1H,s).

[0866] Step B: N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0867]

[0868] To a solution of tert-butyl 4-(4-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (52.6 mg, 0.07 mmol) in DCM (1 mL) was added TFA (0.10 mL, 1.34 mmol) at room temperature. The reaction mixture was stirred at room temperature overnight. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=95 / 5) to give N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (24.0 mg, 52%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400 MHz): δ 1.45 (6H, s), 1.98-2.04 (4H, m), 2.63 (4H, brs), 2.92 (4H, m), 3.51-3.57 (2H, m), 4.15-4.17 (2H, m), 4.78-4.84 (1H, m), 5.02 (2H, s), 6.05 (1H, d, J = 6 Hz), 7.05 (1H, t, J = 8.8 Hz), 7.18-7.20 (1H, m), 7.24-7.26 (4H, m), 7.77-7.81 (1H, m), 7.83 (1H, d, J = 6.0 Hz), 8.68 (1H, s), 10.83 (1H, s). *NH peak not observed.

[0869] Example 59

[0870] This example describes the synthesis of N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 56 .

[0871]

[0872] Step A: tert-Butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate

[0873]

[0874] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 100 mg, 0.15 mmol), tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (51.0 mg, 0.23 mmol), copper(I) iodide (5.76 mg, 0.03 mmol) and TEA (82.0 μL, 0.61 mmol) in DMF (2 mL) was degassed with N. Pd(PPh) (17.47 mg, 0.02 mmol) was added to the reaction mixture and stirred at 90° C. overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (EtOAc only) to give tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (60.9 mg, 53%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.21-1.27(2H,m),1.44(9H,s),1.72(1H,brs),1.81(2H ,d,J=14Hz),1.98-2.05(4H,m),2.45(2H,d,J=6.4Hz),2.69(2H,brs),3.52-3.57(2H,m),4 .09-4.18(4H,m),4.78-4.84(1H,m),4.99(2H,s),5.98(1H,d,J=6.0Hz),7.08(1H,t,J=8. 8Hz),7.19-7.21(1H,m),7.24-7.26(4H,m),7.79-7.81(2H,m),8.68(1H,s),10.84(1H,s).

[0875] Step B: N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0876]

[0877] To a solution of tert-butyl 4-(3-(2-amino-4-(2-fluoro-4-(3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (49.3 mg, 0.07 mmol) in DCM (1 mL) was added TFA (0.10 mL, 1.30 mmol) at room temperature. The residue was diluted with DCM and then neutralized with TEA. The mixture was stirred at room temperature for 10 minutes and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=9 / 1) to give N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (27.0 mg, 64%) as a yellow solid. 1H-NMR (CDCl3, Varian, 400MHz): δ1.20-1.23 (2H, m), 1.82 (2H, d, J = 12.4Hz), 1.98-2.07 ( 5H,m),2.43(2H,d,J=6.8Hz),2.57-2.62(2H,m),3.06-3.10(2H,m),3.52-3.57(2H,m),4. 14-4.18 (2H, m), 4.78-4.84 (1H, m), 5.02 (2H, s), 5.99 (1H, d, J = 6.0 Hz), 7.08 (1H, t, J = 8.6 Hz), 7.18-7.20 (1H, m), 7.24-7.26 (4H, m), 7.78-7.81 (2H, m), 8.68 (1H, s), 10.84 (1H, s). *NH peak not observed.

[0878] Example 60

[0879] This example describes the synthesis of N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. Figure 57 .

[0880]

[0881] A mixture of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 24, 50.0 mg, 0.08 mmol), 1-methyl-4-(prop-2-yn-1-yl)piperidine hydrochloride (19.7 mg, 0.11 mmol), copper(I) iodide (2.88 mg, 0.02 mmol) and TEA (41.0 μL, 0.30 mmol) in DMF (1 mL) was degassed with N. Pd(PPh) (8.74 mg, 7.56 μmol) was added to the reaction mixture and stirred at 90 °C in a sealed tube overnight. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc / MeOH=97 / 3) to give N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-(4-fluorophenyl)-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (15.8 mg, 31%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.33-1.43(2H,m),1.55(1H,m),1.82-2.05(8H,m),2 .25(3H,s),2.43(2H,d,J=6.4Hz),2.83-2.86(2H,m),3.52-3.57(2H,m),4.15-4.18(2 H,m),4.80-4.84(1H,m),5.01(2H,s),5.97(1H,d,J=5.6Hz),7.09(1H,t,J=8.8Hz),7. 20(1H,d,J=8.0Hz),7.24-7.26(4H,m),7.78-7.81(2H,m),8.68(1H,s),10.84(1H,s).

[0882] Example 61

[0883] This example describes the synthesis of N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 58 .

[0884]

[0885] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 26, 50.0 mg, 0.08 mmol) in DMF (1.7 mL) was added 4-(prop-2-ynyl)morpholine (10.6 mg, 0.08 mmol), copper (I) iodide (3.21 mg, 0.02 mmol) and TEA (46.0 μL, 0.34 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (9.74 mg, 8.43 μmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO column chromatography (EtOAc only) to give N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (26.8 mg, 54%) as a cream solid. 1 H-NMR(DMSO-d6,Varian,400MHz): δ0.79-0.84(1H,m),1.11-1.30(6H,m),1.55-1.66(3H,m ),1.79(2H,d,J=11.2Hz),2.32(2H,q,J=12.0Hz),2.42-2.48(5H,m),3.54(4H,s),3.92(2H, q,J=6.9Hz),4.70-4.80(1H,m),5.89(1H,d,J=5.6Hz),6.26(2H,s),7.22-7.26(1H,m),7.4 4(1H,d,J=9.2Hz), 7.78(1H,d,J=6.0Hz), 7.92(1H,d,J=12.4Hz), 8.71(1H,s), 11.1(1H,s).

[0886] Example 62

[0887] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 59 .

[0888]

[0889] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 26, 50.0 mg, 0.08 mmol) in DMF (1.7 mL) was added 1-methyl-4-(2-methylbut-3-yn-2-yl)piperazine (14.0 mg, 0.08 mmol), copper(I) iodide (3.21 mg, 0.02 mmol) and TEA (46.0 μL, 0.34 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After the addition of Pd(PPh3)4 (9.74 mg, 8.43 μmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc / MeOH=50 / 1) to give N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (6.4 mg, 12%) as a milky white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.10-1.18(2H,m),1.22(3H,t,J=6.8Hz),1.24-1.27(1H,m),1. 33(6H,s),1.58-1.66(3H,m),1.75-1.84(2H,m),2.08(3H,s),2.22-2.38(6H,m),3.28-3.36(4H,m) ,3.92(2H,q,J=7.2Hz),4.70-4.80(1H,m),5.98(1H,d,J=6.0Hz),6.09(2H,s),7.18(1H,t,J=9.6Hz ), 7.41 (1H, d, J = 10.8Hz), 7.80 (1H, d, J = 6.4Hz), 7.91 (1H, d, J = 13.2Hz), 8.70 (1H, s), 11.1 (1H, s).

[0890] Example 63

[0891] This example describes the synthesis of N-(4-(2-amino-3-(3-(methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 60 .

[0892]

[0893] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 26, 50.0 mg, 0.08 mmol) in DMF (1.7 mL) was added 1-methyl-4-(prop-2-ynyl)piperidine (12.0 mg, 0.08 mmol), copper (I) iodide (3.21 mg, 0.02 mmol) and TEA (46.0 μL, 0.34 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (9.74 mg, 8.43 μmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=50 / 1) to give N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.0 mg, 2%) as a white solid. 1H-NMR (DMSO-d6, Varian, 400MHz): δ1.10-1.18(2H,m),1.22(3H,t,J=7.2Hz),1.27-1.30(2H,m),1.36-1.48(1H,m ),1.55-1.69(4H,m),1.75-1.82(3H,m),2.10(2H,s),2.27-2.34(2H,m),2.39(2H,d,J=7.2Hz),2.63-2.76(2H,m), 3.30-3.33(3H,m),3.92(2H,q,J=6.8Hz),4.70-4.80(1H,m),5.74(1H,s),5.90(1H,d,J=6.0Hz),6.17(2H,s),7.22 (1H,t,J=9.0Hz),7.42(1H,d,J=10.4Hz),7.75(1H,d,J=6.0Hz),7.91(1H,d,J=12.4Hz),8.71(1H,s),11.1(1H,s).

[0894] Example 64

[0895] This example describes the synthesis of N-(4-((2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-yn-1-yl)pyridin-4-yl)oxy)-3-fluorophenyl)-1-(2-(dimethylamino)-2-oxoethyl)-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the invention. See Figure 61 .

[0896]

[0897] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 26, 50.0 mg, 0.08 mmol) in DMF (1.7 mL) was added 4-(2-methylbut-3-yn-2-yl)morpholine (13.0 mg, 0.08 mmol), copper (I) iodide (3.21 mg, 0.02 mmol) and TEA (0.05 mL, 0.34 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (9.74 mg, 8.43 μmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc only to EtOAc / MeOH=100 / 1) to give N-(4-(2-amino-3-(3-(methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (6.2 mg, 12%) as a white solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.10-1.19(1H,m),1.22(3H,t,J=7.0Hz),1.23-1.27(1H,m),1.3 4(6H,s),1.54-1.66(3H,m),1.77-1.88(2H,m),2.28-2.40(4H,m),3.30-3.32(4H,m),3.51-3.55(3H ,m),3.92(2H,q,J=6.4Hz),4.70-4.80(1H,m),5.99(1H,d,J=5.6Hz),6.12(2H,s),7.18(1H,t,J=9.0 Hz), 7.42 (1H, d, J = 9.2Hz), 7.81 (1H, d, J = 5.6Hz), 7.91 (1H, d, J = 12.4Hz), 8.70 (1H, s), 11.1 (1H, s).

[0898] Example 65

[0899] This example describes the synthesis of N-(4-(2-amino-3-(3-piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 62 .

[0900]

[0901] Step A: tert-Butyl 4-(3-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate

[0902]

[0903] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (intermediate 26, 110 mg, 0.18 mmol) in DMF (3.7 mL) was added tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (41.0 mg, 0.18 mmol), copper (I) iodide (7.06 mg, 0.04 mmol) and TEA (0.10 mL, 0.74 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (21.0 mg, 0.02 mmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / hexane=3 / 1 to EtOAc / hexane=5 / 1) to give tert-butyl 4-(3-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (31.0 mg, 24%) as a yellow solid. 1H-NMR (DMSO-d6, Varian, 400MHz): δ1.01-1.18(2H,m),1.22(3H,t,J=7.0Hz),1.27-1.31(2H,m),1.34( 9H,s),1.56-1.69(6H,m),1.79(2H,d,J=13.2Hz),2.27-2.38(2H,m),2.41(2H,d,J=6.0Hz),3.30-3.32 (3H,m),3.84-3.96(4H,m),4.70-4.80(1H,m),5.90(1H,d,J=6.0Hz),6.19(2H,s),7.20(1H,t,J=8.8Hz ),7.42(1H,d,J=7.6Hz),7.75(1H,d,J=5.6Hz),7.92(1H,dd,J=14.0,2.0Hz),8.71(1H,s),11.1(1H,s).

[0904] Step B: N-(4-(2-amino-3-(3-piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0905]

[0906] To a solution of tert-butyl 4-(3-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (31.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (35.0 μL, 0.45 mmol) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. After cooling to 0 ° C, the reaction mixture was quenched with saturated NaHCO solution and extracted with DCM. The organic layer was dried over Na SO, filtered and concentrated in vacuo. The residue was triturated with DCM and hexane. The resulting solid was collected by filtration and dried under vacuum to give N-(4-(2-amino-3-(3-piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (11.9 mg, 45%) as a beige solid. 1H-NMR(DMSO-d6,Varian,400MHz): δ1.05-1.34(8H,m),1.53-1.71(6H,m),1.79(2 H,d,J=12.4Hz),2.28-2.50(6H,m),2.93(2H,s),3.92(2H,q,J=7.2Hz),4.70-4.80 (1H,m),5.88(1H,d,J=6.0Hz),6.17(2H,s),7.22(1H,t,J=8.8Hz),7.43(1H,d,J= 9.2Hz), 7.75, (1H,d,J=6.0Hz), 7.92(1H,d,J=14.8Hz), 8.70(1H,s), 11.1(1H,s). *Protons from NH were not observed.

[0907] Example 66

[0908] This example describes the synthesis of N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 63 .

[0909]

[0910] Step A: tert-Butyl 4-(4-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl))piperazine-1-carboxylate.

[0911]

[0912] To a solution of N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 26, 120 mg, 0.20 mmol) in DMF (3.7 mL) was added tert-butyl 4-(2-methylbut-3-yn-2-yl)piperazine-1-carboxylate (51.0 mg, 0.20 mmol), copper(I) iodide (7.70 mg, 0.04 mmol) and TEA (0.11 mL, 0.81 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After the addition of Pd(PPh3)4 (23.0 mg, 0.02 mmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc only to EtOAc / MeOH=50 / 1) to give tert-butyl 4-(4-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl))piperazine-1-carboxylate (30.0 mg, 21%) as a cream solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.11-1.19(1H,m),1.22(3H,t,J=7.0Hz),1.22-1.27(2H,m),1.31(9H ,s),1.36(6H,s),1.55-1.63(3H,m),1.79(2H,d,J=11.6Hz),2.32(2H,q,J=9.6Hz),2.48-2.44(4H,m),3.2 6(4H,s),3.92(2H,q,J=7.2Hz),4.70-4.80(1H,m),5.96(1H,d,J=6.0Hz),6.13(2H,s),7.17(1H,t,J=9.0 Hz), 7.39 (1H, d, J = 9.6Hz), 7.80 (1H, d, J = 6.0Hz), 7.91 (1H, dd, J = 14.8, 2.4Hz), 8.70 (1H, s), 11.1 (1H, s).

[0913] Step B: N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0914]

[0915] To a solution of tert-butyl 4-(4-(2-amino-4-(4-(3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)-2-methylbut-3-yn-2-yl))piperazine-1-carboxylate (30.0 mg, 0.04 mmol) in DCM (1 mL) was added TFA (32.0 μL, 0.42 mmol) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. After cooling to 0 ° C, the reaction mixture was quenched with saturated NaHCO solution and extracted with DCM. The organic layer was dried over Na SO, filtered and concentrated in vacuo. The residue was triturated with DCM and hexane. The resulting solid was collected by filtration and dried under vacuum to afford N-(4-(2-amino-3-(3-methyl-3-(piperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-3-cyclohexyl-1-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10.3 mg, 40%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ1.10-1.16 (1H, m), 1.22 (3H, t, J = 7.0Hz), 1.33 (6H, s), 1.52-1 .67(3H,m),1.74-1.81(2H,m),2.27-2.39(3H,m),2.48-2.53(3H,m),2.77(2H,s),3.30-3.32(4H,m ), 3.92 (2H, q, J = 7.6 Hz), 4.70-4.80 (1H, m), 5.98 (1H, d, J = 5.2 Hz), 6.12 (2H, s), 7.19 (1H, t, J = 9.0 Hz), 7.42 (1H, d, J = 9.2 Hz), 7.81 (1H, d, J = 6.0 Hz), 7.92 (1H, d, J = 13.2 Hz), 8.70 (1H, s), 11.1 (1H, s). *No protons from NH were observed.

[0916] Example 67

[0917] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 64 .

[0918]

[0919] A mixture of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28, 60.0 mg, 0.11 mmol), 4-(prop-2-ynyl))morpholine (20.0 mg, 0.16 mmol), copper (I) iodide (4.1 mg, 0.02 mmol) and TEA (58.0 μL, 0.43 mmol) in DMF (1 mL) was degassed with N2. Pd(PPh3)4 (12.0 mg, 10.6 μmol) was added to the reaction mixture at 90 °C and stirred for 4 hours. After cooling at room temperature, the reaction mixture was extracted with EtOAc, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=10 / 1) to give 1,3-diallyl-N-(4-(2-amino-3-(3-morpholinoprop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (10.0 mg, 16%) as a yellow solid. 1 H-NMR (DMSO-d6, Varian, 400MHz): δ2.44(4H,m),3.53(6H,m),4.46-4.50(2H,m),4.57(2H,d,J=5.6Hz),5.12-5.14(2H,m),5.22-5.27(2H,m),5.80- 5.96(3H,m),6.24(2H,brs),7.24(1H,t,J=9.2Hz),7.43(1H,d,J=8.8Hz), 7.79(1H,d,J=5.6Hz), 7.92(1H,d,J=13.2Hz), 8.68(1H,m), 11.04(1H,s).

[0920] Example 68

[0921] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 65 .

[0922]

[0923] To a solution of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28, 50.0 mg, 0.09 mmol) in DMF (1.8 mL) was added 1-methyl-4-(2-methylbut-3-yn-2-yl)piperazine (22.0 mg, 0.13 mmol), copper (I) iodide (3.38 mg, 0.02 mmol) and TEA (0.05 mL, 0.36 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After the addition of Pd(PPh3)4 (10.3 mg, 8.88 μmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH-SiO2 column chromatography (EtOAc only) to give 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (8.0 mg, 15%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.47(6H,s),2.27(3H,s),2.50(4H,s),2.74(4H ,s),4.52(2H,d,J=5.6Hz),4.64(2H,d,J=5.6Hz),5.01(2H,s),5.27(2H,d,J=11.2 Hz),5.34(1H,d,J=5.6Hz),5.41(1H,d,J=10.4Hz),5.96-5.88(2H,m),6.02(1H,d, J=5.6Hz), 7.10(2H,t,J=8.4Hz), 7.82(2H,d,J=6.8Hz), 8.48(1H,s), 11.0(1H,s).

[0924] Example 69

[0925] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 66 .

[0926]

[0927] To a solution of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28, 100 mg, 0.18 mmol) in DMF (1.8 mL) was added 1-methyl-4-(prop-2-ynyl)piperidine (37.0 mg, 0.27 mmol), copper (I) iodide (6.76 mg, 0.02 mmol) and TEA (0.10 mL, 0.71 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (21.0 mg, 0.02 mmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=50 / 1) to give 1,3-diallyl-N-(4-(2-amino-3-(3-(1-methylpiperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.0 mg, 1%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ0.79-0.89(1H,m),1.35-1.44(2H,m),1.85(2H,d,J=12.0Hz),1. 93(2H,t,J=11.4Hz),2.26(3H,s),2.45(2H,d,J=6.4Hz),2.86(2H,d,J=10.8Hz),4.53(2H,d,J=5.6 Hz),4.64(2H,d,J=5.2Hz),5.01(2H,s),5.27(2H,d,J=10.8Hz),5.34(1H,d,J=6.0Hz),5.40(2H,d, J=10.8Hz),5.99-5.88(3H,m),7.12(1H,t,J=8.4Hz),7.84-7.78(2H,m),8.48(1H,s),11.0(1H,s).

[0928] Example 70

[0929] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 67 .

[0930]

[0931] To a solution of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28, 100 mg, 0.18 mmol) in DMF (1.8 mL) was added 4-(2-methylbut-3-yn-2-yl)morpholine (41.0 mg, 0.27 mmol), copper (I) iodide (6.76 mg, 0.02 mmol) and TEA (97.0 μL, 0.71 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (21.0 mg, 0.02 mmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=30 / 1) to give 1,3-diallyl-N-(4-(2-amino-3-(3-methyl-3-morpholinobut-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (1.2 mg, 1%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.47(6H,s),2.64-2.71(4H,m),3.71-3.79(4H ,m),4.52(2H,d,J=6.4Hz),4.64(2H,d,J=5.6Hz),5.02(2H,s),5.27(2H,d,J=10. 4Hz),5.34(1H,d,J=5.6Hz),5.41(2H,d,J=11.2Hz),5.88-6.00(1H,m),6.04(1H ,d,J=6.0Hz),7.10(2H,t,J=8.6Hz),7.85-7.81(2H,m),8.48(1H,s),11.0(1H,s)

[0932] Example 71

[0933] This example describes the synthesis of 1,3-diallyl-N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide, an aspect of the present invention. Figure 68 .

[0934]

[0935] Step A: tert-Butyl 4-(3-(2-amino-4-(4-(1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate

[0936]

[0937] To a solution of 1,3-diallyl-N-(4-(2-amino-3-iodopyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Intermediate 28, 150 mg, 0.27 mmol) in DMF (5.3 mL) was added tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (89.0 mg, 0.40 mmol), copper (I) iodide (10.1 mg, 0.05 mmol) and TEA (0.15 mL, 1.07 mmol) at room temperature. The mixture was degassed by purging and refilling with Ar several times. After adding Pd(PPh3)4 (31.0 mg, 0.03 mmol), the reaction mixture was heated at 90 ° C for 18 hours. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by SiO2 column chromatography (EtOAc / MeOH=50 / 1) to give tert-butyl 4-(3-(2-amino-4-(4-(1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (43.0 mg, 25%) as a yellow solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ0.78-0.88(1H,m),1.21-1.29(4H,m),1.44(9H,s) ,1.65(4H,s),2.46(2H,d,J=6.4Hz),4.52(2H,d,J=6.0Hz),4.64(2H,d,J=5.2Hz),5. 02(2H,s),5.27(2H,d,J=10.8Hz),5.34(1H,d,J=5.6Hz),5.41(2H,d,J=10.4Hz),5. 88-5.98(3H,m),7.12(1H,t,J=8.8Hz),7.48-7.55(2H,m),8.48(1H,s),11.0(1H,s).

[0938] Step B: 1,3-Diallyl-N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

[0939]

[0940] To a solution of tert-butyl 4-(3-(2-amino-4-(4-(1,3-diallyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)-2-fluorophenoxy)pyridin-3-yl)prop-2-ynyl)piperidine-1-carboxylate (43.0 mg, 0.06 mmol) in DCM (1.3 mL) was added TFA (50.0 μL, 0.65 mmol) at room temperature. The reaction mixture was stirred at room temperature for 18 hours. After cooling to 0 ° C, the reaction mixture was quenched with saturated NaHCO solution and extracted with DCM. The organic layer was dried over Na SO, filtered and concentrated in vacuo. The residue was purified by NH—SiO 2 column chromatography (EtOAc / MeOH=10 / 1) to give 1,3-diallyl-N-(4-(2-amino-3-(3-(piperidin-4-yl)prop-1-ynyl)pyridin-4-yloxy)-3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (3.3 mg, 9%) as a white solid. 1 H-NMR (CDCl3, Varian, 400MHz): δ1.24-1.30 (3H, m), 1.83 (2H, d, J = 14.4Hz), 2.44 (2H, d, J = 6.4H z), 2.61 (2H, t, J = 12.2Hz), 3.09 (2H, d, J = 11.6Hz), 4.53 (2H, d, J = 6.4Hz), 4.64 (2H, d, J = 6.0Hz), 5.02 (2H, s), 5.27 (2H, d, J = 10.8 Hz), 5.34 (1H, d, J = 6.0 Hz), 5.41 (2H, d, J = 10.4 Hz), 5.88-5.99 (2H, m), 6.00 (1H, d, J = 6.0 Hz), 7.11 (1H, t, J = 9.0 Hz), 7.80-7.83 (2H, m), 8.49 (1H, s), 11.0 (1H, s). *No protons from NH were observed.

[0941] Example 72

[0942] This example illustrates an enzyme assay used to determine the inhibitory activity of exemplary compounds of formula (I) in one embodiment of the invention.

[0943] All kinase reactions were performed using 5 μL of tyrosine kinase buffer containing 0.2 μg / μL poly (Glu4, Tyr1) substrate, 10 μM ATP, serial dilutions of inhibitors, and incubated at room temperature for 60 minutes. After the indicated incubation times, 5 μL of ADP-GLO TM The reagent (Promega, Madison, WI) was added to the reaction and the plate was incubated at room temperature for 40 minutes. Next, 10 μL of kinase detection reagent was added and after a 40-minute incubation period, luminescence was recorded and the IC was determined. 50 The values ​​were (Table 3). GLOMAX from Promega Corporation (Madison, Wisconsin) was used. TM All 384-well assay plates were read using a Discover microplate luminometer.To graph, analyze data, and calculate all kinase reaction biochemical values, both Microsoft Excel and Prism from GraphPad 7 software (La Jolla, CA) were used.

[0944] Table 3.

[0945]

[0946]

[0947] Example 73

[0948] This example illustrates a cell viability assay for exemplary compounds of formula (I) according to one embodiment of the present invention.

[0949] Cell viability was determined by plating HCC827 or PC9 resistant cells at 1,000 cells per well onto white, transparent bottom 384-well plates. Cells were treated with each TKI at 10 doses ranging from 1 nM to 10,000 nM. After 72 hours of drug treatment, cell viability was measured using CellTiter-Glo 2.0 assay (Promega, Madison, Wisconsin). By continuously exposing cells to EGFR TKI for more than 3 months, EGFR TKI (gefitinib, erlotinib, and osimertinib) resistant cell lines derived from parental EGFR TKI-sensitive HCC827 or PC9 cell lines were formed. Resistant cell lines were designated as PC9 / ER, HCC827 / ER, HCC827 / GR, and HCC827 / OR. All of these resistant cells exhibited 1,000 times more resistance to EGFR TKI than parental cells.

[0950] Table 4 shows the efficacy of the combination of EGFR TKI and the inhibitor of formula (I) in EGFR TKI-resistant cells.

[0951] Table 4.

[0952]

[0953] Unless otherwise specified herein or clearly contradicted by context, the use of the terms "a" and "an" and "the" and "at least one" and similar indicators in the context of describing the present invention (especially in the context of the following claims) should be interpreted to cover both the singular and the plural. Unless otherwise specified herein or clearly contradicted by context, the term "at least one" used after a list of one or more items (e.g., "at least one of A and B") should be interpreted to mean one item (A or B) selected from the listed items or any combination of two or more items (A and B) of the listed items. Unless otherwise specified herein, the terms "including," "having," "comprising," and "containing" should be interpreted as open-ended terms (i.e., meaning "including but not limited to"). Unless otherwise specified herein, the recitation of ranges of values ​​herein is merely intended to serve as a shorthand method of individually referring to each individual value falling within the range, and each individual value is incorporated into the specification as if recited separately herein. Unless otherwise specified herein or clearly contradicted by context, all methods described herein can be performed in any suitable order. Unless otherwise required, the use of any and all examples or exemplary language (e.g., "such as") provided herein is intended merely to better illustrate the invention and does not limit the scope of the invention. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0954] The preferred aspects of the present invention are described herein, including the best mode for implementing the present invention known to the inventor. After reading the foregoing description, the changes in those preferred aspects may become apparent to those of ordinary skill in the art. The inventors anticipate that those skilled in the art may adopt these changes when appropriate, and the inventors intend to put the present invention into practice in a manner different from that specifically described herein. Therefore, where applicable law permits, the present invention includes all modifications and equivalents to the themes recited in the appended claims. In addition, unless otherwise noted herein or otherwise clearly contradicted by context, the present invention encompasses any combination of the above-described elements in all possible variations thereof.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in R 1 is H, alkyl, haloalkyl, halo or CN; R 2 is H, alkyl, haloalkyl, halo or CN; R 3 is H or a halogen; Q is H, CN, halo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, heteroaryl or aryl, wherein the alkenyl or the alkynyl is selected from the group consisting of: -CH=CR 4 (CX′) m (CH 2 ) n NR 5 R 6 、-C≡C(CX′) m (CH 2 ) n NR 5 R 6 、 -CH=CR 4 (CX′) m (CH 2 ) n CHR 5 R 6 、-C≡C(CX′) m (CH 2 ) n CHR 5 R 6 、 -CH=CR 4 (CX′) m (CH 2 ) n NR 7 OR 8 and -C≡C(CX′) m (CH 2 ) n NR 7 OR 8 ; in R 4 is hydrogen or a halogen; X′ is H 2 , (C 1-6 alkyl) 2 or =O; m is 0 or 1; n is 0 or 1 to 3; -NR 5 R 6 forms a 4- to 7-membered heterocyclic ring or does not form a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring, When-NR 5 R 6 When a 4- to 7-membered heterocyclic ring is formed, the 4- to 7-membered heterocyclic ring is -NR 5 R 6 In addition to the nitrogen, it also includes an optional second heteroatom and is optionally substituted with one or more substituents independently selected from the group consisting of: a straight chain C 1 -C 6 Alkyl, branched chain C 3 -C 6 Alkyl, hydroxyl, C 1 -C 6 Alkoxyalkyl, carboxylic acid, straight chain C 1 -C 4 Alkyl carboxylic acids and branched C 3 -C 4 Alkyl carboxylic acid; when -NR 5 R 6 When no ring structure is formed, R 5 Selected from hydrogen, straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 The group is composed of alkyl groups, and R 6 Selected from the group consisting of hydrogen, a linear C optionally substituted with at least one fluorine or at least one hydroxyl group 1 -C 6 Alkyl, branched C optionally substituted by at least one fluorine or at least one hydroxyl 3 -C 6 alkyl and cycloalkyl optionally substituted with at least one fluorine or at least one hydroxyl; -CHR 5 R 6 forms a 4- to 7-membered heterocyclic ring or does not form a ring structure, wherein the heterocyclic ring is a heteroaryl ring or a heterocyclyl ring, When -CHR 5 R 6 When forming a 4- to 7-membered heterocyclic ring, the 4- to 7-membered heterocyclic ring includes one or two heteroatoms and is optionally substituted with one or more substituents independently selected from the group consisting of: a linear C 1 -C 6 Alkyl, branched chain C 3 -C 6 Alkyl, hydroxyl, C 1 -C 6 Alkoxyalkyl, carboxylic acid, straight chain C 1 -C 4 Alkyl carboxylic acids and branched C 3 -C 4 Alkyl carboxylic acids; When -CHR 5 R 6 When no ring structure is formed, R 5 Selected from hydrogen, straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 The group is composed of alkyl groups, and R 6 Selected from the group consisting of hydrogen, a linear C optionally substituted with at least one fluorine or at least one hydroxyl group 1 -C 6 Alkyl, branched C optionally substituted by at least one fluorine or at least one hydroxyl 3 -C 6 alkyl and cycloalkyl optionally substituted with at least one fluorine or at least one hydroxyl; -NR 7 OR 8 No ring structure is formed, R 7 Selected from hydrogen, straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 The group consisting of alkyl groups, and R 8 Selected from the group consisting of hydrogen, a linear C optionally substituted with at least one fluorine, hydroxyl or alkoxy group 1 -C 6 Alkyl, branched C optionally substituted by at least one fluorine, hydroxyl or alkoxy group 3 -C 6 alkyl and cycloalkyl optionally substituted with at least one fluorine, hydroxyl or alkoxy group; G is in R 9 is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl or heteroarylalkyl, wherein the heteroaryl in the heteroarylalkyl may be substituted or unsubstituted; R 10 is H, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, alkyl or cycloalkyl, cycloalkylalkyl, alkenyl or alkynyl, wherein the alkyl, alkenyl or cycloalkyl may be substituted by one, two or three groups selected from the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo, hydroxy, alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino (wherein the two alkyl groups in the dialkylamino may be the same or different), heteroaryl, substituted heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl (wherein the two alkyl groups in the dialkylcarbamoyl may be the same or different) and heterocyclylcarbonyl; and Y is N, CH or C-alkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

3. The compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Q is CN, halo, optionally substituted phenyl, optionally substituted heterocyclyl, or an alkenyl or alkynyl moiety selected from the group consisting of: -CH=CR 4 (CX′) m (CH 2 ) n NR 5 R 6 、-C≡C(CX′) m (CH 2 ) n NR 5 R 6 、-CH=CR 4 (CX′) m (CH 2 ) n CHR 5 R 6 、-C≡C(CX′) m (CH 2 ) n CHR 5 R 6 、-CH=CR 4 (CX′) m (CH 2 ) n NR 7 OR 8 and -C≡C(CX′) m (CH 2 ) n NR 7 OR 8 , in R 4 is hydrogen or a halogen; X′ is H 2 , (C 1-6 alkyl) 2 or =O; m is 0 or 1; n is 0 or 1; -NR 5 R 6 is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group, -CHR 5 R 6 is tetrahydropyranyl, morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group, R 7 Selected from hydrogen, straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 alkyl groups, and R 8 Selected from the group consisting of: a linear C optionally substituted by at least one alkoxy group 1 -C 6 An alkyl group and a branched C 3 -C 6 alkyl.

5. The compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted by alkyl, haloalkyl, halo and / or CN; and (i) Y is CH or (ii) Y is N.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein the compound of formula (I) is a compound of formula (Ib): in It is -C≡C- or -CH=CH-.

7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

8. The compound according to claim 6 or claim 7 or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

9. The compound according to any one of claims 6 to 8, or a pharmaceutically acceptable salt thereof, wherein X′ is H 2 , (C 1-6 alkyl) 2 or = O; and -NR 5 R 6 is morpholinyl, piperazinyl or piperidinyl, each of which is optionally substituted with one or more substituents independently selected from the group consisting of a nitrogen protecting group, an alkyl group, a hydroxyl group, an alkoxy group and an alkoxyalkyl group.

10. The compound according to any one of claims 6 to 9 or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted by alkyl, haloalkyl, halo and / or CN; and (i) Y is CH or (ii) Y is N.

11. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein the compound of formula (I) is a compound of formula (Ic): in It is -C≡C- or -CH=CH-.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 It's all hydrogen.

13. The compound according to claim 11 or claim 12, or a pharmaceutically acceptable salt thereof, wherein R 3 It is a halogen group.

14. The compound according to any one of claims 11 to 13 or a pharmaceutically acceptable salt thereof, wherein X′ is H 2 , (C 1-6 alkyl) 2 or =O; R 7 Select from straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 alkyl groups, and R 8 Select from straight chain C 1 -C 6 Alkyl and branched C 3 -C 6 Alkyl group.

15. The compound according to any one of claims 11 to 14 or a pharmaceutically acceptable salt thereof, wherein R 9 is phenyl substituted by alkyl, haloalkyl, halo and / or CN; and (i) Y is CH or (ii) Y is N.

16. The compound according to claim 1, selected from or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

18. A method for treating or preventing an AXL-mediated disease, a Mer-mediated disease and / or a c-Met-mediated disease in a subject, wherein the disease is selected from the group consisting of papillary thyroid cancer, pancreatic cancer, lung cancer, colon cancer, breast cancer, neuroblastoma, pain, cachexia, dermatitis and asthma, the method comprising administering to a subject in need of such treatment a pharmaceutically effective amount of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.

19. The method of claim 18, wherein the lung cancer is non-small cell lung cancer.

20. A method of inhibiting AXL, Mer and / or c-Met enzymes in a cell, the method comprising administering a pharmaceutically effective amount of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof to a cell in need of such inhibition.